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ABSTRACT 
 The role of various polyglutamine (polyGln) aggregated states in the disease 
mechanism of expanded CAG repeat disorders continues to be a perplexing subject. We 
are interested in learning more about these species and the relationship between the 
aggregation pathways. We have developed an innovative staining technique that allows, 
for the first time, the visualization of small polyGln aggregates, which we refer to as 
aggregation foci (AF), that are functionally distinguished by their ability to serve as seeds 
for amyloid growth. The aggregation foci stain should prove useful in the Huntington’s 
disease research as a tool for the identification of a functional class of aggregates that was 
previously undescribed. The ability to account for different aggregates may provide a 
better correlation with neurodegeneration.  Using this method we were able to detect at 
least four phenotypic classes of aggregates in stable PC12 cells engineered for inducible 
expression of different polyGln repeat length forms of a green fluorescent protein-fused 
huntingtin (htt) exon-1 fragment:  1) small, recruitment-competent, cytoplasmic AF, 2) 
large, cytoplasmic, perinuclear, green-fluorescent, recruitment-inert htt aggregates, 3) 
cytoplasmic, perinuclear, green-fluorescent, recruitment-competent aggregates, and 4) 
small, nuclear, recruitment-inert, green-fluorescent aggregates. Each species can be found 
either in isolation or co-existing within the same microscope field depending on the time 
post-induction and Gln repeat-length. In our studies, AF tend to be the earliest species 
that appear in the cells.  The PC12 cells generally did not exhibit indications of toxicity 
due to the polyGln species, and thus provided a good model to study the aggregation 
pathway without the bias of cell death. Biochemical data were gathered to understand the 
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properties of each distinct aggregate specie. We also examined the ability of two separate 
compounds (curcumin and demecolcine) to alter the aggregation pathway. Each 
experiment was designed to obtain knowledge about possible precursor/product 
relationships that exist among the species, with the ultimate goal of gaining insight into 
the aggregation pathways responsible for the formation of the amyloid-like AF and larger 
inert aggregates that arise in these the cell lines expressing various polyGln repeat-
lengths. We interpret this data as indicating that the two species are on competing 
assembly pathways.   
 viii
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CHAPTER 1  
LITERATURE REVIEW 
1.1 Protein folding disorders: 
OVERVIEW 
 A large number of human diseases arise from the inability of peptides or proteins 
to properly assume their native conformation. These conditions, often collectively 
referred to as protein conformational, or protein folding disorders, span diverse 
conditions that are widespread and are not confined to any particular organ or tissue (see 
Table 1.1 for a summary of amyloidoses) [Carrell and Lomas 1997; Uversky 1999; 
Ahmad et al. 2005; Westermark et al. 2005; Chiti and Dobson 2006]. Conformational 
disorders arise when there is a change in the size, shape, or amount of a protein resulting 
in the deposition of an aberrant form – which may be amyloid or some other type of 
protein aggregate – within tissues. Protein folding disorders can be categorized into two 
major groups: 1) those involving only the brain, and 2) those affecting the remainder of 
the body. This section will provide a brief introduction to the protein folding disorders 
that result in amyloid or amyloid-like deposits; after which, a more detailed description of 









peptide or protein 
Native structure(s) 
of peptide or 
protein #
Affected tissue / 
Syndrome 









unknown (See Table 1.2) 
Cerebral cortex, 
Purkinje cells, basal 
ganglia, etc. 
Alzheimer’s disease  β-amyloid precursor protein (Aβ) Intrinsically unfolded 
Cerebral cortex, 
hippocampus, basal 
forebrain, etc.  
Spongiform 
encephalopathies  Prion protein (APrP) 
Intrinsically unfolded; α-
helices Brain 
Parkinson’s disease α-synuclein Intrinsically unfolded Substantia nigra 
Amyotrophic lateral 
sclerosis Superoxide dismutase 1 β-sheet Motor neurons 




Cystatin C (ACys) α+β, cystatin-like Brain 
Peripheral – Systemic (S) or Localized (L)  
AL amyloidosis – 
Light chain (S,L)  
Immunoglobulin light 
chains (AL) β-sheet 
AH amyloidosis –  
Heavy chain (S,L) 
Immunoglobulin heavy 
chains (AH) β-sheet 
Skin, nerves, heart, GI 
tract (includes tongue), 




AA amyloidosis – 
Inflammation-
associated (S) 
Serum amyloid A protein 
(AA) α/β 
Spleen, liver, kidneys, 
adrenals, lymph nodes. 
vascular Secondary to 
chronic infections, 
reactive tumors 
Familial & senile 
systemic amyloidosis 
(S,L) 
Transthyretin (ATTR) β-sheet Predominately liver, most organs & tissues 
Hemodialysis 









peptide or protein 
Native structure(s) 
of peptide or 
protein #
Affected tissue / 
Syndrome 
Lysozyme 
amyloidosis (S) Lysozyme (ALys) α+β, lysozyme fold 
Visceral organs & 
tissues 
Familial, sporadic & 
aortic (S,L) 
Apolipoprotein (AApoAI, 
AApoAII, AApoAIV) α-helices 
Visceral organs & 
tissues 
Familial amyloidosis 





(AFib) Coil? Kidney 
Familial British dementia 
(S) ABriPP (ABri) Majority coil, some α+β Central nervous system 
Familial Danish dementia 
(S) ADanPP (ADan) Predicted β-sheet Central nervous system 
Diabetes mellitus 
type II (L) 
Islet amyloid 
polypeptide (AIAPP) or 
amylin 
Natively unfolded Islets of Langerhans (pancreas) 
Medullary thyroid 
carcinoma (L) (Pro)calcitonin (ACal) 50% coil : 50% α-helix C-cell thyroid tumors 
Isolated atrial 
amyloidosis (L) 
Atrial natriuretic factor 




Insulin (AIns) Largely α-helical Liver, kidney, spleen, pancreas 
Senile aortic, medin 
amyloidosis (L) Lactadherin (AMed) Coil Heart 
Familial corneal 
amyloidosis (L) Kerato-epithelin (AKer) Largely α-helical Eyes 
Familial corneal 
amyloidosis (L) Lactoferrin (ALac) α+β combination Eyes 
#Based on the Structural Classification of Proteins (SCOP), Protein Data Bank (PDB), or 
Advanced Protein Secondary Structure Prediction Server (APSSP). 
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A natively folded protein can become pathogenic for a variety of reasons, 
including posttranslational processing or the improper trafficking of the protein [Chai et 
al. 1999; Amaral 2004; Lee et al. 2004; Gunawardena and Goldstein 2005; Luo et al. 
2005]. The majority of conformational disorders, however, occur as a result of a change 
in the protein from a normally soluble state into an aggregated state, where the aggregates 
range from soluble, oligomeric structures to large, insoluble, ”amyloid” or amyloid-like 
fibrils. This aggregation is normally associated with a conformational change.  
Aggregated proteins either accumulate within the cell (examples are inclusions of 
huntingtin and neurofibrillary tangles of tau) or outside the cell (amyloid plaques in 
Alzheimer’s disease, amyloid fibrils in other amyloid diseases, diffuse, non-amyloid 
deposits in AD).  The overall effect is that there is a reduction in the amount of the 
normal protein and an increase in the misfolded protein. While some aggregation diseases 
may exhibit a component of a loss of function phenotype (generally intracellular 
aggregation disorders), due to the reduction in normal protein levels, for many of these 
diseases the principle effects appear to be due to toxic gains of function.  
AMYLOID STRUCTURE 
Amyloid fibrils, by classical definition, are extracellular protein aggregates 
[Pepys 2006] that: (a) exhibit a cross-β structure (β-sheets run parallel to the fibril axis, 
and the β-strand components run perpendicular to the axis) as demonstrated by x-ray 
diffraction (see Figure 1.1) [Sunde et al. 1997]; (b) that specifically bind Congo red (CR) 





Figure 1.1: Proposed β-strand structures. (A) Cross-β spine structure of amyloid fibrils 
(Taken from [Nelson et al. 2005]). Carbon atoms are colored purple or gray/white, 
oxygen is red, and nitrogen is blue. The backbone of each β-strand is represented as an 
arrow with protruding side chains. The “dry” interface (composed of side chains Asn2, 
Gln4, and Asn6) is located between the two sheets, while the solvated surfaces are 
exposed. (B) Ribbon diagram and detailed conformational views of the human 
monomeric β2-microglobulin (Taken from [Trinh et al. 2002]). (C) Model of a single 
strand of residues 15-36 of the amyloid fibril core β-sheet cross-section (Adapted from 
[Shivaprasad and Wetzel 2004]). Model was created by J.T. Guo and Y. Xu based on 
cysteine accessibility and disulfide cross-linking [Shivaprasad and Wetzel 2006]. Carbon 
backbone is colored green, hydrogen is gray/white, oxygen is red, nitrogen is blue, and 
yellow is sulfur. (D) Cartoon depiction of antiparallel β-sheets of Abeta fibril. Residues 
12-21 are red and residues 30-40 are blue. (Taken from [Tycko 2006]).  
5 
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observed under polarized light microscopy [Puchtler 1962]; and (c) that bind the yellow 
fluorescent dye thioflavin T (ThT), another molecule thought to bind to β-sheets [Sunde, 
Serpell et al. 1997]. Actual amyloid deposits have also been shown to contain glycan 
molecules, such as heparan sulfate [Nelson et al. 1991] and to bind serum amyloid P 
(SAP) component [Pepys et al. 1994].  In contrast to the above restrictive definition of 
amyloid, the term has been adopted by the protein structural and biophysical community 
to refer to a type of aggregated protein folding motif that has the structural properties of 
amyloid (cross-β, dye-binding, etc.), even if the aggregate has been generated in vitro or 
intracellularly.  Thus, for the purposes of this dissertation, the term amyloid or amyloid-
like will be used interchangeably and will refer to non-native, aggregated, β-structures 
that have the ability to self-propagate.  
Over the past decade, several structural models of this amyloid fibril folding motif 
have been proposed. These models include the cross-β spine (Figure 1.1A) proposed by 
Eisenberg and coworkers [Nelson, Sawaya et al. 2005], the polar zipper model [Perutz et 
al. 1994] (discussed in Section 1.2), as well as various other antiparallel β-strand models 
(Figure 1.1B-1D) [Trinh et al. 2002; Shivaprasad and Wetzel 2004; Shivaprasad and 
Wetzel 2006; Tycko 2006; Bu et al. 2007]. These structures are based on data obtained 
using a variety of methods including, solid-state NMR (SSNMR), hydrogen-deuterium 
exchange, mutational analysis, atomic force microscopy (AFM), X-ray diffraction, and 
transmission electron microscopy (TEM).   
Each model has several similarities including the accepted cross-β structure, the 
intermolecular packing that occurs between the β-sheets [Shivaprasad and Wetzel 2004], 
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and the hydrogen bonding that occurs between the main chain and side chain amino acids 
[Perutz et al. 1994; Trinh et al. 2002]. Several of the proposed models suggest that the 
core region, despite differences among their primary sequences, is composed of two to 
four β-sheets that intimately interact with one another [Chiti and Dobson 2006].   
Despite the observed similarities, there are also numerous differences among the 
various models. These differences include the nature of side chain involvement, β-strand 
length and arrangement (parallel or antiparallel), the conformation of regions outside of 
the core, and the number of β-sheets that comprise a protofilament (the filamentous fibril 
building block of amyloid fibrils).  Other factors that differ significantly are the spacing 
between the β-sheets of the core and the number of peptide residues that are actually 
incorporated into the core [Fandrich and Dobson 2002]. In the case of insulin amyloid 
fibrils, the presence of disulfide bonds also affects the β-sheet packing [Jimenez et al. 
2002]. In polyglutamine peptide amyloid, the side chains may become involved in 
hydrogen bonding to each other or to the β-sheet peptide backbone [Perutz et al. 2002].  
The conformation found in isolated fibrils is ultimately determined by some 
combination of thermodynamics and kinetics.  Protein aggregates tend to be quite stable, 
so that, whether the precursor is an intrinsically unfolded protein or a stably folded 
protein, fibrils occupy a lower free energy and hence are thermodynamically favored.  At 
the same time, reaction kinetics can determine which of the essentially equally stable 
polymorphic amyloid states [Kodali and Wetzel 2007] are formed in a fibril formation 
reaction.  More generally, even though the fibril state exists and is thermodynamically 
favored, fibrils will not form unless the reaction is kinetically feasible, for example by 
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virtue of a weakening of the native state of a folded precursor, the presence of a fibril 
seed, or a surmountable nucleation barrier [Kodali and Wetzel 2007].  
FUNCTIONAL AMYLOID 
Amyloid-like fibrils are not always associated with pathology. Some proteins 
have been shown to produce amyloid fibrils not associated with tissue toxicity [Stefani 
and Dobson 2003; Uversky and Fink 2004]. This type of amyloid is referred to as 
functional amyloid, where the amyloid structure is found to be beneficial to the living 
organism rather than associated with a disease-state. A few examples of functional 
amyloid are the bacterial protein curlin [Chapman et al. 2002] that is produced by 
Escherichia coli and used to mediate attachment to host proteins for colonization; the 
Saccharomyces cerevisiae (yeast)  prion proteins Ure2p and Sup35p [Osherovich et al. 
2004] that confer alternate non-pathogenic phenotypes; and mammalian melanosomes 
[Berson et al. 2003], which are lysosome-like organelles responsible for the production of 
the pigment melanin. There are also amyloid deposits not known to be either pathogenic 
or beneficial [Haggqvist et al. 1999].  
NUCLEATION-DEPENDENT MECHANISM 
Spontaneous amyloid fibril formation is normally considered to occur via 
nucleation-dependent polymerization (see Figure 1.2) [Ferrone 1999] followed by 
elongation or growth of the fibril. This is rather controversial, however, and in some 
cases fibrils grow without a required nucleation step by a process called “downhill 













Figure 1.2: General schematic representations of aggregation initiation and growth 
by monomer addition.  (A)  Downhill aggregation.  In this class of aggregate assembly, 
all monomers, and all aggregates, are equally capable of participating in an effective 
collision to form a larger particle.  There is no energy barrier to initiation of the 
aggregation reaction (as indicated by the relative sizes of the arrows).  (B)  Nucleated 
growth.   In this class of aggregate assembly, the overall reaction is limited by the 
energetically unfavorable formation of a critical species called the nucleus.  Once the 
nucleus begins to elongate by monomer addition, the aggregation reaction becomes 
essentially irreversible.  In this illustration, the nucleus is depicted as a special form of 
the monomer, but, classically, the nucleus is conceived as an oligomer; both appear to be 
possible.  More complex schemes are also possible.  For example, although spherical 
oligomers appear to form by downhill aggregation, their conversion to fibrils – if it 
happens – could be considered to be the nucleation event for amyloid formation, 
effectively drawing components of both A and B.  These schemes ignore the further 
complexity that aggregation reactions often require an initial misfolding of the monomer.  
This is not a concern for amyloidogenic peptides like Aβ and polyglutamine, however, 




The conversion of the protein into a fibril can be monitored by many means, 
including light scattering, ThT fluorescence, atomic force microscopy (AFM), electron 
microscopy (EM), and centrifugation coupled with high performance liquid 
chromatography (HPLC) (which is useful for following the disappearance of the 
monomeric species). Fibril formation is often preceded by a lag phase associated with the 
formation of a nucleus or other, oligomeric states. Once the nucleus has been established 
(rate-limiting step), the growth (elongation) of the fibril, by addition of either monomers 
[Lomakin et al. 1996; Lomakin et al. 1997; Collins et al. 2004; O'Nuallain et al. 2005] or 
oligomers [Kumar et al. 2007; Vestergaard et al. 2007] , occurs very rapidly.  Whatever 
the mechanistic source of the lag phase (nucleus formation, oligomer formation), it may 
be eliminated by the addition of preformed fibrillar seeds [Naiki et al. 1997; Serio et al. 
2000; O'Nuallain et al. 2005].  Experimental conditions as well as certain kinds of 
mutations have also been shown to decrease the lag phase [Uversky et al. 2002; Pedersen 
et al. 2004].  
AGGREGATE MORPHOLOGIES  
 As mentioned above, there are a variety of aggregate types and morphologies that 
go well beyond the amyloid designation.  Morphologies of protein aggregates in the 
literature include amyloid fibrils of various polymorphic states, spherical oligomers of 
various diameters, and linear and annular protofibrils.  The word ‘amorphous’ is 
sometimes applied to protein aggregates that do not easily fit into previously described 
definitions or exist in highly variable structures or which maintain their native-like state 
in the aggregate.  Proteins capable of making amyloid fibrils are often also capable of 
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making other aggregate morphologies, and it is frequently assumed – but rarely if ever 
proved – that there are precursor-product relationships between these forms. 
In 1996, Wood and colleagues discussed the effects of pH on the ability of the 
amyloid beta peptide to form aggregates [Wood et al. 1996]. Their results demonstrated 
that aggregates grown at physiologically relevant pH (7.4) exhibit characteristics of 
standard amyloid fibrils, i.e. a high affinity for Congo red, possessed twists along the 
longitudinal axis, were approximately 100 Å in width, as evidenced by EM, and were 
excellent seeds for fibril elongation. In contrast, aggregates produced at a more acidic pH 
(5.8) did not bind CR, were thicker and shorter (Figure 1.3), and were also poor seeds for 
further fibril formation.  
 In another example, IAPP (a 37aa peptide associated with the amyloid found in 
patients with Type II diabetes), amorphous aggregates were observed to form in vitro via 
EM from a full-length synthetic human IAPP peptide [Higham et al. 2000]. Within 24 
hours, these structures had completely converted into amyloid fibrils, which were 
confirmed not only by EM but also by ThT response, thus demonstrating the complicated 
nature of fibril formation.  
Within the last decade, new aggregate species have been identified. One of these 
species was named protofibrils by the authors who first described them [Harper et al. 
1997; Walsh et al. 1997]. Protofibrils are small, filamentous aggregates that appear early 
in fibril formation reactions. Their role in the mechanism of mature amyloid fibril 
assembly remains controversial, and may vary depending on the peptide involved [Kodali 














Figure 1.3: Electron micrographs of Aβ aggregates. (Images taken from [Wood, 
Maleeff et al. 1996]). (A) pH 7.4 Aβ(1-40) fibrils. 230µM peptide was incubated for 48 
hours at 37°C in phosphate buffered saline. (B) pH 5.8 Aβ(1-40) aggregates. 230µM 






components of mature fibrils and not intermediates observed during fibril assembly. 
Some protofibrils are annular in shape, and this has suggested a particular hypothesis for 
their cytotoxicity [Harper et al. 1997; Walsh et al. 1999; Lashuel et al. 2002].   
Another recently described aggregate is the class called spherical oligomers 
[Kayed et al. 2003].  These are sometimes referred to as ADDLs (Aβ diffusible ligands) 
[Lambert et al. 1998] or Aβ56* [Cheng et al. 2007].  The presence of various kinds of 
small, non-fibrillar Aβ aggregates in vivo has also been described [Roher et al. 1996; 
Cleary et al. 2005]. Oligomers and protofibrils have been identified in vitro in a host of 
protein systems, such as β-amyloid [Harper et al. 1997; Walsh et al. 1997; Kheterpal et 
al. 2003; Williams et al. 2005],  α-synuclein [Conway et al. 2000], transthyretin [Quintas 
et al. 2001], polyGln proteins [Poirier et al. 2002], β2-microglobulin [Gosal et al. 2005], 
and immunoglobulin light chain [Ionescu-Zanetti et al. 1999]. Although they have a 
distinct, non-amyloid morphology, some oligomers/protofibrils give a ThT response and 
have significant β-structure (but not so much as mature fibrils) [Kodali and Wetzel 2007] 
(See Figure 1.4). The identification of such species has led to the idea that these smaller 
structures are responsible for the toxicity observed in neurodegenerative disorders 
[Conway et al. 2001; Klein et al. 2001; Bucciantini et al. 2002; Walsh et al. 2002; 
Schaffar et al. 2004; Malisauskas et al. 2005; Glabe and Kayed 2006] 
  Although it is well documented that protofibrils exist, a question remains whether 
they are “on-pathway” [Harper et al. 1999; Serio et al. 2000; Plakoutsi et al. 2005; 
















Figure 1.4: Electron micrograph images of Aβ arctic mutant protofibrils and fibrils.  
(Images adapted from [Kheterpal et al. 2003]). (A) Aβ arctic mutant  protofibrils obtained 
16 hours post-incubation at room temp. (B) Negatively stained electron micrograph of 
mature Aβ arctic fibrils. The arctic mutant is an Aβ peptide mutation at E22G that is 




intermediates during the formation of fibrils. Several experiments conducted support both 
hypothesis (reviewed in [Kodali and Wetzel 2007]). 
A particular example supporting an “on-pathway” role of oligomers in fibril 
formation was demonstrated in a yeast prion model [Serio et al. 2000; Serio et al. 2001] 
where the Lindquist group showed that fluid oligomeric intermediates underwent a 
“conformational conversion” upon association with the nucleus. Once the interaction had 
been established, rapid assembly of an amyloid fibril ensued. Other evidence for “on-
pathway” fibril formation was demonstrated in the protein α/β acylphosphatase in 
Sulfolobus solfataricus [Plakoutsi et al. 2005] where early, enzymatically active 
aggregates were observed that had secondary structure but did not exhibit any β-structure 
by circular dichroism (CD) or fourier transform infrared spectroscopy (FTIR). As time 
progressed, these aggregates slowly converted to more amyloid-like structures: loss of 
enzymatic activity, contained extensive β-sheets, and were ThT and CR positive. 
Transmission EM also revealed that these latter aggregates contained structures 
reminiscent of spherical oligomers and protofibrils.  
Two other pieces of evidence that suggest that oligomer/protofibrils are “on-
pathway” intermediates come from polyglutamine diseases: Machado-Joseph Disease 
(MJD) [Ellisdon et al. 2006] and Huntington’s disease (HD) [Poirier, Li et al. 2002]. In 
the first example, MJD, it was shown that the ataxin-3 protein formed fibrils through a 
two-step mechanism [Ellisdon, Thomas et al. 2006], and that fibril formation was 
nucleation-dependent [Ellisdon et al. 2007]. The first step involved the formation of a 
protofibril within the Josephin domain of the protein, and the second step involved the 
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conversion of the protofibril to a fibril.  In the second example, HD, it was demonstrated 
that recombinant htt exon-1 fragments can be induced in vitro to form aggregates similar 
to the spherical oligomers and protofibrils described in other amyloid systems [Poirier et 
al. 2002; Wacker et al. 2004].  As in other amyloid systems, however, the mechanistic 
interrelationships between these various aggregated states and their possible roles in 
pathogenesis have not been established with certainty.  
Contrastingly are the reports of oligomer/protofibrils being formed “off-pathway” 
[Collins et al. 2004; Gosal et al. 2005]. The Weissman group performed kinetic studies 
that showed, in a yeast prion model, that amyloid formation occurred from monomer 
addition to a nucleus and that this pathway was separate and competitive with the 
formation of potentially toxic oligomers [Collins et al. 2004]. Other evidence supporting 
an “off-pathway” mechanism was demonstrated in vitro by the use of a recombinant β2M 
protein [Gosal, Morten et al. 2005] where two competing pathways were observed: a 
nucleation-dependent pathway leading to amyloid fibril formation and a rapid, 
nucleation-independent pathway yielding flexible “worm-like” fibrils.    
As suggested in a current study, the aggregation pathway, not surprisingly, may 
involve the formation of both “on-” and “off-pathway” intermediates [Thakur 
unpublished data]. In recent years it has become increasingly clear that the sequences 
flanking the polyGln region are very important in modulating aggregation. For example, 
it has been shown that the polyproline region, C-terminal to the Gln stretch, alters the rate 
of aggregate formation and destabilizes the aggregate but does not change the 
aggregation mechanism, i.e. aggregation still occurs in a nucleation-dependent 
17 
mechanism [Bhattacharyya et al. 2006]. More recently, the effects of the first 17 aa on htt 
aggregation have also been explored [Rockabrand et al. 2007; Thakur unpublished data]. 
Our group has found that the presence of htt’s first 17 aa rapidly accelerates polyGln 
aggregation, alters the aggregate morphology, and changes the aggregation mechanism 
(non-nucleated) [Thakur unpublished data]. For example, at least four morphologically 
different aggregates are formed. The earliest species appear to be recruitment-
incompetent oligomers/protofibrils, while the later species that are formed are 
recruitment-competent fibrils (reminiscent of the fibrils produced from synthetic peptides 
containing only polyGln or polyGln and polyproline). The mechanistic relationship 
between the various types of aggregates is not clear; however, the data suggest that some 
of the observed aggregates may be “on-pathway”, while other species may be “off-
pathway”.  
The exact role(s) that oligomers, “off-pathway” aggregates, and protofibrils play 
in disease pathogenesis is contentious and unresolved. As alluded in the previous 
paragraph, perhaps, there are multiple pathways by which amyloid fibrils can form, some 
directly producing amyloid from monomers, and some involving on-pathway 
intermediates like protofibrils. Some may involve toxicity, while others do not. Indeed, 
accessibility to these pathways may even be protein specific. Further research is needed 
to address these critical questions.  
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1.2 Polyglutamine diseases: 
OVERVIEW 
 The term neurodegenerative disease refers to any condition in which brain and/or 
spinal cord cells die or become dysfunctional.  These diseases are comprised of a 
multitude of illnesses involving, but not limited to, dementia and/or the loss of motor 
skills (ataxia). In the early 1990s, it was found that the expansion of an unstable 
trinucleotide repeat was associated with several related neurological disorders [Fu et al. 
1991; La Spada et al. 1991; Fu et al. 1992]. To date, at least 15 neurological disorders 
ranging from Huntington’s disease to forms of mental retardation occur due to a triplet 
codon (trinucleotide) expansion (Table 1.2). Each of the trinucleotide repeat disorders 
can occur in either the coding exon sequences (such as in the polyglutamine repeat 
diseases), spliced out of the intron sequences (such as in Friedreich’s ataxia), or in the 5’ 
or 3’ untranslated regions (as found in fragile X syndrome or myotonic dystrophy). A 
summary of these gene mutations are shown in Figure 1.5. Each mutation confers a 
different toxic effect, which will be discussed later in the chapter.  
Of these trinucleotide repeat disorders, at least nine are caused by an expansion of 
a polyglutamine sequence (polyGln) within their respective proteins (Table 1.3), with 
Huntington’s disease (HD) being the most common in the population. The remaining 
CAG repeat diseases are spinobulbar muscular atrophy (SBMA), dentatorubral-
pallidoluysian atrophy (DRPLA), and the spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7 and 
17.   
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Clinical features upon expansion 
(CGG)nFragile X syndrome 
(FRAXA) 
6-60 > 200 
Mental retardation, enlarged testes, 
connective tissue defects, 
behavioral abnormalities  
(CCG)nFragile XE mental 
retardation (FRAXE) 4-39 200-900 
Mental retardation 
(GAA)nFriedreich’s ataxia 
(FRDA) 6-32 200, 1700 






Myotonia, weakness, cardiac 
conduction defects, insulin 
resistance, cataracts, testicular 




syndrome (FXTAS) 6-60 60-200 
Ataxia, tremor, Parkinsonism, 
dementia 
(CTG)nSpinocerebellar ataxia 
8 (SCA8) 16-34 > 74 
Ataxia, slurred speech, involuntary 
eye movements 
(CTG)nHuntington disease-
like 2 (HDL2) 7-28 66-78 
Chorea, dystonia, cognitive deficits, 











Figure 1.5: Gene location of trinucleotide expansions. Green represents the start codon 
(ATG) at the beginning of an exon (gray). Red is representative of a stop codon (TAA) 
signaling the end of the coding region. The purple areas represent untranslated regions, 
and the dark blue represents non-coding intron regions. Huntington’s disease-like 2 (SCA 
12) is not shown; however, the mutation occurs in a non-coding spliced exon of the 
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Table 1.3: Polyglutamine neurodegenerative diseases. 
CAG repeat length 
Disease Gene locus Normal Pathological 







Xq13-21 9-36 38-62 
Motor weakness, 




disease (HD) 4p16.3 6-34 36-121 




ataxia 1 (SCA1) 6p23 6-44 39-82 
Ataxia, slurred speech, 
spasms, cognitive 
impairments 
SCA2 12q24.1 15-31 36-63 
Ataxia, polyneuropathy, 
decreased reflexes, infancy 




14q32.1 12-41 62-84 Ataxia, Parkinsonism, spasms 
SCA6 19p13 4-18 21-33 
Ataxia, difficulty in 
articulating, involuntary 
eye movements, tremors 
SCA7 3p12-21.1 4-35 37-306 Ataxia, blindness, infancy variant with cardiac failure 
SCA17 6q27 25-42 47-63 






12p13.31 6-36 49-84 Ataxia, seizures, choreoathetosis, dementia 
22 
For these expanded CAG repeat diseases, longer repeat expansions lead to earlier 
ages of onset and increased disease severity (Figure 1.6) [Gusella and MacDonald 2000]. 
In the remainder of this chapter, the polyGln diseases will be discussed with a particular 
emphasis on Huntington’s disease, the proposed mechanisms of cell dystrophy, and the 
model systems that have been created in order to study these devastating diseases. 
POLYGLUTAMINE DISEASE CHARACTERISTICS 
There are many similarities and differences among the various polyglutamine 
diseases. This section will summarize some of the characteristics found among these 
diseases. For instance, all of the polyglutamine diseases, except spinobulbar muscular 
atrophy (SBMA), which is X-linked recessive [Belsham et al. 1992; Ferlini et al. 1995], 
are dominantly inherited [Wilmot 1998]. Also the diseases generally occur during mid-
life and are progressive (see review by [Fischbeck 2001]), causing neuronal dysfunction 
and eventually neuronal death [Ross 1995; Taylor et al. 2002; Bates 2003]. The 
instabilities observed in these diseases occur in both germline and somatic cells 
(reviewed by [Bates 2002]). Especially in the case of HD, DRPLA, SCA1, and SCA3, 
somatic instabilities are generally higher in the central nervous system than in peripheral 
tissues [Telenius et al. 1994; Chong et al. 1995; Ueno et al. 1995; Lopes-Cendes et al. 
1996; Tanaka et al. 1996; Hashida et al. 1997; Cancel et al. 1998]. As repeat length 
increases, the disease progresses more rapidly and onset appears earlier (see review by 
[Gusella and MacDonald 2000]).  
GGA A 
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Figure 1.6: Observed inverse correlation between trinucleotide repeat expansion 
and age of onset.  (A) The longer the glutamine repeat the more complete penetrance and 
earlier onset. (B) Data compiled from the literature (Figure and Legend from [Gusella and 
MacDonald 2000]) were used to calculate the mean age at onset (denoted by ‘+’) 
associated with various CAG repeat lengths and the best-fit curve (denoted by a smooth 
line), using a simple exponential decay model for the relationship, in each of the 
polyglutamine disorders. The age of onset of homozygotes for the various disorders is 
also shown (filled circles), plotted according to the longer of their two expanded CAG 
repeats. (DRPLA, dentatorubropallidoluysian atrophy; HD, Huntington’s disease; MJD, 
Machado-Joseph disease; SBMA, spinal and bulbar muscular atrophy; SCA, 
































 Interestingly, the proteins produced in each disease are expressed ubiquitously 
throughout the brain and other tissues; however, only a subset of neurons appear to be 
affected (Figure 1.7 for selective summary) [Young 1998; Bates 2002]. Some of the 
diseases share overlap of the affected regions; however, there are also differences in the 
areas attacked. Table 1.4 summarizes the proteins produced, the cells affected and the 
area(s) of the cell where detectable aggregates accumulate. Similar pathological 
thresholds are observed for the CAG repeat disorders (~35-40 Gln repeats), excluding 
SCA-6, which has a slightly lower threshold [Bates 2002].  Because of these very similar 
expansion-threshold lengths, a common pathogenic mechanism involving the polyGln-
rich region has been suggested for these disorders [Cha and Dure 1994; Paulson and 
Fischbeck 1996].   
Another major characteristic shared by the polyGln disorders is the formation of 
insoluble nuclear and/or cytoplasmic aggregates, which exhibit a fibrillar morphology 
[DiFiglia et al. 1997] and can be detected with antibodies to the disease protein [Davies et 
al. 1997; Scherzinger et al. 1997], ubiquitin, or polyGln (1C2).  1C2 is an antibody that 
was originally raised against TATA binding protein (TBP) and selectively recognizes 
polyGln stretches on Western blots [Trottier et al. 1995].   
  As mentioned in the preceding section, expansion of the polyglutamine sequence 
in the CAG trinucleotide diseases occurs in the coding region of the genes, resulting in 
the transcription and translation of the gene into the protein product, which then becomes 
misfolded and prone to aggregate. It is widely accepted that the mechanism by which the 
polyGln expansion causes diseases is by imparting a toxic “gain of function” (GOF)  
 
Figure 1.7: Depiction of the brain pathology in five of the polyGln diseases. Darker 
shaded areas represent severe pathology where the lighter shaded areas indicate varying 




Table 1.4: Polyglutamine localization. 
Disease Protein product Expanded protein localization Affected cells 
SBMA Androgen receptor (AR) 
Nuclear / 
cytoplasmic 
Anterior horn and bulbar 
neurons, dorsal root 
ganglia, brainstem 
HD Huntingtin (htt) Nuclear / cytoplasmic 




SCA1 Ataxin-1 (At1) Nuclear / cytoplasmic 
Cerebellar Purkinje cells, 
dentate nucleus, inferior 
olive, brainstem 
SCA2 Ataxin-2 (At2) Cytoplasmic 
Cerebellar Purkinje cells, 
brainstem, fronto-temporal 
lobes, substantia nigra, 
inferior olive and pons 
SCA3 – 
MJD  Ataxin-3 (At3) 
Nuclear / 
cytoplasmic 
Cerebellar dentate neurons, 
basal ganglia, brainstem, 
spinal cord 
SCA6 Calcium channel (CACNAIA) 
Cytoplasmic/ cell 
membrane 
Cerebellar Purkinje cells, 
dentate nucleus, inferior 
olive, cerebellar granule 
cells 
SCA7 Ataxin-7 (At7) Nuclear / cytoplasmic 
Cerebellum, brainstem, 
macula, visual cortex, 
inferior olive 
SCA17 TATA box-binding protein (TBP) Nuclear 
Caudate nucleus, putamen, 
thalamus, frontal cortex, 
temporal cortex, Purkinje 
cells 
DRPLA Atrophin (drplap) Nuclear / cytoplasmic 
Cerebellum, cerebral 
cortex, basal ganglia, Luys 
body (subthalamic nucleus)
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mutation to the affected protein [Wilmot 1998; Bates 2002] that increases with longer 
Gln repeats [Ross 1997; Klockgether and Evert 1998; Evert et al. 2000].  Evidence 
suggests that the gain of function is the ability of the protein to access a non-native state 
that is toxic to neurons.  Supporting evidence for this discovery was presented by Ordway 
and colleagues who demonstrated that in an unrelated protein, hprt 
(hypoxanthine/guanine phosphoribosyltransferase), which exhibited an abnormal CAG 
expansion of 150 repeats, the polyGln tract was directly responsible for generating a 
similar late-onset, progressive, neurodegenerative disorder [Ordway et al. 1997]. This 
suggested that the polyGln tract was responsible for causing neuronal dysfunction and 
subsequent neurodegeneration and that the protein context played a role in defining other 
characteristics of the disease. Some groups interpret their data as indicating that toxicity 
is caused not by a gain of function but by the loss of normal protein function (LOF); this, 
however, is a much less widely-accepted theory [Zhuchenko et al. 1997; Cattaneo et al. 
2001; Katsuno et al. 2004].  
COMMON AMYLOID FEATURES 
 Polyglutamine proteins possess many of the same features as other amyloidogenic 
proteins (see Figure 1.8). Polyglutamine aggregates formed at 37°C have been shown to 
exhibit fibrillar morphology by EM that is comparable to an amyloid fibril [Scherzinger 
et al. 1997; Thakur and Wetzel 2002]. Earlier studies revealed huntingtin aggregates 
expressed in patient brains exhibited an apple green birefringence when stained with 
Congo red and examined using polarized light microscopy [Huang et al. 1998; McGowan 
et al. 2000], while other groups have found htt inclusions to be CR negative 
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Figure 1.8: Common amyloid features exhibited by polyglutamine peptides/proteins. 
(A) Electron micrographs of Q37 synthetic aggregates grown in PBS at 37 °C. (B) Aβ(1-
40) fibrils grown in PBS at 37 °C. A Hitachi 500 electron microscope was used to obtain 
images. Samples were adsorbed onto mica grids and stained with 0.05% potassium 
phosphor-tungstate (KPTA) solution. (Adapted from [Chen et al. 2002].) (C) Congo red 
birefringence of isolated Huntington’s disease frontal cortex. (D) Congo red 
birefringence of Alzheimer’s disease frontal cortex. C,D images were obtained via cross-
polarizers and light microscopy. (Taken from [Huang et al. 1998]). Both types of images 
represent the fibrillar morphology and presence of cross β-sheets.  
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[Karpuj et al. 1999]. However, other data has shown that many aggregates generated 
from a synthetic polyglutamine peptide, while efficient in binding Congo red, are much 
less efficient in displaying the green birefringence seen in other amyloid fibrils [Chen, 
Berthelier et al. 2002]. Polyglutamine aggregates (synthetic, fusion, or natural) also 
exhibit a ThT response [Chen et al. 2002; Ellisdon et al. 2006]. Another commonality 
between aggregates of simple polyGln peptides and other amyloid fibril systems is the 
presence of a lag phase during fibril growth (see above) (Figure 1.9) that can be 
shortened or eliminated by the addition of pre-formed fibrillar seed [Chen et al. 2002; 
Thakur and Wetzel 2002; Bhattacharyya et al. 2005]. Amyloid-like character is also 
suggested by the microstructure EMs of neuronal inclusions [DiFiglia, Sapp et al. 1997] 
and the abilities of aggregates in brain tissue and transformed cells to recruit monomeric 
polyglutamine molecules [Osmand et al. 2006]. Finally, the most important similarity is 
that polyglutamine aggregates also exhibit a cross-β structure, which is the hallmark of all 
amyloid proteins (Figure 1.10) [Perutz et al. 1994; Thakur and Wetzel 2002; Sharma et 
al. 2005].  
HUNTINGTON’S DISEASE 
  Huntington’s disease (HD) is a progressive autosomal dominant 
neurodegenerative disorder that was first characterized in the late 1800s by Dr. George 
Huntington and is the most common of the nine CAG repeat diseases.  Dr. Huntington 







Figure 1.9: Polyglutamine nucleation-dependent polymerization by monomer 
addition. ([Bhattacharyya et al. 2005]) An unfavorable folding event (nucleation) occurs 
with monomeric polyGln. Elongation occurs after an initial binding step to an extended 
conformational monomer. Subsequent monomer additions to the altered conformation 














Figure 1.10: Proposed structural models for polyglutamine proteins are comparable 
to amyloid proteins.  (A) Computer-generated structure of two paired anti-parallel β-
strands of polyGln linked together by main chain and side chain hydrogen bonds. (Taken 
from [Perutz, Johnson et al. 1994]). (B) β-sheet β-turn model of expanded polyGln.  Light 
blue – carbon, dark blue – nitrogen, red – oxygen. (Taken from [Ross et al. 2003]).   
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described the clinical manifestation of an illness (“hereditary chorea”) he observed 
among three families residing in New York.  Patients with the illness were described as 
having involuntary, jerky movements (chorea) and significantly retarded voluntary 
movements (bradykinesia), combined with cognitive impairment, and which had adult 
onset and an advancing development that was eventually fatal.  He also noted the 
hereditary nature of the disease.  Among people of European descent, the prevalence of 
the disease is 3-4 per 100,000 people, and it’s estimated that another 15-30 out of 
100,000 of the Caucasian population are at risk of developing the disease [Harper 2002].   
In 1983, the HD gene (interesting transcript, IT15) was mapped near the vicinity 
of a DNA marker, D4S10, located on chromosome 4p16.3 [Gusella et al. 1983].  The 
gene contains 67 exons and spans ~180 kb (Figure 1.11).   After 10 years of research, the  
genetic defect responsible for HD was found to be localized in the first exon of the IT15 
gene, which encodes a 350-kDa protein, huntingtin [Group 1993].  The disease-causing 
mutation is the expansion of an unstable, polymorphic CAG trinucleotide repeat within 
exon 1 of the HD gene.  This CAG repeat (found in the N-terminus) translates into a 
polyGln tract that is expressed in the huntingtin (htt) protein.  Located just downstream of 
the polyGln region there is also a proline-rich stretch containing approximately 21 
prolines.  The sequence of htt exon 1 is MATLEKLMKAFESLKSF(Q)n 
(P)11QLPQPPPQ AQPLLPQPQ(P)10GPA VAEEPLHRPKK. As discussed above for 
expanded CAG repeat diseases in general, polyGln repeat length is directly correlated to 
disease severity [Gusella and MacDonald 2000].  People who have a repeat length of 






Figure 1.11: Structure of HD gene and translated protein.  
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HD (See Figure 1.6 and 1.12).  There is an ambiguous CAG repeat length, 36-40, where 
some people develop the disease and others do not [Myers 1998].  As with the other 
polyGln diseases, there is an inverse correlation between repeat length and age of onset, 
where the longer the CAG repeat, the earlier the age of onset [Duyao et al. 1993] (see 
Figure 1.6).  
CHARACTERISTICS OF NORMAL AND EXPANDED HUNTINGTIN 
Huntingtin is a highly conserved protein that is expressed throughout the body 
and which has no functional homology to any known protein.  However, it has been 
shown that wildtype htt plays important roles in embryonic development including 
gastrulation [Duyao et al. 1995; Nasir et al. 1995; Zeitlin et al. 1995; Dragatsis et al. 
1998], neurogenesis [White et al. 1997; Reiner et al. 2003], and formation of 
extraneuronal tissue [Dragatsis et al. 1998]. In recent years, there has been growing 
evidence that normal htt is also involved in RNA biogenesis [Faber et al. 1998; Boutell et 
al. 1999; Passani et al. 2000; Takagaki and Manley 2000; Strehlow et al. 2007], 
membrane association and vesicle/protein trafficking [Li et al. 1995; Kalchman et al. 
1997; Wanker et al. 1997; Truant et al. 2006; Truant et al. 2007], and iron homeostasis 
[Hilditch-Maguire et al. 2000].  
Even though htt is ubiquitously expressed, the only known pathological changes 
that occur in HD are specific to the brain and are characterized by selective neuronal 
degeneration and loss [Ross 1995; Huq 1998; Bates 2002].  The most striking atrophy 
occurs in the caudate nucleus and putamen, which together form the neostriatum within 
the basal ganglia.  A secondary effect due to caudate atrophy is an enlargement in the  
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Figure 1.12: Distribution of HD CAG repeat lengths on normal and HD chromosomes. Histogram plot of HD CAG repeat 
sizes found on the1212 normal chromosomes (black bars) and 1212 HD chromosomes (red bars), from the same individuals, 

















































































































































































































lateral ventricles. Other than these major affected areas, there is 10-20% overall 
deterioration of the brain.  The reduction occurs in the cerebral hemispheres, the 
cerebellum, the brainstem, the diencephalons, and the spinal cord [Forno 1979].   
Loss of neurons in both the putamen and caudate show a gradient correlating to 
disease progression [Bruyn 1979; Roos et al. 1985; Vonsattel et al. 1985; Myers et al. 
1988; Heinsen et al. 1994].  To determine the severity of neurodegeneration, a grading 
scale of 0 to 4 (mild to severe), based on microscopic and gross deterioration of the basal 
ganglion, was created so that a patient could be graded semiquantitatively on the severity 
of the disease (Figure 1.13) [Vonsattel et al. 1985; Myers et al. 1988].   Also, there is a 
severe loss in the medium-sized spiny neurons (MSNs) but a preservation of the large 
striatal neurons [Cicchetti et al. 2000].  MSNs are inhibitory projection neurons that 
encompass more than 95% of the neuronal cells in the striatum and use γ-aminobutyric 
acid (GABA) as their neurotransmitter. Other than the basal ganglion, the next most 
severely affected region is the cerebral cortex, with the greatest loss in layer VI and 
significant loss in layers III and V [de la Monte et al. 1988].    
At the subcellular level, normal length huntingtin is most often localized in the 
cytoplasm as a soluble protein; however, aggregates arising from the expanded form are 
often found in the nucleus as well as the cytoplasm. As mentioned previously, the 
expanded protein accumulates into insoluble, fibrillar aggregates [Davies et al. 1997; 
Scherzinger et al. 1997] that primarily contain N-terminal htt fragments that leads to 
pathology [DiFiglia et al. 1997; Sapp et al. 1997; Gutekunst et al. 1999]. A hallmark of 




Figure 1.13: Huntingtin accumulation causes neurodegeneration of the brain. (A) 
Normal brain section of the caudate nucleus, nucleus accumbens, and putamen. (B-D) 
Progressive neuronal loss of HD patients’ brain sections as graded via the Vonsattel 
method. (B) early HD grade 2, (C) mid HD grade 3, (D) late HD grade 4.  (Images taken 











[Davies et al. 1997; DiFiglia et al. 1997; Gutekunst et al. 1999; Sieradzan et al. 1999; 
Wheeler et al. 2000].   NII have been found in the MSNs of the striatum but are most 
prevalent in the large striatal neuron, which do not undergo neurodegeneration 
[Kuemmerle et al. 1999]. Moreover, NII are rarely observed in neurons of the globus 
pallidus and cerebellum [Gutekunst et al. 1999]. In general, NIIs range from 3 – 5µm in 
diameter and generally adopt one of two shapes: the majority are spherical (55%); while 
the remainder are elliptical (ovoid) [DiFiglia et al. 1997; Becher et al. 1998; Gutekunst et 
al. 1999].  
Other aggregated states of huntingtin, besides NII, have been described.  Neuropil 
aggregates (NA) localize in the white matter outside of discernable cell bodies and are 
assumed to be located in the axons, dendrites, and synapses. They tend to be round to 
oval in shape [DiFiglia et al. 1997; Gutekunst et al. 1999] and are typically larger than 
NII. Both NII and NA have been shown to stain positively for ubiquitin (an indication 
that the protein has been targeted for degradation [Alves-Rodrigues et al. 1998; Sieradzan 
et al. 1999]) and CREB binding protein (CBP) (which also contains a polyGln tract and 
therefore indicates that huntingtin inclusions can sequester other polyGln-containing 
proteins) [DiFiglia et al. 1997; Preisinger et al. 1999; Nucifora et al. 2001]. Another class 
of aggregates, often seen in conjunction with NII, is perikaryal aggregates. This type of 
aggregate is generally smaller (0.3 – 1.5µm) than the NII and exhibit a round to oval 
appearance [Gutekunst 2002]. However, these structures are found in a perinuclear 
location [Huang et al. 1998; Heiser et al. 2000].  Each of these types of aggregates have 
been shown to exihibit Congo red blue-green birefringence, again suggestive of an 
38 
amyloid-like structure [McGowan et al. 2000]. In vitro data have shown that it is possible 
to produce both detergent-soluble [Muchowski et al. 2000] and detergent-resistant htt 
aggregates [Cooper et al. 1998; Kazantsev et al. 1999; Chen et al. 2001], with the latter 
representing end-stage aggregates.  
It has long been recognized that the aggregation and deposition of misfolded 
proteins are the pathological hallmarks for many neurodegenerative diseases [Ross and 
Poirier 2005]. However, the presence of these inclusion bodies correlate poorly with 
other neurodegenerative characteristics [Terry et al. 1991; Tompkins and Hill 1997], 
especially in HD [Gutekunst, Li et al. 1999], introducing questions about the role of 
aggregates in the disease process. It has been hypothesized that inclusion bodies may 
represent an end stage structure in a multi-step aggregation process [Ross and Poirier 
2005] and that early events, including the formation of misfolded monomers [Weissmann 
2005; Nagai et al. 2007] or soluble oligomeric/protofibrillar intermediates [Poirier et al. 
2002; Bucciantini et al. 2004; Katsuno et al. 2004; Wacker et al. 2004; Mukai et al. 
2005], which directly arise from the presence of an expanded polyGln sequence, may be 
responsible for cellular toxicity. However, there is no consensus on what the toxic species 
is, whether the intermediates are “on-pathway” or “off-pathway”, or the precise role of 
aggregation in the disease mechanism. 
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1.3 Disease Mechanisms in Huntington’s Disease: 
OVERVIEW 
Despite the fact that the genetic abnormality is well characterized, the underlying 
mechanism of neurodegeneration in Huntington’s disease has not yet been unequivocally 
elucidated [Ross et al. 1999; Ross 2002; Ross 2004; Bett 2006].  A schematic 
representation of the proposed pathogenic mechanisms is shown in Figure 1.14. The 
widely accepted view is that the HD mutation causes a toxic gain of function, where the 
aberrant protein inherits additional properties that render it cytotoxic [Ross 1997; Wilmot 
1998; Bates 2002]. Alternatively, there may be a loss of normal htt functionality that 
results in neurodegeneration [Cattaneo et al. 2001].  In support of a loss of function 
mechanism, huntingtin gene expression must be required for normal development, since 
huntingtin knock-out mice die early in embryogenesis [Duyao et al. 1995; Jones 2002]. 
At the same time, several lines of evidence argue against loss-of-function being the major 
disease mechanism.  Patients homozygous for the HD mutation are not more severely 
affected than patients who are heterozygous for the mutation [Wexler et al. 1987; Myers 
et al. 1989], and a patient with only one viable copy of the normal polyGln length htt 
gene did not develop HD [Ambrose et al. 1994]. Several gain of function hypotheses are 
described in greater detail in this section. 
Compounding the difficulty in identifying the toxic species is the critical issue of 
establishing the nature of the cellular events that are associated with HD symptoms.  
Should we be looking for overt cell death, or for more subtle sub-lethal dystrophic events 
 
Figure 1.14: Model representing modes of HD cellular pathogenesis. (Taken from 





that are more difficult to observe and quantify?  The brain atrophy evident at autopsy is a 
clear indication that cell death occurs during the development of HD, but does this 
account for early symptoms or is it only an end-stage event?  Is the loss of cell mass 
really due to cell death or to cell shrinkage?  Are there earlier events in HD progression, 
such as synaptic loss and neurite retraction that are responsible for disruptions in 
neuronal circuitry associated with abnormal motor neuron function?  Clearly, identifying 
and validating the molecular species responsible for HD requires a correct perspective on 
the abnormal biology behind the disease symptoms and progression, and the lack of 
certainty on these central questions contributes to our inability to define the key 
molecular players. 
EXPANDED HUNTINGTIN AGGREGATE FORMATION 
  Many researchers believe that some aspect of polyGln protein misfolding and 
aggregation is an early, necessary event in HD pathogenesis. It has been shown that  
directing the aggregate to the nucleus by introducing a nuclear localization signal (NLS) 
causes cellular toxicity [Cooper et al. 1998; Hackam et al. 1999; Yang et al. 2002]. 
Furthermore, numerous experiments have demonstrated that a reduction in aggregate 
burden can rescue neuronal damage [Yamamoto et al. 2000; Kazantsev et al. 2002]. In 
contrast, several lines of evidence suggest that protein aggregation is not directly linked 
to disease pathogenesis, in that aggregate burden does not always correlate well with cell 
death [Cummings and Zoghbi 2000; Tobin and Signer 2000].  It is possible, however, 
that good correlations are not always observed because the genuinely toxic aggregate 
species are not observable or quantifiable.  Furthermore, it is possible that htt inclusions 
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offer protection against neurotoxic effects by sequestering smaller, potentially more toxic 
oligomers [Kopito 2000].  A number of mechanisms of aggregate toxicity have been 
postulated, and these will be reviewed below.  The strong indications of a central, early 
role for htt aggregates in the disease mechanism argues for a closer look at the nature of 
the aggregated species in the cell.  In addition, regardless of their role in pathogenesis, 
aggregates are a hallmark of HD and deserve attention on that basis alone. 
TOXIC FRAGMENT HYPOTHESIS 
  One theory regarding the pathogenic mechanism of HD is the “toxic fragment 
hypothesis”, which suggests that following proteolytic processing, full-length mutant htt 
generates N-terminal fragments that accumulate and aggregate in the nucleus leading to 
toxicity [DiFiglia, Sapp et al. 1997; Martindale et al. 1998; Saudou et al. 1998]. Full-
length htt contains several proteolytic cleavage sites within the first five exons (Figure 
1.15) [Li and Li 2004], which are sensitive to caspase-3, calpain, and aspartic 
endopeptidase cleavage. Caspases are enzymes that play essential roles in apoptosis and 
inflammation. Calpains are a group of calcium-dependent cysteine proteases. Aspartic 
endopeptidases are another class of intracellular proteases. Recently, it was shown that 
mutation of two calpain cleavage sites in mutant htt renders the protein less susceptible to 
proteolytic cleavage and reduces cell toxicity in an in vitro cell culture model [Gafni et al. 
2004]. N-terminal mutant htt fragments have been shown to be more toxic in model 
systems than their full-length protein counterpart [Hackam et al. 1998; Lunkes and 
Mandel 1998; Martindale et al. 1998; Lunkes et al. 2002]. It has been proposed that the 












Figure 1.15: Proteolytic processing of full-length mutant huntingtin generates 
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aggregates in the nucleus [Lunkes and Mandel 1998; Martindale et al. 1998; Hackam et 
al. 1999; Li et al. 2000].  This hypothesis, as far as it goes, accounts for the localization 
of aggregates in the nucleus, but does not offer any clues to why aggregates might be 
toxic.  The remaining portions of this section deal with this issue. 
TRANSCRIPTIONAL DYSREGULATION / RECRUITMENT-SEQUESTRATION 
It is known that expanded htt aggregates can recruit proteins, such as certain 
transcription factors and co-factors, in a polyGln-mediated manner (See Table 1.5) 
[Davies, Turmaine et al. 1997; DiFiglia, Sapp et al. 1997; Scherzinger, Lurz et al. 1997; 
Jiang et al. 2003], thus sequestering them and compromising their ability to function  
normally.  This recruitment and sequestration provides an attractive mechanism for 
cellular dysfunction. PolyGln-specific sequestration is likely mediated by the ability of 
amyloid-like polyGln aggregates to highly selectively elongate via recruitment of other 
polyGln sequences into the growing aggregate  [Chen et al. 2001]. This model is the basis 
of the recruitment-sequestration hypothesis. In the past decade, it has also become 
increasingly clear that several transcriptional pathways are altered in mouse models of 
HD as well as patients with Huntington’s disease [Cha 2000; Luthi-Carter et al. 2000; 
Luthi-Carter et al. 2002], and recruitment of transcription factors is one mechanism by 
which this might occur.   
Two well characterized examples where polyGln-containing transcription factors 
have been shown to be sequestered by htt aggregates will be discussed. In the first 
example, TATA binding protein (TBP), an essential polyGln containing transcription  
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Table 1.5: Huntingtin-interacting proteins. 
Protein Possible cellular role Reference 




localization with NIIs 
[Huang et al. 1998; Boutell 
et al. 1999; Kazantsev et al. 
1999; Steffan et al. 2000; 
Nucifora et al. 2001] 




Transcriptional repressor complex. 
Cellular localization altered in HD 
brain  
[Boutell et al. 1999; Jones 
1999] 
SP1 and TAFII130 
Transcriptional activator and co-
activator [Dunah et al. 2002] 
BDNF Neurotrophic factor required for striatal neuronal survival [Zuccato et al. 2001] 
HAP1 Cytoskeletal, microtubule, and vesicle functions [Li et al. 1995] 
HIP1 Cytoskeletal, microtubule, and vesicle functions 
[Kalchman et al. 1997; 
Wanker et al. 1997; 
Singaraja et al. 2002] 
α-Adaptin Cytoskeletal, microtubule, and vesicle functions  
[Faber et al. 1998; Gusella 
and MacDonald 1998] 
Caspase-3 Apoptotic pathway [Goldberg et al. 1996] 
HIP2 Ubiquitin-conjugating enzyme [Kalchman et al. 1996] 
GAPDH Glycolytic enzyme [Burke et al. 1996] 
Cystathionine β 
synthase Amino acid metabolism 
[Boutell et al. 1999; Jones 
1999] 
Calmodulin Intracellular calcium binding and sensing [Bao et al. 1996] 
HYP A, B, and C 
Non-receptor signaling, protein 
degradation, and pre-mRNA 
splicing. Interaction enhanced by 
lengthening of polyGln tract 
[Faber et al. 1998; Passani 
et al. 2000] 
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factor involved in the separation of double stranded DNA, was found to interact with 
mutant N-terminal htt in a polyGln-dependent manner and was recruited into the 
polyglutamine aggregates [Schaffar et al. 2004]. In vivo, TBP has also been shown to be 
present in HD inclusions [Huang et al. 1998]. 
Secondly, cAMP response element (CRE)-regulated genes have been implicated 
in HD pathogenesis [Wyttenbach et al. 2001; Sugars et al. 2004]. The cAMP response 
element-binding protein (CREB) binds the CRE promoter, and upon phosphorylation, 
recruits the polyGln-containing co-activator CBP. This is an essential process in genetic 
transcription. It has been shown that CBP can be recruited into polyglutamine aggregates 
in multiple model systems, as well as in HD patients [Kazantsev et al. 1999; Steffan et al. 
2000; Nucifora et al. 2001]. Therefore it is easy to imagine how aberrant interactions with 
such vital transcription factors can lead to cellular dysfunction. For example, it was 
demonstrated that mutant N-terminal htt directly interacts with and inhibits the 
acetyltransferase activity (responsible for histone acetylation) of CBP and p300/CBP-
associated factor. Furthermore, the reduction can be reversed by treatment with histone 
deacetylase (HDAC) inhibitors [Steffan et al. 2001; Bodai et al. 2003].  In an elegant 
demonstration of the important role of CBP sequestration in cell death, the Ross group 
showed that recruitment of endogenous CBP into exon1 aggregates killed cells, but that 
over-expression of a CBP molecule lacking the polyGln stretch protects cells from this 
recruitment, presumably by being impervious to recruitment and by providing the 
functions of the recruited endogenous CBP [Nucifora et al. 2001]. 
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Another transcriptional pathway that has been shown to be dysfunctional in HD 
involves the interaction of normal htt and repressor element 1 transcription factor–
neuron-restrictive silencer factor (REST-NRSF) [Boutell et al. 1999; Holbert et al. 2001; 
Zuccato et al. 2001; Dunah et al. 2002], which is a transcriptional repressor responsible 
for binding neuron-restrictive silencer elements (NRSEs) in the nucleus. This pathway is 
implicated in the transcription of neuroprotective proteins such as brain-derived 
neurotropic factor (BDNF) [Zuccato, Ciammola et al. 2001]. When htt becomes 
expanded, it fails to bind properly, resulting in the accumulation of REST-NRSF in the 
nucleus, and the transcriptional repression of genes regulated by NRSEs [Zuccato et al. 
2003]. This further supports the hypothesis that mutant htt can interfere and dysregulate 
normal transcriptional processes leading to pathology and ultimately toxicity.  
The recruitment-sequestration mechanism is a favored explanation to describe the 
interference of mutant htt in various transcriptional processes, where the expanded 
protein is thought to play a role in recruiting vital proteins from their normal locations 
and depositing them either in htt inclusions or other abnormal cellular locations thereby 
rendering them unable to perform their normal functions.  It is easy to imagine how these 
interactions can contribute to cellular dysfunction.  
TOXICITY DUE TO COMPROMISING PROTEIN QUALITY CONTROL  
Chaperones 
The dominating presence of htt inclusion bodies throughout brains of various HD 
model systems suggests that the aggregated protein somehow escapes the many quality 
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control systems within a cell. The first of those mechanisms is chaperone proteins. 
Chaperone proteins are known to assist proteins in folding to their native conformations, 
help to refold abnormally folded proteins, and to liberate proteins from an aggregated 
protein in both normal and stress conditions [Hartl 1996]. Many molecular chaperones 
are also heat shock proteins (Hsps), which are expressed in response to an environmental 
stress [Lodish 2004]. Two major classes of molecular chaperones are Hsp70 and Hsp40, 
which jointly act in an ATP-dependent manner to properly fold misfolded proteins [Bett 
2006].  
 Chaperone proteins are often found localized within polyGln aggregates in HD 
transgenic mice [Jana et al. 2000; Hay et al. 2004] as well as brains of patients with 
polyGln diseases [Alves-Rodrigues et al. 1998; Cummings et al. 1998; Chai et al. 1999; 
Schmidt et al. 2002]. These findings indicated that aggregated polyGln proteins were 
recognized as misfolded, and therefore, much attention was given to understanding the 
roles of molecular chaperones in the disease process. The two most studied chaperones in 
HD are Hsp70 and Hsp40. Several studies have been performed in which these two 
molecular chaperones were overexpressed [Cummings et al. 1998; Warrick et al. 1999; 
Chan et al. 2000; Jana et al. 2000; Kobayashi et al. 2000; Sittler et al. 2001; Zhou et al. 
2001]. The results indicate that the overexpression of the Hsp70 and Hsp40 combination 
in cell cultures profoundly inhibited polyGln aggregation and that this correlated with a 
decrease in cellular toxicity [Cummings et al. 1998; Jana et al. 2000; Kobayashi et al. 
2000; Sittler et al. 2001; Zhou et al. 2001]. It was also shown that overexpression of 
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Hsp70 in Drosophila suppressed neurodegeneration [Warrick et al. 1999], and the effect 
was more dramatic when both Hsp70 and Hsp40 were overexpressed [Chai et al. 2001].  
Another interesting observation was that Hsp40 and Hsp70, when expressed in 
cell-free and yeast systems, altered the biochemical properties of mutant polyGln 
proteins, rendering the aggregates more soluble than previously described as well as 
delayed the formation of ordered-amyloid fibrils [Muchowski, Schaffar et al. 2000].  
Furthermore, addition of the chaperones to in vitro polyGln aggregation reaction was 
only effective when they were added during the lag phase, suggesting that chaperones 
were most active on earlier forming species rather than the inclusions themselves 
[Muchowski et al. 2000; Wacker et al. 2004].  Yet further data suggesting the importance 
of molecular chaperones in the disease mechanism was provided by the Hartl group in 
2004. They showed that in vitro the Hsp70/Hsp40 combination was effective in inhibiting 
the negative interactions of expanded htt and TBP [Schaffar et al. 2004]. With the 
substantial data presented, one can see the importance of molecular chaperones in HD.  
Ubiquitin-Proteasome System 
The ubiquitin-proteasome system (UPS) is responsible for regulating protein 
turnover and is vital for many cellular processes, including differentiation, antigen 
presentation, cell survival, cell cycle control, as well as the elimination of misfolded or 
damaged proteins [Ciechanover 1994]. The proteasome is barrel-shaped multiprotein 
complex that is responsible for the breakdown and clearance of short-lived nuclear and 
cytosolic proteins as well as ubiquitin-tagged misfolded proteins [Ciechanover 2006]. 
Degradation by the UPS involves many successive steps. First, the misfolded proteins are 
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tagged for clearance by the covalent attachment of a polyubiquitin chain. This 
conjugation is ATP-dependent and typically involves three enzymes: ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3). 
Together these enzymes compose the ubiquitin ligase system [Hershko and Ciechanover 
1998; Taylor et al. 2002]. With the linkage of four or more ubiquitin molecules to the 
substrate, a recognition signal is generated that allows the substrates to be shuttled to the 
proteasome, via escort and chaperone proteins, where they are degraded [Hershko and 
Ciechanover 1992; Jentsch 1992; Richly et al. 2005; Weihl et al. 2006].     
HD inclusion bodies have been shown to be ubiquitinated, suggesting that the 
UPS has targeted the aggregated proteins for degradation [Alves-Rodrigues et al. 1998; 
Cummings et al. 1998; Chai et al. 1999; Sieradzan et al. 1999; Waelter et al. 2001]. Both 
Hsp40 and Hsp70 chaperones have been shown to be involved in the clearance of 
misfolded proteins via the UPS [Bercovich et al. 1997].  However, once the polyGln-
containing proteins have appreciably aggregated, they appear to be resistant to 
degradation by the UPS [Cummings et al. 1999; Verhoef et al. 2002]. It has been 
suggested that impairment may be a direct result of the misfolded polyGln proteins 
getting ‘trapped’ within the proteasome [Jana et al. 2001; Holmberg et al. 2004] or the 
inability of the proteasome to cleave between successive Gln residues [Goellner and 
Rechsteiner 2003; Holmberg et al. 2004; Venkatraman et al. 2004], therefore limiting its 
normal activity. However, data have shown that impairment of the proteasome can occur 
in the absence of visible aggregates, suggesting other factors, such as the presence 
soluble, potentially toxic species, also contribute to this impairment [Bennett et al. 2005].  
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Other supporting evidence for the impairment of the UPS by polyGln aggregates 
was provided by the Kopito lab, in which they used two non-related aggregating proteins 
(Q103-GFP and CFTR-GFP) [Bence et al. 2001]. In both instances, they utilized a 
fluorescence-based measurement for UPS activity, where higher fluorescence intensities 
indicated a more severe disruption of UPS activity. In each case, protein aggregation led 
to the accumulation of intracellular ubiquitin and, thus, cell cycle arrest. This impairment 
yielded an increase in aggregate production, which was suggested, may result in the 
increase of the ubiquitin conjugates [Mayer et al. 1989] and other UPS substrates that are 
aberrantly expressed in diseased neurons [Raina et al. 2000]. Therefore, as more protein 
accumulated, the UPS became more impaired.   
Autophagy-Lysosome Pathway 
Another commonly proposed mechanism by which aggregate-prone proteins are 
removed is through the autophagy-lysosome pathway, which is induced by a stress 
response. Autophagy is a process that involves bulk degradation of the cell’s own 
components through encapsulation and enzymatic processing. There are three primary 
forms of autophagy: macroautophagy, microautophagy, and chaperone-mediated 
autophagy. Macroautophagy, typically referred to as autophagy, is the most common 
form and occurs after an induction signal (often stress) when a flat membrane cistern 
engulfs a portion of the cytoplasm, forming a double membrane vacuole 
(autophagosome) [Williams et al. 2006]. After vacuole formation, the autophagosome 
fuses with a digestive lysosome, which is responsible for the breakdown. Ultimately, the 
breakdown products are returned to the cytoplasm [Klionsky and Ohsumi 1999; 
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Stromhaug and Klionsky 2001; Mizushima 2004]. Microautophagy, which has been 
characterized the least, involves the invagination of the lysosomal membrane to sequester 
portion of the cytoplasm for degradation [Kim and Klionsky 2000]. Chaperone-mediated 
autophagy, in contrast to the other two forms, is more selective and involves the direct 
translocation of cytosolic proteins containing a specific pentapeptide sequence motif to 
the lysosome [Massey et al. 2004].  
Because it was demonstrated that aggregated htt is inefficiently degraded by the 
UPS [Verhoef et al. 2002], it was proposed that the autophagy-lysosome pathway may be 
responsible for the clearance of aggregated polyGln proteins [Qin et al. 2003; Ravikumar 
et al. 2003; Webb et al. 2003; Iwata et al. 2005; Berger et al. 2006; Shibata et al. 2006]. 
Clearance by this pathway is proportional to polyGln repeat length, and wild-type 
proteins are less susceptible to autophagy than the mutant form [Ravikumar et al. 2002; 
Webb et al. 2003; Berger et al. 2006]. It was shown that inhibiting autophagy increased 
the accumulation of aggregates thereby inhibiting the clearance of mutant htt [Qin et al. 
2003; Ravikumar et al. 2004], and enhancing autophagy resulted in the more rapid 
clearance of both soluble and aggregated species of expanded htt [Williams, Jahreiss et 
al. 2006].  
Aggresomes 
When aggregated proteins are unable to be degraded or refolded by the normal 
quality control mechanisms, the cells can sequester aggregates by a microtubule-
mediated process and transport them to a cytoplasmic site near the centrosomes [Johnston 
et al. 1998; Ross and Poirier 2005]. These structures are referred to as aggresomes. 
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Clearance of the aggresomes is often accomplished through autophagy. The protein 
within an aggresome is largely surrounded by a structural protein known as vimentin 
[Johnston, Ward et al. 1998]. Aggresome formation involves the trafficking of mutant 
proteins and the rearrangement of intermediate filaments around the perinuclear inclusion 
[Kopito 2000]. 
Data suggests that inclusion body formation, containing htt and molecular 
chaperones, primarily occurs due to this inability to be degraded by the normal protein 
quality control systems. It has been suggested that these inclusions, aggresomes, which 
generally have a perinuclear location, are similar in structure to cystic fibrosis 
transmembrane conductance regulator (CFTR) aggresomes [Johnston, Ward et al. 1998] 
that occur when the proteasome’s degradative capacity is exceeded. Aggregates 
expressed in transiently transfected cell models of HD have many characteristics 
reminiscent of aggresomes [Qin et al. 2003]. Several groups have shown that inhibiting 
microtubule polymerization inhibits the formation of aggresomes [Johnston et al. 1998; 
Garcia-Mata et al. 1999; Webb et al. 2004].  One interesting possible mechanism of cell 
dysfunction caused by aggregation involves the normal cellular trafficking of aggregates 
to the perinuclearly located aggresome [Chang et al. 2006].  Thus, the inability of 
mitochondria to be correctly trafficked through the neuronal processes along 
microtubules, which are also involved in shuttling aggregates, could lead to energy 
starvation at the synapse and synaptic retraction. 
Whether or not the aggregates themselves are toxic remains to be answered. 
However, a substantial amount of evidence has shown that aggregates are both handled 
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by, and can impair, normal protein quality control mechanisms [Hartl 1996; Cummings et 
al. 1998; Johnston et al. 1998; Chai et al. 1999; Jana et al. 2001; Waelter et al. 2001; 
Ravikumar et al. 2002; Verhoef et al. 2002; Qin et al. 2003; Holmberg et al. 2004; 
Schaffar et al. 2004]. It is therefore important to continue the search for the toxic species 
and to investigate each of their roles in cellular dysfunction and death.  
TOXICITY BY AXONAL TRANSPORT IMPAIRMENT 
Another important development in unfolding the mystery of HD pathogenesis, 
was the discovery that htt localizes with microtubules and synaptic vesicles suggesting a 
role in vesicle trafficking by axonal transport [Gutekunst et al. 1995; Lee et al. 2004; 
Webb et al. 2004; Gunawardena and Goldstein 2005; Truant et al. 2006]. Axonal 
transport is a microtubule-dependent system that is responsible for the movement of 
various cargo, such as mitrochondria, proteins, lipids, and synaptic vesicles, to and from 
the cell body [Feany and La Spada 2003; Chang et al. 2006]. 
Pertinent to this idea, was the detection of two significant cytoskeletal associated 
proteins that interact with htt, huntingtin-interacting protein (HIP1) and huntingtin-
associated protein (HAP1) [Li, Li et al. 1995; Kalchman et al. 1997].  It has been reported 
that mutant htt binds antagonistically to synaptic vesicles decreasing the association of 
HAP1 resulting in a decrease in glutamate release in HD mouse brain sections [Li et al. 
2003]. It was also shown that HIP1 has a decreased affinity for htt with expanded 
polyGln suggesting that HIP1 and htt interactions may be crucial for cellular function 
[Kalchman, Koide et al. 1997].  Data available on both of these interacting proteins 
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suggest a loss of function mechanism and will not be further addressed in this 
dissertation. 
  The presence of htt inclusion bodies are well documented in human HD patients 
[DiFiglia et al. 1997; Gutekunst et al. 1999] as well as in various other models of HD 
[Lunkes and Mandel 1998; Hollenbach et al. 1999; Kazantsev et al. 1999; Bates 2002; 
Rubinsztein 2002; Bates 2003; Feany and La Spada 2003; Marsh et al. 2003; Thompson 
and Marsh 2003; Gunawardena and Goldstein 2005; Chang et al. 2006]. Often these 
inclusions are found associated with microtubules [Tukamoto et al. 1997; Muchowski et 
al. 2002; Trushina et al. 2003; Webb et al. 2004; Iwata et al. 2005; Chang et al. 2006; 
Truant et al. 2007], suggesting a role for the impairment of axonal transport in HD.  
It has been shown that in a Drosophila model expressing N-terminal htt 
fragments, inclusion bodies are formed in axonal processes and organelle accumulation is 
also present, suggesting a blockage of axonal transport [Gunawardena et al. 2003], which 
may be a direct result of the presence of the large aggregates and their ability to sequester 
vital polyGln-containing proteins necessary for axonal transport [Lee et al. 2004]. It was 
also recently shown, in a primary neuronal culture, that the presence of expanded htt 
aggregates was responsible for impairing mitochondrial trafficking, causing an 
accumulation of mitochondria, while aggregate-free sites were unaffected [Chang et al. 
2006]. Thus, the concept of impaired axonal transport by the presence of htt inclusions 
can undoubtedly be imagined.  
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TOXICITY CAUSED BY EXCITOTOXICITY AND OXIDATIVE STRESS 
It has also been suggested that calcium-dependent, glutamate-mediated 
excitotoxicity plays a pivotal role in HD pathogenesis [Greene and Greenamyre 1996; 
Tabrizi et al. 1999]. This mechanism will not be described in significant detail.  Briefly, 
this theory proposes that subpopulations of striatal neurons (MSNs) become sensitive to 
glutamate release due mainly to changes in N-methyl-D-aspartate (NMDA) receptors 
[Freese et al. 1990], which can be correlated to neuronal death [Olney et al. 1971].    
  There has been a tremendous amount of data that demonstrates mitochondria 
dysfunction in HD (reviewed in [Lin and Beal 2006]). For example, htt has been shown 
to be associated with mitochondria in both truncated and full-length mutant htt models 
[Gutekunst et al. 1998; Panov et al. 2002; Yu et al. 2003; Choo et al. 2004], thus 
suggesting another impairment of normal cell processes by the presence of these 
inclusions.  
This section has addressed the various mechanisms by which Huntington’s 
disease pathogenesis is thought to occur. Some central questions surrounding HD are 
whether or not the aggregated proteins are themselves toxic, if the aggregation process is 
responsible for toxicity, or if early or later cellular events trigger dystrophy. While many 
theories have been posed, the exact mechanism is still unknown and the toxic species 
have not been identified. However, the disease mechanism is likely to involve several 
factors and multiple pathways that ultimately lead to cellular dysfunction and death.  
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1.4 Model Systems: 
OVERVIEW 
 HD is a late-onset disorder, and therefore, the changes that are observed in the 
patients’ brains are likely representative of late-stage pathological events or in 
combination with some early-stage pathogenesis. However, the limited availability of 
pre-symptomatic and early-stage HD patient material has made it difficult to study the 
exact causes of neurodegeneration in situ. Considering HD lesions are localized in the 
brain, tissue samples can only be feasibly obtained post-mortem. For these reasons, it was 
important to develop alternative model systems that recapitulate the deleterious effects 
seen in HD. With the identification in 1993 of the IT15 gene responsible for HD, it has 
been possible to create both synthetic and genetic variations of the htt protein product. 
 Through the years, there have been many model systems created that include 
virtually every phylum, including in vitro synthetic peptide models, cell and yeast 
models, invertebrate models, and vertebrate models. Although there isn’t a perfect model 
for HD, the hope is that collectively the information gained from each model will provide 
new insights into the mechanism(s) of disease. The goal of this section will be to provide 
a summary of the various model systems created and a brief synopsis of the results and 
limitations associated with each.  
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IN VITRO MODELS 
 The use of chemically synthesized polyGln peptides and recombinant fusion 
proteins have been particularly important models for studying the biochemical, 
biophysical, and structural characteristics of polyGln-containing proteins [Scherzinger et 
al. 1997; Chen and Wetzel 2001; Wetzel 2005] because they bypass many complications 
that can arise due to studying whole animal systems. In synthetic models, various length 
polyGln peptides can be solubilized by exposure to disaggregating solutions, subjected to 
ultracentrifugation in order to remove any small oligomeric species, and then 
resuspended in physiological solutions [Wetzel 2005].  
Aggregation kinetics and thermodynamics have been thoroughly studied in these 
models, and a great deal of knowledge has been acquired about the folding properties of 
these proteins as well. These accomplishments were made using various techniques, such 
as ThT and Congo red birefringence, which shed light on the β-sheet structure of the 
fibrillar protein [Scherzinger et al. 1997; Huang et al. 1998; Chen et al. 2002]. Dynamic 
light scattering, which increases as particles increase in size and number, has been used to 
measure the kinetics of aggregation; however, this method is generally used in 
conjunction with one or more methods due to the problem of larger aggregates 
dominating the signal [Lomakin et al. 1999].  
Another important observation from in vitro models is the ability of polyGln 
proteins to exhibit recruitment-competency [Berthelier et al. 2001; Berthelier and Wetzel 
2003]. Data from in vitro models reveal that simple polyGln sequences can self-assemble 
into aggregates and that this process is nucleation-dependent [Chen et al. 2001; Chen et 
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al. 2002; Ross et al. 2003]. At the same time, studies on larger fragments that include 
flanking sequences to polyGln indicate more complex aggregation mechanisms that 
include initial rapid formation of amyloid-like aggregates [Ellisdon, Pearce et al. 2007] or 
non-amyloid oligomeric aggregates (huntingtin; [Thakur] involving the flanking 
sequences.  
CELL MODELS 
 There have also been many yeast and mammalian cell models developed that have 
had great impacts in the HD field. Such models are simpler than animal models but at the 
same time, compared to in vitro models, allow a better understanding of how the 
misfolded proteins behave in a more complex mixture of other cellular components.  
Yeast model   
  Saccharomyces cerevisiae has often been used to explore the relationship between 
polyGln aggregation and toxicity and other cellular components including chaperones. 
Yeast models are relatively simple to generate and study and do not feature huge cell-to-
cell variations of the total proteome as is evident in mammalian cell culture models. Most 
commonly these yeast models are designed to express variant htt exon 1 constructs. As 
seen in other eukaryotic systems, the polyGln repeat length is directly correlated to 
aggregate formation. While yeast cells do not appear to be actually killed by expanded 
polyGln aggregates, their growth is retarded, and it is in this context that expanded 
polyGln is said to be toxic in yeast.  After some confusion about the yeast strain 
dependence of this toxic effect, it was shown that Rnq1, a yeast prion, is required for 
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polyGln aggregation, which directly correlates with cellular toxicity, and that upon 
deletion of Rnq1, aggregation and toxicity were both suppressed [Meriin et al. 2002].  
The overexpression of both Hsp40 and Hsp70 have been found to attenuate polyGln 
aggregation and alleviate cellular toxicity [Muchowski, Schaffar et al. 2000]. 
Interestingly, it has also been observed that the molecular chaperone Hsp104 is required 
for polyGln aggregation [Krobitsch and Lindquist 2000], and upon its deletion, virtually 
none of the detected protein is found in an aggregated form.  A similar counter-intuitive 
ability of Hsp104 to promote the formation of a yeast prion was described previously 
[Schirmer and Lindquist 1997]. 
More recently, the role of the polyGln flanking sequences have been found to 
have a profound influence on the toxicity in yeast associated with the protein [Dehay and 
Bertolotti 2006; Duennwald et al. 2006; Duennwald et al. 2006].  Introduction of a htt 
construct containing the proline-rich region of exon 1 creates morphologically different 
aggregates, which are generally smaller than the well-described insoluble polyGln 
aggregates [Dehay and Bertolotti 2006; Duennwald et al. 2006]. Next, deleting this 
polyproline region slowed aggregate formation [Dehay and Bertolotti 2006]. Also, the 
deletion of this region created a more insoluble aggregate compared to a construct that 
includes the polyproline region. Furthermore, yeast expressing the proline flanking 
sequences in htt exhibited less toxic effects than cells expressing a htt construct lacking 
the proline-rich region [Dehay and Bertolotti 2006].  The ability of a proline-rich 
sequence to suppress polyGln aggregation and weaken aggregate structure can also be 
observed in vitro using simple polyGln peptides (Bhattacharyya et al 2006).   
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Mammalian cell models 
   There have been a host of transient and stably transfected mammalian cell culture 
models developed that constitutively or inducibly overexpress fusion proteins of either 
truncated or full-length huntingtin DNA constructs (See Table 1.6 for a summary of the 
various models and the major findings associated with each model) [Lunkes and Mandel 
1998; Martindale, Hackam et al. 1998; Saudou, Finkbeiner et al. 1998; Li et al. 1999; 
Preisinger et al. 1999; Sanchez et al. 1999; Wellington et al. 2000; Apostol et al. 2003; 
Aiken et al. 2004]. In transient expression models, plasmid DNA is introduced into the 
cells by various delivery methods, usually via a lipid-mediated carrier, and expression is 
only detectible for up to one week. This effect is due to the fact that a majority of the 
DNA introduced to the cells does not make it into the nucleus for transcription. The DNA 
that manages to get into the nucleus becomes diluted with the dividing cells until it is no 
longer observable. The transient effect is solely due to the lack of integration of the 
plasmid DNA into the genome of the dividing cell line. 
In contrast, stably transfected models depend on the recombination of a delivered 
transgene into the model system’s genome. This technique involves introducing the 
plasmid DNA, which spontaneously inserts itself into the genome of the model organism, 
and selecting for this rare event by the use of drug resistance or a phenotypic alteration. 
Once incorporation occurs, the transgene will replicate in synchrony with the dividing 
cell, theoretically creating a stable, long-lasting genotype. Addition of an inducible 
promoter to a stable transfectant creates a stable genotype in which transgene expression 
is controlled by the addition or removal of an inducing (suppressing) agent. 
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Table 1.6: Cellular models of Huntington’s disease.   





Wildtype htt protective 
against mutant htt 






Mutant htt aggregate 
formation dependent on 
repeat length, concentration, 
& time 
[Scherzinger 
et al. 1999] 
Cos-7, 
SK-N-SH Transient 
Exon 1  
Q23, 53, 74 
Mutant htt increased 
reactive oxygen species 
[Wyttenbach 





Cleavage of mutant htt 
results in N-terminal 





HEK293 Stable, inducible 
Exon 1 
fragments 
Q20, 51, 83 
Mutant htt form detergent-
resistant aggresome 
inclusions. Inhibition of 








PolyGln aggregates are 
detergent-resistant, located 




et al. 1999; 
Preisinger et 
al. 1999] 
PC12  Stable, inducible 
Exon 1 
Q20, 150 
Benign htt diffuse in the 
cytoplasm; mutant htt 
diffuse in the nucleus and is 
susceptible to stress 
[Li, Cheng 
et al. 1999] 
PC12  Stable, inducible 
Exon 1  




Drug screen coupled with 
Drosophila: disruption of 






PC12 Stable, inducible Exon 1 Q103 
Drug screen showed caspase 
inhibitors protected against 
cell death 
[Aiken, 
Tobin et al. 
2004] 
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Table 1.6. Continued 





Exon 1  
Q23, 74 
Mutant htt formed 
cytoprotective aggresomes 








Nuclear localization of 




N2a Stable, inducible 
Exon 1  
Q16, 60, 150 
Increased polyGln 
expression = decreased 
proteasomal processing, 
mitochondrial membrane, 
activated caspases  
[Jana et al. 
2001] 
IMR Transient Full-length Q82 
Mutant htt more resistant to 
proteolysis than normal. N-
terminal cleavage products 








Transient Exon 1      Q17, 68 
Nuclear localization 




et al. 1998] 
Primary 
cortical Transient 
Full-length     
Q15, 44, 128 
Increasing Gln length and 





et al. 1998] 
* N-terminal fragments = various shortened Exon 1 fragments that do not necessarily 
contain the first 17 amino acids (region preceding Gln stretch). Exon 1 differs from exon 
1 fragments in that “fragments” represents truncation after the Gln sequence. Synthetic 




 The rat pheochromocytoma cell line, PC12, is one of the most commonly used 
mammalian cell lines to study neurodegenerative diseases [Warren and Chute 1972; 
DeLellis et al. 1973; Greene and Tischler 1976; Schubert and Whitlock 1977; Chai et al. 
1999; Li et al. 1999; Wyttenbach et al. 2001; Apostol et al. 2003; Aiken et al. 2004]. Like 
neurons, PC12 cells synthesize and store dopamine and norepinephrine, which are 
catecholamine neurotransmitters, and upon treatment with nerve growth factor (NGF) can 
be transformed into a more neuronal-like appearance with long, extended neuritic 
processes [Greene and Tischler 1976]. The most ideal cell models are those involving the 
use of primary neuronal cultures; however, these models are not immortal and generally 
more difficult to maintain.  
  There has been a great variety in the types of cells studied and the polyGln length 
transfected. In spite of this variety, common features have emerged. There appears to be a 
polyGln repeat length dependence for aggregation [Lunkes and Mandel 1998; Kazantsev 
et al. 1999]; toxicity requires nuclear localization of the aggregate [Saudou et al. 1998; 
Yang et al. 2002]; and the overexpression of chaperone proteins reduces aggregate 
burden and/or toxicity [Cummings et al. 1998; Sittler et al. 2001; Firdaus et al. 2006]. 
However, these findings appear to indicate cell background independence because a 
number of models have utilized the non-neuronal-like cell lines [Cooper et al. 1998; 
Zeron et al. 2001; Skinner et al. 2002; Firdaus et al. 2006]. Regardless of the simple 
eukaryotic model used, yeast or mammalian cells, these systems provide the framework 




 Invertebrate models, such as Caenorhabditis elegans (worm) and Drosophila 
melanogaster (fly), are also now being used to study neurodegenerative diseases  (See 
Table 1.7) [Jackson et al. 1998; Satyal et al. 2000; Link 2001; Driscoll and Gerstbrein 
2003; Marsh et al. 2003; Marsh and Thompson 2006; Slepko et al. 2006; Brignull et al. 
2007]. These models are important because they represent simple multicellular organisms 
and have a greater rank than in vitro systems, yeast, and cell cultures. Both the worm and 
the fly have been utilized for studying neurodegenerative disorders largely because of 
their rapid generation times and fully functional nervous systems, which are absent in the 
above presented models. In both models, many neuronal dysfunction characteristics are 
exhibited. For instance, in Drosophila, a commonly used, easily measured assessment of 
dysfunction is the degree of climbing activity in a glass tube. Another common endpoint 
used in neurodegeneration research is the loss of the photoreceptors of the eye in 
response to expression of disease proteins.  
  Invertebrate models of HD are created from either truncated or full-length htt 
constructs. Simple glutamine sequences, without the htt context, have also been explored. 
In the Drosophila models, virtually all the reported systems are placed under the control 
of the upstream activating sequence (UAS), which does not express until crossed with fly 
strains that express the yeast transcriptional activator GAL4. GAL4 is present in every 
cell of the nervous system from embryogenesis forward [Robinow and White 1988]. 
Jackson’s group [Jackson et al. 1998] used gmr, which is another common 
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Table 1.7: Invertebrate models of Huntington’s disease. 












Drosophila UAS polyQ Gmr-GAL4 
Q27, 
108 Eye retina 50% lethal 
[Marsh et al. 
2000] 





















[Satyal et al. 
2000] 
C. elegans GFP polyQ myo-2 Q19, 82 
Pharyngeal 
wall muscle Unreported 
[Satyal et al. 
2000] 





[Faber et al. 
1999] 










Abbreviations: Upstream activating sequences (UAS), glass multimer reporter (gmr), 
green fluorescent protein (GFP), glutamine (Q) 
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driver for neurodegenerative studies that is expressed in all the cells of the eye [Ellis et al. 
1993]. Regardless of the driver used, the most commonly targeted organ for 
neurodegeneration is the eye. Drosophila models have shown striking neuronal 
degeneration, with apoptotic hallmarks, which are highly correlated with the polyGln 
repeat length, as well as the identification of chaperones that suppress polyGln-associated 
toxicity [Jackson et al. 1998; Kazemi-Esfarjani and Benzer 2000]. More recently, it has 
also been shown that when a Q20 sequence was co-expressed with a Q93 sequence 
[Slepko et al. 2006], inclusions formed at a much faster rate than when the Q93 was 
expressed alone. The observed aggregation kinetics correlated well with an increase in 
toxicity, which was not seen in Drosophila expressing only Q20. Furthermore, by day 10 
of the experiment, the majority of the aggregates present were found in the nucleus.  
PolyGln toxicity has also been evaluated in C. elegans by expressing various Gln 
constructs in the muscle or sensory neurons. As in the fly model, progressive 
neurodegeneration occurs in a polyGln length-dependent manner; however, toxicity is not 
observed until a second toxin is introduced [Faber, Alter et al. 1999]. In C. elegans, the 
heat shock response has also been shown to be activated under the stress of expanded Gln 
proteins. This effect can be alleviated by co-expression of a yeast chaperone Hsp104 
[Satyal et al. 2000], which reduces the appearance of polyGln aggregates and the 
associated developmental delay.  
In C. elegans, behavioral assays are used to determine dysfunction in a specific 
neuron [Faber, Alter et al. 1999; Parker, Connolly et al. 2001], where an unhealthy worm 
is slower to respond to a touch response compared to its healthy counterpart. For 
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example, worms expressing a 150 Gln repeat formed aggregates that increased as the 
animal aged, which correlated with the progressive neurodegeneration of sensory neurons 
[Faber, Alter et al. 1999]. In another example, worms that expressed expanded polyGln 
repeats exhibited touch insensitivity, whereas worms expressing normal lengths did not 
possess this characteristic [Parker, Connolly et al. 2001].    
The invertebrate models share many of the same features of HD that are observed 
in the human disease [Marsh et al. 2003; Brignull et al. 2006; Slepko et al. 2006], such as 
the presence of polyGln aggregates and progressive degeneration. Both Drosophila and 
C. elegans models provide excellent systems for combining cellular complexity and 
behavioral phenotypes. 
VERTEBRATE MODELS 
 Although the aforementioned models are well-studied, have relatively quick 
generation times, are relatively easy to work with, and are readily available, they still lack 
the complexity of higher eukaryotic species. Mice and rats share significant homologies 
with humans, including similar proteomes and basic anatomical features. Furthermore, all 
mammals share similar nervous, digestive, and circulatory systems, which stresses the 
importance of developing vertebrate models depicting human disease. Finally, the N-
terminal segment of mouse and rat huntingtin is very similar to the human [Barnes et al. 
1994; Schmitt et al. 1995], while there is no recognizable exon1 or polyGln sequence in 
Drosophila huntingtin [Li et al. 1999], and there is no huntingtin homolog at all in C. 
elegans [NCBI 2007]. 
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 Mouse models of HD can be grouped into two different categories 1) the 
transgenic model, in which a portion of the mutated gene is expressed under the control 
of various exogenous promoters, including bacterial and yeast artificial chromosomes 
(BAC and YAC, respectively), and 2) the knock-in / knock-out models, in which an 
expanded Gln repeat containing huntingtin gene is engineered at the mouse IT15 locus 
(See Table 1.8 for a summary) [Sipione and Cattaneo 2001; Bao et al. 2002; Bates 2002; 
Rubinsztein 2002; Levine et al. 2004].  
 Hdh is the mouse homolog of the human HD gene and has been shown to share a 
91% identity with the human huntingtin protein [Barnes et al. 1994]. A homozygous 
knock-out of this full-length murine gene results in embryonic lethality [Duyao et al. 
1995], which is accompanied by an increase in apoptosis in the embryonic ectoderm 
[Zeitlin et al. 1995]. These studies demonstrated the importance of htt during 
development, and also proved that simply the loss of htt function could not account for 
the neurodegeneration seen in HD. The lack of an HD-like phenotype in knock-out 
models, is generally interpreted as proof of the expanded polyGln imparting a gain of 
function activity. Furthermore, an Hdh heterozygous knock-out resulted in a normal 
phenotype, reinforcing this belief [Duyao et al. 1995; Zeitlin et al. 1995].  
 Transgenic mouse models expressing truncated forms of mutant htt develop a 
progressive neurological phenotype that includes tremors, NII, hypokinesis, failure to 
gain weight, abnormal gait, a lack of coordination, limb clasping, and a reduced response 
to stimuli [Bates 1998; Sipione and Cattaneo 2001]. These mice were constructed to
Table 1.8: Mouse models of Huntington’s disease. 
Neuropathology Model design (Promoter / gene 
size/ Gln repeat) Behavioral disorder 
Inclusions Cell loss 
Reference 
Transgenic Hdh models     
HD promoter; exon 1 R6/2 line:    
Q20, 115, 150 
Onset at 2 mo. Tremors, 
abnormal gait, learning 
deficit, hypokinesis, 
diabetes 
NII and NA throughout 
brain, fewer dendritic 
spines 
Overall atrophy. Fontal cortex, 
dorsal striatum, and Purkinje 
cells (late stage) 
[Mangiarini 
et al. 1996] 
Mouse prion promoter; First 171 aa. 
Q16, 44, 82 
Onset 5 mo. with Q82. 
Tremors, abnormal gait, 
hypokinesis, weight 




nuclear accumulation of 
htt 
Overall atrophy. Striatum [Schilling et al. 1999] 
Tet-off (camKIIα-tTA) promoter; 
exon 1 Q94 
Onset in 50% by 2.5 mo. 








et al. 2000] 
HD YAC transgenic. Full-length 
gene Q18, 46, 72, 128 
Onset 3 mo. with Q72, 




Striatum Striatal cell loss, cortical atrophy with Q128 
[Hodgson et 
al. 1999; 
Slow et al. 
2003] 
CMV promoter; full-length gene, 
Q16, 48, 89 






throughout the brain 
20% cell loss in striatum of 
some animals 
[Reddy et al. 
1998] 
Rat neuron-specific enolase 
promoter; 3-kb N-terminal fragment, 
Q18, 48, 100 
Onset 3-4 mo. with 
Q100 
Inclusions in Q100, few 
in Q46; dystrophic 
neuritis observed 






Table 1.8. Continued 
Neuropathology Model design (Promoter / gene 
size/ Gln repeat) Behavioral disorder 
Inclusions Cell loss 
Reference 
Knock-in Hdh models     
Endogenous mouse HD gene Hdh 
promoter; Q50, 92, 111 None determined 
PolyGln- and age-
dependent htt nuclear 
relocalization at 1.5 mo. 
Some inclusions >6 mo. 
None observed [Wheeler et al. 1999] 
Neo and Hdh promoter; Q20, 111 
Onset ~2 mo. and show 




and inclusion  
None observed [White et al. 1997] 
Hdh promoter; Q72, 80 Early onset aggressive behavior 
Late inclusions, 
hippocampus, repeat 
instability in striatum 
Long term potentiation 
impaired 
[Shelbourne 
et al. 1999] 
Hdh promoter; Q71, 94 None determined Striatal cell swelling in response to NMDA 




Hdh promoter; full-length gene,   
Q80, 150 
Onset 6 mo. Q150 
homozygote, 15 mo. 
heterozygote. Motor task 
deficits, abnormal gait, 
hypoactivity 
NII Q150 mainly in 
striatum. Htt nuclear 
relocalization 
Reactive gliosis [Lin et al. 2001] 
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express much larger CAG repeats than are actually seen in late-onset Huntington’s 
disease. The life span is also shortened compared to transgenic mice expressing full-
length mutant htt [Bates 2002]. As is the case for the human disease, the mechanism(s) 
responsible for the phenotype are unknown. 
 Knock-in models are an improvement over previous transgenic models because 
Gln repeats can be precisely inserted into the endogenous mouse HD gene 
and expression is controlled by the mouse’s own promoter. This is in contrast to the 
random transgene incorporation into the mouse germline. Mild and very late onset 
neuronal phenotypes have been observed in these knock-in mice; phenotypes are more 
severe in homozygotes  [Sipione and Cattaneo 2001].  
 Knock-in mice are more similar to the human disease than the other transgenic 
mice expressing the truncated or full-length protein in that the expression levels are more 
comparable to those of wildtype and affected tissues are more widespread in the brain 
and peripheral tissues [Sipione and Cattaneo 2001]. This is due, in part to inheriting the 
normal control elements that are associated with expressing the species specific gene 
under the mouse promoter. A progressive neuronal phenotype and selective 
neurodegeneration is also observed in transgenics (including knock-ins) expressing the 
mutant full-length protein [Bates 1998].  
  There are many similarities among these various murine models and the human 
disease. For example, a great deal of CAG repeat instability is observed both in different 
vertebrate models and in humans. The largest degree of expansion, within the human 
brain, was noted in the caudate and putamen, while the smallest repeats were in the 
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cerebellum [Telenius et al. 1994]. CAG instability was also observed in a couple of the 
knock-in models [Shelbourne et al. 1999; Wheeler et al. 1999] and in the R6 transgenic 
models [Bates et al. 1997; Mangiarini et al. 1997]. Many of these models have been 
reported to exhibit progressive phenotypes [Mangiarini et al. 1996; Reddy et al. 1998; 
Hodgson et al. 1999; Schilling et al. 1999; Laforet et al. 2001; Lin et al. 2001], but the 
majority of this type of characterization has been performed on the R6/2 mice [Carter et 
al. 1999; Lione et al. 1999].  
The propensity to form polyGln-containing inclusions is a hallmark of HD in 
humans [DiFiglia et al. 1997; Becher et al. 1998; Gutekunst et al. 1999] that is also found 
in many of the vertebrate models. PolyGln aggregate pathology similar to the inclusions 
observed in humans has been described in every HD mouse model [Mangiarini et al. 
1996; White et al. 1997; Reddy et al. 1998; Hodgson et al. 1999; Schilling et al. 1999; 
Shelbourne et al. 1999; Wheeler et al. 1999; Yamamoto et al. 2000; Laforet et al. 2001; 
Lin et al. 2001; Levine et al. 2004]; however, the precise role of these aggregates in HD 
pathogenesis is still unclear.  
Although there are many questions still unanswered, several important discoveries 
about the molecular basis of HD have been acquired from each of these model systems.  
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CHAPTER 2  
PROJECT RATIONALE AND SUMMARY 
 The most common of a family of trinucleotide repeat neurodegenerative 
disorders, Huntington’s disease is an autosomal dominant disease caused by a glutamine 
expansion in the N-terminus of the gene encoding the huntingtin protein [Bates 2002].  
The expanded polyGln itself is thought to be responsible for the pathogenesis of the 
disease. Indeed, the severity of the disease increases with the length of the polyGln repeat. 
As in all these trinucleotide repeat diseases, the expansion of the polyGln tract induces 
misfolding of the protein, which then forms insoluble cytoplasmic and/or nuclear 
aggregates within affected neurons [Davies, Turmaine et al. 1997; Scherzinger, Lurz et 
al. 1997].  The length of the polyGln sequence (~35 Glns) associated with disease is very 
similar for most of these disorders and correlates well with the length-dependent 
aggregation properties observed in vitro [Harper and Newcombe 1992; Evert, Wullner et 
al. 2000]. Recent experiments using cell systems support the idea that polyGln aggregates 
are cytotoxic due to their ability to recruit other critical cellular proteins, via their own 
polyGln components [Davies, Turmaine et al. 1997; McCampbell et al. 2000; Nucifora et 
al. 2001].  In addition, it has been shown in another CAG repeat disease that some 
neuronal aggregates, which are not polyGln-rich, are capable of recruiting polyGln 
proteins [Takahashi et al. 2001]. On the other hand, it has also been postulated that the 
formation of large, insoluble aggregates is a defense mechanism that has the beneficial 
effect of sequestering smaller, more cytotoxic misfolded protein aggregates, thereby 
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rendering them harmless [Klement et al. 1998; Saudou, Finkbeiner et al. 1998]. These 
seemingly contradictory findings demonstrate that the aggregation phenomenon is 
complex and may involve multiple discrete or interdependent pathways featuring 
different misfolded and aggregated states with unique physical and biological properties.  
 To help distinguish different aggregated states, we have developed a cell-based 
method capable of identifying intracellular aggregates based on whether or not they are 
able to actively recruit biotinylated-monomeric Q28 peptide. This method was initially 
developed using transiently transfected cell models in which various lengths of htt-
polyGln-green fluorescent protein (GFP) fusion constructs were introduced via liposome-
mediated delivery. The optimized biotinyl-polyGln system was then applied to a more 
robust and reproducible model of stably-transfected PC12 cells capable of inducible 
expression of htt with different polyGln repeat lengths.  In these inducible cell models, 
punctate areas were visible with the polyGln recruitment stain but not by the GFP 
fluorescence typically used to discern aggregates in such models. The actively recruiting 
species were designated aggregation foci (AF) [Osmand 2004; Osmand, Berthelier et al. 
2006]. For reasons not entirely understood, these htt-inducible cells do not exhibit cell 
toxicity due to the presence of expanded polyGln htt molecules [Apostol, Kazantsev et al. 
2003], in contrast to some other models [Li, Cheng et al. 1999; Aiken, Tobin et al. 2004]. 
This intrinsic property of the cell line has provided a unique opportunity to dissect the 
aggregation process without the complication of cell death.  
The goal of this dissertation research was to: (a) develop a method for identifying 
and validating the polyGln recruitment-competency within a cellular model of htt 
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overexpression; (b) optimize the cells for htt-polyGln-GFP expression; (c) characterize 
and investigate the potential role(s) of each of the various observed aggregated states in 
aggregate propagation by examining their functionality and structure over time; and (d) 
study the roles of various cellular functions in the formation and flux of AF and other 
aggregates. The majority of this characterization was completed using 
immunofluorescence microscopy to monitor the appearance and disappearance of AF and 
htt-polyGln-GFP aggregates in a time-dependent manner. Further biochemical 
characterization was achieved by isolating and examining a series of cell fractions that 
contained the htt-polyGln-GFP proteins of interest. Each fraction was examined for its 
reactivity with anti-GFP and 1C2-binding (anti-polyglutamine) antibodies using Western 
blot assays. An attempt was also made to functionally characterize each fraction for their 
abilities to support in vitro polyglutamine elongation  using a microtiter plate assay 
[Berthelier et al. 2001].  
Finally, two compounds directed at specific cellular processes were investigated 
for their ability to alter the aggregate formation pathway(s), which will be discussed in 
Chapter 7. These compounds exhibit specific effects on AF and htt-polyGln-GFP 
aggregates in the inducible cell system. These data suggest several possible modes for 
aggregate formation in cells, which are addressed in greater detail in the Discussion and 
Conclusions sections in Chapter 9. Taken together, the data obtained from these studies 
and the protocols that have been developed can be used to dissect the basic principle of 
htt aggregation in vivo and provide a platform to identify and quantitatively evaluate 
novel therapeutic interventions to treat patients with this devastating human condition.  
77 
CHAPTER 3 
MATERIALS AND METHODS 
3.1 Polyglutamine Constructs and Synthetic Peptides: 
HTT DNA CONSTRUCTS 
The DNA constructs used for all experiments were a generous gift from Alex 
Kazantsev at the Center for Aging and Neurodegeneration, Massachusetts General 
Hospital, Charlestown, MA. The original DNA constructs used were all truncated htt 
exon-1-polyGln-GFP fusions (htt-Qn-GFP) [Kazantsev et al. 1999; Preisinger et al. 1999; 
Michalik et al. 2001]. Exon-1 of the HD gene contains the CAG repeat region, which is 
translated into a polyGln stretch within the huntingtin protein. For a number of reasons, 
the exon-1 fragment of htt, rather than the full-length molecule, is frequently used as a 
model system for studying outcomes of expanded polyGln expression. Truncated htt 
constructs were initially used because it has been shown in a mouse model that the HD 
inclusions contain processed N-terminal htt fragments [Martindale, Hackam et al. 1998], 
and that these fragments were more toxic than the mutant full-length protein [Hackam et 
al. 1998; Lunkes and Mandel 1998].  More recently, N-terminal fragment models have 
been further validated with evidence that caspase release of an N-terminal portion of htt 
is likely to be a critical step in the disease mechanism [Sawa et al. 2005; Maglione et al. 
2006]. 
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The truncated constructs were composed of the first 17 amino acids (aa) of htt 
exon 1, followed by the Gln repeat expansion with alternating CAG/CAA for added 
stability [Michalik et al. 2001], and an in frame fusion with GFP at the C-terminus of 
truncated htt exon 1 (htt-Qn-GFP, Q25, 47, 65, and 103) (see Figure 3.1B).   
Complete htt exon 1 GFP constructs were used to create a stable htt-inducible cell 
line (generously supplied by Leslie Thompson at the University of California, Irvin, and 
Aleksey Kazantsev at Massachusetts General Institute for Neurodegenerative Disease 
[Apostol, Kazantsev et al. 2003]), which will be discussed in detail in Section 3.2. These 
constructs also contained the first 17 aa of huntingtin exon 1, the Gln repeat stretch, the 
polyproline region, and the GFP tag, as indicated in Figure 3.1A. Cells containing these 
constructs were available in 25, 47, and 103 Gln repeat lengths. The cells expressing 
complete htt exon 1 constructs will be designated as 25QP, 47QP, and 103QP. Also for 
the htt-inducible cells, we had one cell line expressing a truncated form of htt exon 1 
(Figure 3.1B). This cell line will be referred to as Q103.  
POLYGLUTAMINE PEPTIDE PREPARATION 
Synthetic polyGln peptides were utilized for the polyGln-recruitment stain 
(Section 3.3) and as control samples for the polyGln microtiter plate elongation assay 
(Section 3.7), see Figure 3.1C. All peptides were prepared by custom solid-phase 
synthesis from the Keck Biotechnology Center at Yale University 
(http://info.med.yale.edu/wmkeck). The polyGln sequences were flanked by pairs of 
lysine (Lys or K) residues to enhance solubility by conferring a net positive charge on the
CAG 
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Figure 3.1: PolyGln constructs and peptide sequences. (A) Complete htt exon 1 









peptide at a neutral pH [Chen and Wetzel 2001].  We utilized biotinylated peptides as 
well, which were created by an N-terminal derivatization during the synthesis. The 
biotinylated peptide was enhanced by the addition of a polyethylene glycol (PEG) spacer 
between the biotin moiety and the polyGln peptide [Osmand, Berthelier et al. 2006]. 
Peptides were purified by disaggregation and HPLC [Berthelier et al. 2001; Chen and 
Wetzel 2001], and stored at -80°C in 1- or 5-ml aliquot stock solutions in extension 
buffer (1X phosphate buffered saline (PBS) and 0.01% Tween® 20) with 5% dimethyl 
sulfoxide (DMSO) or PBS alone.  
Solubilization and Disaggregation of Peptides 
Peptides were dissolved at 0.5mg/ml in a 1:1 mixture of trifluoroacetic acid (TFA, 
#28901, Pierce, Rockford, IL) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, #52517, 
Sigma-Aldrich, St. Louis, MO) for 24 hour. The solvents were evaporated in a fume hood 
under a stream of argon and further lyophilized under a vacuum for one hour. The peptide 
residue was resuspended in an equal volume of cold water, adjusted to pH 3.0 by TFA, 
and allowed to dissolve for at least 15 minutes at 4°C. The sample was then subjected to 
ultracentrifugation at 100,000xg overnight at 4°C to remove any aggregate contaminants. 
All but the bottom 10% of the supernatant was carefully removed and stored at 4°C while 
the exact peptide concentration was determined by reverse-phase high-performance 
liquid chromatography (RP-HPLC, Hewlett-Packard, Palo Alto, CA) fitted with a Zorbax  
SB-C3  column. Biotinylated-PEG-K2-Q28-K2 peptides were diluted to a final 
concentration of 500nM in extension buffer, aliquoted, flash frozen, and stored at -80°C.  
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A more complete description of the disaggregation protocol has been published 
[O'Nuallain et al. 2006].  
Preparation of Polyglutamine Aggregates 
K2Q47K2 peptides were subjected to the above disaggregation protocol; after 
which, the concentration was adjusted to 10µM (44µg/ml) in 1X PBS. The peptide 
solution was then incubated at 37°C for 24 hours, snap frozen, and subjected to an 
additional 24 hour incubation at -20°C [Berthelier, Hamilton et al. 2001]. Aggregates 
were aliquoted, snap frozen, and stored at -80°C.  
3.2 Cell Culture and Treatment: 
MAINTENANCE 
PC12 Cells 
Two cell lines, PC12 and SH-SY5Y cells, were utilized for the transient 
expression model systems. Rat pheochromoctyoma (PC12) cells are an adherent cell line 
that were established in the 1970s to provide a model system that displayed neuronal 
characteristics but was easier to work with than primary neuronal cultures [Warren and 
Chute 1972; Greene and Tischler 1976]. For these reasons, PC12 cells are commonly 
used as mammalian cells to study neurodegenerative diseases [Li, Cheng et al. 1999; 
Apostol, Kazantsev et al. 2003; Aiken, Tobin et al. 2004]. PC12 cells were graciously 
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donated by Erik Schweitzer in the Department of Physiological Science and Neurology at 
the Brain Research Institute, University of California, Los Angeles, CA.   
 PC12 cultures were maintained in Dulbecco's Modification of Eagle's Medium 
(DMEM) supplemented with 5% fetal bovine serum (FBS), 5% horse serum (HS), and 
penicillin/streptomycin antibiotics (complete growth medium). Media and supplements 
were purchased from MediaTech, Inc. (Herndon, VA), Hyclone, (Logan, UT), and 
Calbiochem (San Diego, CA) unless otherwise noted. All cells were grown at 37°C in 
5.0% carbon dioxide (CO2) and at 98% relative humidity.  The media was changed every 
third day, and the cultures were passaged weekly.  
SH-SY5Y Cells 
To create an even more physiologically relevant mammalian culture, a human 
neuroblastoma cell line, SH-SY5Y (American Type Culture Collection (ATCC) – #CRL-
2266, Manassas, VA) was used. These cells are a third generation clone that was 
established from the parental SK-N-SH cells. Although SH-SY5Y cells grow as a 
mixture of adherent and floating cells, they can be differentiated with 10µM retinoic acid 
(RA) to generate a more adherent phenotype. Like the PC12 cells, SH-SY5Y cells exhibit 
many neuronal characteristics. These cells, irrespective of differentiation, actively 
produce many neurotransmitters that are found in the normal human brain. Although SH-
SY5Y cells are less commonly used than PC12 cells (probably because they are more 
difficult to maintain) there have been several reports of their use in neurodegenerative 
disease research [Grierson et al. 2001; Ho, Carmichael et al. 2001; Wyttenbach, 
Sauvageot et al. 2002; Olivieri et al. 2003]. SH-SY5Y cells were cultured in a 1:1 
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mixture of DMEM and Ham’s F12 Medium supplemented with 10% FBS and 
penicillin/streptomycin antibiotics.  
 Stable, htt-inducible PC12 Cells 
We also had available several htt-inducible PC12 cell models that expressed 
various polyGln lengths (25QP, 47QP, 103QP, and Q103; detailed in Section 3.1) 
[Apostol, Kazantsev et al. 2003].  Protein expression within these cells was controlled by 
an ecdysone-inducible promoter and was regulated by Ponasterone (#H101-01, 
Invitrogen, Carlsbad, CA), an insect steroid. The htt-inducible PC12 cells were cultured 
in DMEM supplemented with 10% HS, 5% FBS, 15mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer, and antibiotics. Dilution cloning on these cells will 
be discussed in the next subsection.  
The ecdysone-inducible mammalian expression systems were created using a co-
transfection of a vector (pVgRXR) containing a heterodimer receptor that would bind to a 
hybrid ecdysone response element and a vector containing the cDNA of interest (pIND) 
(see Figure 3.2). In the presence of the inducing agent (Ponasterone), a stable transfectant 
can be established. Selection for this stably incorporated transgene was maintained with 
concurrent treatment of 100µg/ml G418 (#11811-023, Invitrogen) and 200µg/ml Zeocin 
(#R250-01, Invitrogen) antibiotics. These cells maintain their stability for at least 1.5 
years when stored in liquid nitrogen; furthermore, the transgene is stable up to passage 25 
once reconstituted.   
The day prior to transfection, induction or differentiation (in the case of SH-
SY5Y cells), cells were seeded onto poly-D-lysine coated glass coverslips and allowed to 
 
Figure 3.2: Ecdysone-inducible mammalian expression system. This is a schematic 
representation of how the htt-inducible cells were generated (Taken from [Invitrogen 
2002]).   
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adhere for a minimum of 16 hours. PC12 cells were plated at a density of 150,000 cells/ 
cm2 in either 6-, 12-, or 24-well microplates. SH-SY5Y cells were seeded at 50,000 
cells/cm2 density in 24-well microplates. SH-SY5Y cells were differentiated with 10µM 
RA for seven days prior to transfection. Htt-inducible PC12 cells were plated at a density 
of 50,000 or 100,000 cells/cm2, depending on the length of time in culture, into a 24-well 
microplate.  
DILUTION CLONING 
We received four htt-inducible PC12 cell lines: 25QP, 47QP, 103QP, and Q103.  
Although all these cells were expressing the selectable marker, they were not uniform cell 
lines.  In general, only a small percentage of these cells exhibited good expression of the 
transgene, as indicated by GFP fluorescence.  To obtain a more uniform cell line, it was 
necessary to subclone.  As received from the Thompson lab, only the Q103 cells had 
been subjected to subcloning and hence were enriched for a high percentage of htt-
polyGln-GFP expressing cells. These cells had been subcloned, pooled, and flow sorted 
(MoFlo cell sorter, Cytomation, Fort Collins, CO) [Apostol, Kazantsev et al. 2003]. The 
other three cell lines were not of very high clonal integrity and needed to be enriched.  
Dilution cloning, or subcloning, is a process by which a polyclonal cell population 
is serially diluted until a population of one or two cells has been achieved. This 
population, a subclone, is then plated and allowed to reach confluency. Ideally during 
cellular division, the characteristics of the original one or two cells will be passed on to 
the next generation of cells. By performing this technique, one should be able to achieve 
a fairly homogenous monoclonal population of cells.   
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 Dilution cloning was performed as described in “Culture of Animal Cells. A 
Manual of Basic Technique” [Freshney 1987]. Cells were treated with Cellstripper (#25-
056-CI, MediaTech) to detach the culture. Cells were resuspended in complete growth 
media (described in Section 3.2), counted, and serially diluted to achieve approximately 
one cell/100µl of media (10 cells/1ml of media). Once the correct dilution had been 
found, 100µl/well of cells were plated into 96-well plates and cultured until ~80% 
confluency had been achieved.  
When the cells had reached this confluency, the cultures were detached and 
divided between a well in a 96-well microtiter plate and a well in a 24-well plate. The 
sample in the 24-well plate was maintained for continual growth. The sample in the 96-
well plate was subjected to induction with 5µM ponasterone, and htt-polyGln-GFP 
expression was monitored for several days beginning 24 hours post-induction. Clones 
were chosen based on their percent GFP expression, and presumably percent htt-polyGln 
expression. The highest percentage of expressing cells was chosen as the most optimal 
clones.  
Ideally, to match the Q103 cells, the samples should have also been flow sorted, 
which would have allowed for an even purer population of cells. This was not possible; 
however, even without the use of a flow cytometer, we were able to achieve a high clonal 
integrity with our cell lines.  
TRANSFECTION  
 PC12 and RA differentiated SH-SY5Y cells were transiently transfected with the 
htt-Qn-GFP constructs using the liposome-mediated LipofectAMINE PLUSTM reagent 
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(#18324-012 and 11514-015, Invitrogen), according to manufacturer’s instructions. In 
this method of transfection a cationic lipid is mixed with the DNA to produce a positively 
charged liposome. The net positive charge of the liposome/DNA complex is attracted to 
the negatively charged plasma membrane. Upon their fusion, the liposome becomes 
engulfed by the cell where the DNA is then deposited and travels to the nucleus. It is 
unclear the exact mechanism that allows the DNA to cross the nuclear membrane 
[Felgner et al. 1987]. 
 The day prior to transfection, PC12 cells were plated on poly-D-lysine coated glass 
coverslips at a density of 150,000 cells/cm2. SH-SY5Y cells were plated at a density of 
50,000 cells/cm2 and differentiated for seven days with 10µM retinoic acid. In both cell 
lines, the DNA was complexed with the PLUS reagent at a ratio of 2µg DNA to 10µL 
PLUS reagent in 100µl of serum- and antibiotic-free media for 15 minutes at room 
temperature. During incubation, 10µl of LipofectAMINE reagent was diluted in 100µl of 
serum- and antibiotic-free media. The two mixtures were then combined and incubated 
for an additional 15 minutes at room temperature. Complete media was replaced by 
serum- and antibiotic-free media in each well prior to the addition of the liposome/DNA 
complexes. After the 15 minutes of incubation, the liposome/DNA complexes were 
gently mixed into each well and incubated at 37°C in 5% CO2 for 5 hours; after which, 
fresh media containing twice the normal serum was added to each well. Coverslips were 
removed at 16, 24, 48, and 72 hours post-transfection, fixed and permeabilized (Section 
3.2), and subjected to the polyGln-recruitment stain discussed in Section 3.3.  
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INDUCTION 
 At least 16 hours prior to induction, stable, htt-inducible PC12 cells were detached, 
counted, and plated at a density of 50,000 – 100,000 cells/cm2 on poly-D-lysine coated 
glass coverslips located in 24-well microplates. Just prior to the addition of inducing 
agent, the growth media was exchanged for 1ml/well of fresh complete growth media. To 
each well, 5µM ponasterone (stock = 1.1mM in absolute, ethanol) was added. Cells were 
maintained under constant induction for 16, 24, 48, 72, 96, 120, 144, or 168 hours, with 
the induction media being changed every day. At each time point, the cells were fixed 
and permeabilized (Section 3.2) and subjected to the polyGln-recruitment stain discussed 
in Section 3.3.  
Compound Treatment 
In experiments where stable htt-inducible cells were treated with inhibitory 
compounds, the compounds were introduced simultaneously with the ponasterone. 
Curcumin has been shown to be an effective for its anti-inflammatory, anti-oxidant, anti-
tumor, and most importantly, anti-amyloid compound [Kelloff et al. 1996; Lim et al. 
2005; Yang et al. 2005]. The stock solution of curcumin was prepared at a concentration 
of 10mM in absolute ethanol. The day of induction curcumin was diluted into complete 
growth media to concentrations of 0.1, 1, or 10µM. Cells were treated for 24 hours; after 
which, they were fixed, permeabilized (Section 3.2), and subjected to the polyGln-
recruitment stain (Section 3.3).  
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Two antimitotic compounds were also tested: nocodazole and demecolcine. These 
compounds have been shown to depolymerize microtubules [Luduena and Roach 1991; 
Nishiyama and Fujii 1992; Wang et al. 1998]. Demecolcine was dissolved in absolute 
ethanol to a concentration of 10mg/ml (27mM) then further diluted in ethanol to 2µg/ml. 
Prior to induction and compound treatment, dilutions were made in complete growth 
media to the final concentrations of 50, 200, 400, and 1000ng/ml. Treatment was 
continued for 24 hours then the cells were fixed, permeabilized, and stained for polyGln-
recruitment competency and cell nuclei (Section 3.3).  
Nocodazole was resuspended in ethanol to a concentration of 10mg/ml (33mM) 
and further diluted to 2µg/ml in ethanol. Before the cells were treated, dilutions were 
again made in complete growth media to concentrations of 50 and 400ng/ml. Cells were 
fixed, permeabilized, and stained with 100µg/ml Hoechst 33342 (stock solution was 
10mg/ml diluted in water, #H-3570, Molecular Probes, Eugene, OR) for 30 minutes at 
37°C. Hoechst fluorescent dye is a nucleic acid specific reagent that exhibits blue 
fluorescence upon excitation.   
FIXATION AND PERMEABILIZATION OF COVERSLIPS 
At the specified time points, coverslips with the attached transfected or induced 
cells were subjected to fixation and permeabilization. The process of fixation halts the 
life processes taking place within the culture; thereby preserving a snapshot of the culture 
for microscopic analysis. Permeabilization is necessary to gain access into the 
intracellular structures.  
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There are two widely accepted protocols for the fixation and permeabilization of 
cell cultures: 1) subquential treatments with acetone and methanol and 2) the use of a 
cross-linking reagent, such as paraformaldehyde, followed by a detergent 
permeabilization [Melan and Sluder 1992; Allan 2000]. Each method has been reported 
to stabilize both soluble and insoluble proteins in their native cellular locations [Melan 
and Sluder 1992].  
In initial transient transfection experiments, coverslips were washed with 1X PBS, 
immediately fixed in acetone for 10 minutes, and allowed to air-dry overnight. The 
coverslips were permeabilized the following day by incubating in cold methanol (100%) 
for 5 minutes; after which, the coverslips were washed in Tris-buffered saline containing 
0.01% Tween® 20 (TBST). This method, however, proved inefficient in our system due 
to the leaching of the GFP from the cellular cytoplasm [Kalejta et al. 1999]. All data 
shown were therefore obtained from cells fixed using a paraformaldehyde solution and 
permeabilized using 0.2% Triton® X-100 detergent.  
Coverslips were washed with 1X PBS and fixed for 15 minutes at room 
temperature with Cytofix buffer (#554655, BD Biosciences, Rockville, MD), a neutral 
pH-buffered solution containing 4% paraformaldehyde. The coverslips were washed 
again with 1X PBS and permeabilized with cold 0.2% Triton® X-100 for 5 minutes. After 
permeabilization, the coverslips were washed with 1X TBST and subjected to the 
polyGln-recruitment stain detailed in Section 3.3. 
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3.3 Polyglutamine-recruitment Stain: 
 Upon fixation and permeabilization, the coverslips were subjected to the polyGln-
recruitment stain (Figure 3.3), which relies on the specific ability of amyloid-like polyGln 
proteins to recruit biotinylated Q28 monomeric protein. After each addition or incubation, 
the coverslips were washed extensively with 1X TBST. Prior to incubation with the 
biotinylated monomer, coverslips were blocked with streptavidin / biotin (#SP2002, 
Vector Laboratories, Burlingame, CA) to eliminate any non-specific biotin binding. 
Briefly, cells were incubated with cold (4°C) streptavidin for 15 minutes followed by 15 
minutes of incubation with cold (4°C) biotin.  
  After the blocking step was complete, cells were incubated with 100nM of 
biotinylated Q28 monomer (stock solution was 500nM) for 2 hours at room temperature. 
Several incubation times and temperatures were explored; however, the 2 hour, room 
temperature incubation provided the most consistent results with the lowest background.  
The coverslips were then incubated with 100µg/ml Hoechst 33342 (Molecular Probes) for 
30 minutes at 37°C, washed, then incubated with a 1:200 dilution of a red streptavidin-
conjugated Alexa Fluor® 594 (stock solution was 2mg/ml, #S-32356, Molecular Probes) 
for 1 hour at room temperature. This dye was used for the detection of the incorporated 
biotinylated monomer. Coverslips were washed exhaustively with 1X TBST followed by 




Figure 3.3: Schematic representation of polyGln-recruitment staining protocol. Transfected / induced cells were removed 
at various time points and subjected to the above staining protocol.  Blue fluorescence represented cell nuclei (stained with 
Hoechst), green fluorescence was indicative of htt-polyGln-GFP expression, and red fluorescence represented polyGln 
recruitment-competent foci.  
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 Coverslips were mounted onto slides with the cell-side up using an aqueous 
fluorescent mounting medium (#S3023, DakoCytomation, Carpinteria, CA), and a cover 
glass was applied for microscopic analysis. Green fluorescence was indicative of the htt-
polyGln-GFP fusion constructs, blue fluorescence represented cell nuclei, and red 
fluorescence corresponded to polyGln recruitment-positive regions.  
3.4 Microscopy and Flow Cytometry: 
IMMUNOFLUORESCENCE MICROSCOPY 
Images were obtained using a Leica DMRB fluorescent microscope equipped 
with a SPOT RT color camera (Diagnostic Instruments, Inc., Sterling Heights, MI) and 
SPOT Advanced, version 3.5.2 imaging software (Diagnostic Instruments).  Data was 
analyzed using Image-Pro Plus software (Windows version 4.5, Media Cybernetics, Inc., 
Silver Springs, MD) or Adobe Photoshop 5.5 (San Jose, CA).  The microscope was fitted 
with a brightfield differential interference contrast (DIC) analyzer, a DAPI/blue 
fluorescent protein (BFP) filter (excitation 360/40nm, emission 460/50nm, with a 
bandwidth 400nm), a Texas red filter (excitation 560/40nm, emission 630/60nm, 
bandwidth 595nm), and a FITC/GFP filter (excitation 480/30nm, emission 535/40nm, 
bandwidth 505nm).  DIC microscopy utilizes the contrast between background and 
specimen to generate an image of the unstained structures.  The DIC analyzer was used in 
conjunction with all experiments to observe overall cell morphology.   
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FLOW CYTOMETRY 
Transient transfection efficiencies were initially confirmed using a FACScan 
(Becton-Dickinson, San Jose CA). Htt-Qn-GFP expression was monitored by the 
excitation of the GFP fusions at 488nm (FL-1, 530nm emission). At least 10,000 events 
were collected for each sample. Data was analyzed using Cell Quest software version 1.2 
(Becton-Dickinson).   
3.5 MTS Reduction Assay: 
Cell viability was determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (#G3580, Promega, Madison, WI) according to manufacturer’s 
instructions. CellTiter 96® is a colorimetric assay that contains a tetrazolium compound 
MTS (3-(4,5-demethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-
2H-tetrazolium) and PES (phenazine ethosulfate, an electron coupling reagent), which is 
converted to water-soluble formazan by NADH- or NADPH-, presumably.  The 
formazan product can then be quantified by measuring the absorbance at 490nm.  
Absorbance is directly proportional to the number of viable cells [Promega 2005]. MTS 
reduction is generally considered to be an indication of the health of cell mitochondria 
[Gschwind 1997].  When used previously to observe the response of PC12 cells to 
polyGln aggregates, MTS reduction gave a read-out entirely in agreement with other 
assays for cell viability, eg., lactate dehydrogenase release and propidium iodide 
exclusion [Yang et al. 2002]. 
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Briefly, cells were detached, counted and seeded into 96-well microplates at least 
16 hours prior to induction and/or compound treatment. Cells were induced with 5µM 
ponasterone as previously described (Section 3.2, Cell Culture and Treatment, Induction). 
At the appropriate time point, the inducing medium was exchanged for 100µl of complete 
growth medium/well. To each well, 20µl of CellTiter 96® AQueous One Solution reagent 
was added, and the plate was incubated at 37°C for 4 hours. After incubation, absorbance 
readings were taken at 490nm on a SynergyTM HT multi-detection microplate reader 
(BioTek Instruments, Inc., Winooski, VT). Data were analyzed using Microsoft Excel 
2000 (Microsoft Corporation).  
3.6 Preparation and Fractionation of Cell Lysates: 
PREPARATION OF CELL LYSATES 
There are two common techniques for the lysis of cells: 1) physical means or 2) 
the use of detergents. Lysis by physical means employs a method that physically ruptures 
the cell membrane. Sonication, freeze/thawing, and grinding are a few examples of 
physical lysis. There are some drawbacks associated with this technique. Often during 
physical disruption, a localized heating may occur, which can lead to the denaturation or 
aggregation of cellular proteins[Alberts 1994]. Another problem is the lack of 
consistency with making lysates. Cells are not homogenous and will therefore dissociate 
at various rates. Because of this, there is little control over the rate and extent of cellular 
components being disrupted[Alberts 1994].   
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The other means of lysing a cell is by the use of detergents. Detergents disrupt the 
lipid barrier surrounding the cells by solubilizing the proteins and interfering with the 
interactions that hold them together. This type of lysis is generally milder than physical 
disruption. However, detergent lysis is often used in conjunction with sonication for a 
more complete means of releasing cellular proteins. There are several detergents 
available: ionic, zwitterionic, and nonionic. The latter two types are less denaturing than 
the ionic detergents, which tend to destroy protein activity. Various detergents have been 
shown to have different capabilities of dissolving aggregates. For example, SDS (sodium 
dodecyl sulfate) treatment has been shown inefficient at dissolving late-stage fibrillar htt 
aggregates [Davies et al. 1997; DiFiglia et al. 1997; Kazantsev et al. 1999]; whereas, 
early forming htt exon-1 aggregates have been found susceptible to treatment with the 
detergent [Poirier, Li et al. 2002]. Although there are no formal guidelines for choosing 
the proper detergent for studying aggregates, we tried to choose a detergent that has not 
been shown to have solubilizing effects on polyGln aggregates.   
We chose to use detergent lysis followed by sonication in order to release the 
cellular proteins. Triton® X-100 is a nonionic detergent that is commonly used for the 
isolation of proteins [Barbero et al. 1984]. Triton® X-100 was chosen largely because it 
was also used we used during our polyGln recruitment stain. Cell lysates were prepared 
from htt-inducible cells using a balanced salt solution containing the following 
constituents: 150mM sodium chloride (NaCl), 0.1% Triton® X-100, 50mM Tris, 50mM 
HEPES, 1mM EDTA (ethylenediamine tetraacetic acid ), and  a cocktail of inhibitors of 
various classes of proteases (#P8340, Sigma-Aldrich). The addition of protease inhibitors 
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was necessary to prevent the unwanted proteolytic degradation of the sample [Roskams 
2002]. 
At specified time points that correlated with the microscopic data, i.e., 24-72 
hours post-induction, cells were detached, counted, and disrupted using the lysis buffer. 
Cell lysates were prepared at a density of ~2.0x107 cells/200µl of lysis buffer. Whole cell 
lysates were sonicated for 20 seconds and divided into two portions, one of which was 
retained for analysis at a later time. The other portion was subjected to fractionation by 
either centrifugation or gel filtration.    Lysates were prepared, snap frozen, and stored at 
-80°C for future analysis. Protein concentrations were determined using the Coomassie 
Plus – Better Bradford Assay (#23236, Pierce, Rockford, IL). 
FRACTIONATION BY GEL FILTRATION 
Two separate methods were used to isolate the observed polyGln species: 1) size 
exclusion chromatography (gel filtration) and 2) differential centrifugation. Gel filtration 
is used to separate proteins based on their size, where larger proteins elute faster than 
smaller proteins.  
Q103 lysate samples were sonicated briefly, and 200µl (~8mg/ml) of the total 
sample was loaded onto a Sephacryl® S500HR resin (#S500HR-100ML, Sigma-Aldrich). 
The same buffer used for cell lysis was also used for protein elution. Fractions were 
collected immediately and until triple the bed volume (10ml) had been achieved. A total 
of 67 fractions were collected in 500µl volumes each. After the fractions had been 
collected, absorbance readings at 280nm (wavelength specific for proteins) and protein 
concentrations were obtained for each sample.   
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FRACTIONATION BY DIFFERENTIAL CENTRIFUGATION 
Differential centrifugation relies on the fact that there are many proteins with 
different masses within the cell suspension that will separate at different rates. For this 
reason whole cell lysates (W) were subjected to two centrifugation speeds: a slower 
speed to pull down the larger particles and a higher speed to collect the smaller 
aggregated species (refer to Figure 3.4). The samples were briefly sonicated and 
centrifuged at 15,000xg for 30 minutes at 4°C. The supernatant (S1) was transferred to a 
new tube, and the pellet was washed twice with lysis buffer. The combined washes and 
supernatant (S1) from the first centrifugation was subjected to a 100,000xg spin for 30 
min at 4°C. Both the pellet from the 15,000xg (P1w) and the pellet from the 100,000xg 
(P2) were resuspended, separately, in lysis buffer. Protein concentration was determined 
on each fraction (W, P1w, P2, and S2 – final supernatant fraction) before further analysis. 
Our hypothesis was that the P1w fraction would contain the largest aggregates; the P2 
fraction would contain the smaller, nuclear aggregates and aggregation foci; and the S2 
fraction would contain monomeric protein. Fractionation by differential centrifugation 
provided a good way for separating the large aggregates from the smaller aggregates and 
monomeric protein. Several wash steps had to be introduced in order to release the sticky 
proteins from cellular debris. However, this method proved useful for the crude 
separation of proteins.  
Cell lysate preparation 
15,000x g 30min Pellet 1 washed & 
resuspended in lysis 
buffer (P1w)
100,000x g 30min 
Supernatant 2 (S2) 
Pellet washed 2X 
w/ lysis buffer 
Sonicate  
Induced cells 
Supernatant 1 (S1) 
Pellet 2 (P2) 
resuspended 
in lysis buffer 
Figure 3.4: Schematic representation of polyGln aggregate isolation protocol by differential centrifugation. Cell lysates 
are prepared from cells 24-72h post-induction. The lysates were subjected to a medium and low speed centrifugation step. Both 




3.7 Protein Gel Electrophoresis and Western Blot Analysis: 
PROTEIN GEL ELECTROPHORESIS 
The fractionated cell lysates were then subjected to protein gel electrophoresis (a 
technique used for separating proteins according to their net charge: smaller proteins 
migrate faster than large ones) and Western blot analysis. Commonly, protein separation 
is performed on polyacrylamide gels [Laemmli 1970]. Proteins are often found in 
complexes or aggregated states. When the goal of an experiment is to study individual 
proteins or gain information about the non-aggregated state, it is important to denature 
the protein prior to loading the sample onto the gel. SDS is an ionic detergent that is 
commonly used for this purpose. SDS treatment abolishes the effects of any differences 
in shape, so proteins are separated solely on their masses.  
Two gels were loaded with equal amounts of material (~9µg/well prepared from 
~2x107 cells) were loaded into a 10-well pre-cast NuPAGE® (polyacrylamide gel 
electrophoresis) 4-12% Bis-Tris gel from Invitrogen Corporation (#NP0321BOX) and 
subjected to electrophoresis under denaturing conditions (according to manufacturer’s 
instructions). After which, one gel was stained with Coomassie Blue (a protein specific 
dye) and the proteins from the other gel were electrotransferred onto 0.2µm nitrocellulose 
membranes (#LC2000, Invitrogen) using the XCell II Blot Module (#E19051, 
Invitrogen). Transfer of the proteins took ~2 hours at 35 Volts.  
WESTERN BLOT ANALYSIS  
Nitrocellulose membranes containing the cell lysate proteins were analyzed for 
their reactivities to anti-GFP (#sc-8334, Santa Cruz Biotechnology, Santa Cruz, CA) and 
1C2 (#MAB1574, Chemicon, Temecula, CA) (anti-polyglutamine) antibodies. Briefly, 
each membrane was blocked with 1% Casein (in TBST) for 1h and exposed to either the 
1C2 or anti-GFP antibody at a 1:1,500 or 1:150 dilution, respectively, for 1 hour at room 
temperature. The membranes were washed with 1X TBST and then exposed to a 
horseradish peroxidase (HRP) conjugated goat-anti-mouse or rabbit secondary antibody 
(depending on the primary antibody) at a 1:10,000 dilution (Jackson Laboratories, Bar 
Harbor, ME) for 1 hour. After thoroughly washing the membranes with 1X TBST, 
Luminol (#sc-2048, Santa Cruz), a chemiluminescent product, was used to detect 1C2 
and anti-GFP reactive protein bands. The membranes were exposed to autoradiography 
film and developed using Kodak supplies.  
3.8 Microtiter Plate Extension Assay: 
Centrifuged fractions of htt-inducible cell lysates were examined for their ability 
to support polyGln recruitment as measured by the microtiter plate polyGln extension 
assay [Berthelier, Hamilton et al. 2001]. Cell lysate material (~9µg/well) was coated into 
the wells of a 96-well plate and allowed to air dry overnight at 37°C. As a positive 
control for polyGln extension, synthetic K2Q47K2 aggregates (80ng/well) were also 
immobilized in the microplates. The plates were thoroughly washed with extension buffer 
(1X PBS with  0.01% Tween® 20) and blocked for 1 hour in a 0.3% Gelatin solution. The 
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plates were again washed and incubated with 100µl/well of either extension buffer 
(negative control) or 100nM biotinylated Q28 monomer (the same concentration as used 
in the microscopy experiments) for 1-3 hours.  
After monomer incubation, the plates were washed then incubated with 
100µl/well of a 100ng/ml streptavidin-labeled Europium (Eu) solution (0.5% bovine 
serum albumin (BSA)) for 1 hour. The plate was again washed, and europium released by 
the addition of 100µl/well of an enhancement solution (#1244-105, PerkinElmer, 
Waltham, MA). Eu-incorporation was measured by time-resolved fluorescence in a 
Victor2 1420 Multi-label Counter (EG&G Wallac, Gaithersburg, MD). Europium counts 
were converted to femtomoles using a determined standard curve.   
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CHAPTER 4 
FLUORESCENCE METHODS FOR AGGREGATE DETECTION 
4.1 Rationale:   
It is well documented that polyGln aggregates are present in HD disease tissue, 
and in various models of HD and other CAG repeat diseases [DiFiglia et al. 1997; Ross 
1997; Lunkes and Mandel 1998; Hackam et al. 1999; Kazantsev et al. 1999; Bates 2002; 
Marsh et al. 2003]; however, it is unclear the precise role they play in the disease 
mechanism. There have been much evidence supporting a toxic role of the aggregates 
themselves [Cooper et al. 1998; Hackam et al. 1999; Yamamoto et al. 2000; Kazantsev et 
al. 2002; Yang et al. 2002]; conversely, there is also speculation that the aggregates are 
not directly linked to toxicity [Cummings and Zoghbi 2000; Tobin and Signer 2000]. It 
has also been proposed that aggregates represent an end stage in an aggregation process 
with multiple steps [Ross and Poirier 2005]. This is suggestive that early events, 
including the formation of misfolded monomers [Weissmann 2005; Nagai et al. 2007] or 
soluble oligomeric/protofibrillar intermediates [Poirier et al. 2002; Bucciantini et al. 
2004; Katsuno et al. 2004; Wacker et al. 2004; Mukai et al. 2005] accelerated by the 
expansion of the polyGln sequence, may actually be responsible for cellular toxicity. 
Nevertheless, there is not an agreement on which species actually exist in the cell and 
which are toxic; furthermore, it is also not known whether the intermediate species are 
“on-” or “off-pathway” in aggregate formation.  
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In vitro, polyGln proteins have been shown to form a host of aggregate types with 
different sizes, shapes, and functional characteristics [Wetzel 2006]. Among these, 
amyloid-like fibrils are highly ordered structures that are capable of growth by monomer 
addition [Lomakin et al. 1996; Lomakin et al. 1997; Berthelier et al. 2001; Chen et al. 
2002; Collins et al. 2004; O'Nuallain et al. 2005]. Smaller polyGln aggregates were more 
potent, on a weight basis, than larger aggregates at recruiting biotinyl-monomer [Chen, 
Berthelier et al. 2001]. Currently, aggregate detection methods are not optimal and often 
rely on the fluorescence associated with fusion proteins for identification or antibodies 
that recognize the presence of polyGln sequences. Methods such as these may not be 
sufficient to recognize every aggregated species that might be present and may not be 
specific enough to distinguish among aggregate types and to detect the most toxic 
species. Therefore, much attention has been given to the need for more sensitive 
detection methods, which should help reveal the aggregation pathway.  
In vitro discoveries in our lab [Berthelier et al. 2001; Chen et al. 2001; Chen et al. 
2002] led to the development of a highly sensitive stain that recognizes areas active in 
recruiting free polyGln monomer [Osmand, Berthelier et al. 2006], allowing for the first 
time a functional staining method for better characterizing aggregated species. Initially, 
this stain was developed using HD patient and animal brain tissue, but its success in these 
settings raised the possibility that such an assay may also be beneficial in characterizing 
aggregates in cell culture. The polyGln recruitment stain was adapted and applied to 
various cell culture models. In this chapter, we will discuss the optimization of the new 
detection method, the problems and limitations of the technique, and the caveats of the 
microscopic evaluations.  
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In our cell models, htt-polyGln expression was monitored by the presence of a 
GFP-fusion tag. The GFP fluorescence yields two expression patterns: diffuse and 
punctate. Diffuse fluorescence, in such models, is assumed to be representative of 
monomeric species [Lunkes and Mandel 1998; Preisinger et al. 1999; Apostol et al. 
2003], and punctate fluorescence is always used synonymously with the term “aggregate” 
[Fink 1998; Johnston, Ward et al. 1998; Lunkes and Mandel 1998; Garcia-Mata et al. 
1999; Kazantsev, Preisinger et al. 1999; Preisinger, Jordan et al. 1999; Apostol, 
Kazantsev et al. 2003]. It must not be overlooked that punctate centers of fluorescence 
may also represent a collection of monomers trapped in an organelle, such as a lysosome, 
proteasome, or aggresome. However, for the purposes of this dissertation, this 
terminology will be adopted; therefore, “diffuse fluorescence” and “monomer” will be 
used interchangeably, as will “punctate fluorescence” and “aggregate”. As will be seen 
later, this usage is validated by our experimental results. Aggregation foci (AF), which 
were identified using the new functional stain, are punctate sites found within the cell that 
actively recruit externally added polyGln monomer. AF and polyGln recruitment-
competency will be used equivalently.  
4.2 Detection by Fluorescence: 
As mentioned above, the AF stain was originally developed in using HD patient 
and animal autopsied brains [Osmand, Berthelier et al. 2006]. This method was modified 
for the use in cell cultures (see Section 3.3). One modification to the original protocol 
was the method of detection. The preferred method for visualizing AF in cell cultures 
was fluorescence. Some major reasons for this was because our protein of interest already 
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had a fluorescent tag associated with it, and the use of fluorescence allowed for the ability 
to incorporate multiple colors (theoretically, as many as four) within the same 
experiment. For our experimental purposes, three fluorescent labels were utilized: 1) 
green – expressed upon transfection / induction of htt-polyGln-GFP fusion proteins, 2) 
blue – Hoechst dye used to stain the cell nuclei, and 3) red – streptavidin-conjugated 
Alexa Fluor® 594 dye used to detect biotinylated polyGln monomer (see Section 3.3). 
These three fluorescent labels were chosen for their different absorption properties, which 
made it possible for the simultaneous detection of multiple events / species (Figure 4.1).   
4.3 Determination of the Correct Incubation Conditions: 
The polyGln recruitment stain was optimized primarily in the transiently 
transfected cell models expressing htt-Q47-GFP constructs. Various 
concentrations of biotinylated polyGln monomer (10nM, 50nM, 100nM, and 500nM) 
were incubated with fixed and permeabilized cells for 16 hours at room temperature 
(Section 3.3). The concentration that gave the most consistent results and the best 
fluorescence signal, while keeping the background to a minimum, was 100nM. After the 
optimal concentration had been decided, incubation times (1 hour – 16 hours) and 
temperatures (room temperature, 4°C, and 37°C) were varied. Incubation at room 
temperature provided the best signal-to-noise ratio, while incubation at 37°C provided 
excessive background, presumably due to the self-aggregation of the monomer. 
Irrespective of temperature below 25°C, incubation for 16 hours with the biotinylated 






























Figure 4.1: Absorption spectra of fluorescent dyes used for detection. Dashed lines 
represent the excitation spectra, while solid lines represent the emission spectra. Blue 
color is for Hoechst dye, green color is for GFP fusion proteins, and red color is for 
Alexa Fluor 594® streptavidin-conjugated dye. (Created using Spectra Viewer from 









checked with the stably transfected PC12 cells, and polyGln recruitment competency was 
slightly diminished after prolonged incubation (16 hours) with 100nM of the biotinylated 
monomer; therefore, the protocol was modified such that incubation with 100nM 
biotinylated polyGln monomer was carried out at room temperature for 2 hours prior to 
staining (Figure 3.3). Figure 4.2 shows the optimal conditions for both the transiently 
transfected cells and the stably transfected PC12 cells. 
4.4 Image Exposure Time Variations: 
When working with different fluorescence entities, one problem that is often 
encountered is the various camera exposure times that are required for each fluorescent 
dye and for varying degrees of fluorescent intensities using the same fluorochrome. An 
example of the latter is the situation in which both monomer and aggregate were present 
within the same microscopic field. Monomeric expression had much less fluorescence 
intensity than an aggregated structure. This is probably due to the concentration of the 
protein at any one location or the compact folding of the htt- polyGln-GFP protein, which 
presumably brings many GFP into close proximity creating a much more intense object. 
 In order to collect interpretable data, two exposure times of the green image 
where taken so that both types of species could be more properly characterized (Figure 
4.3). The first exposure was taken at 500 milliseconds (msec) to capture the diffuse 
entities, while the second image was exposed using the automatic / default exposure time 
(< 1 msec). Images taken from both exposure times are necessary so that all species can 
be accounted for. Exposure times for red images also had to be modified from the normal 











Figure 4.2: Optimal AF staining conditions in a transient and stable htt exon-1 cell 
models. (A) Transiently transfected PC12 cells expressing htt-Q47-GFP constructs. (B) 
SH-SY5Y cells transiently transfected with htt-Q47-GFP constructs. 100nM biotinylated 
monomer was incubated for 16 hours at room temperature before staining in each of the 
transient models. (C) Stable 47QP PC12 cells. 100nM biotinylated monomer was 
incubated for 2 hours at room temperature prior to staining. Fluorescence color is blue for 











Figure 4.3: Various exposure times needed to photograph different fluorescence 
entities. Both images are of the same field of stable 103Q cells 24 hours post-induction. 
(A) 500 msec exposure time. (B) <1 msec exposure time. Blue color is cell nuclei and 
green color is htt-polyGln-GFP protein. The white box shows that diffuse protein was 
photographed only when the longer exposure time (A) was utilized, which caused the 
aggregated species to be overexposed. Therefore, two exposures of such images were 
necessary to account for all species present.  
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captured at a 1 second exposure time to account for the diminished fluorescence intensity 
and the photobleaching of the Alexa Fluor 594® dye. Blue images were exposed to the 
camera using the default settings and were the last fluorescence images taken in the series 
because of the high stability of the fluorochrome. 
Development and optimization of the AF stain allowed, for the first time in cell 
cultures, the observation of a class of aggregates capable of further growth by monomer 
addition, as is especially evident in Figure 4.2C. This new technique promised to be very 
beneficial in characterizing multiple aggregated species and their roles in the aggregation 
pathway.  
4.5 Fluorescence Microscopy Caveats: 
As will be shown later, we identified a number of morphological forms of htt 
exon-1 in our cell models, including dispersed fluorescence normally interpreted as 
monomeric protein, as well as several different types of aggregates. It is appropriate in 
this discussion of the fluorescence microscopy to include some caveats and rationales for 
some of the assumptions we make in the interpretation of our microscopy data.  
There were limitations to the types of analysis that could be performed using a 
two dimensional imaging system. For example, subcellular localization of the protein 
(nuclear/cytoplasmic or co-localization) could not be irrefutably confirmed. In many 
images presented throughout this dissertation, there will be an apparent co-localization of 
the different polyGln species. The only thing that can be said for certain is that, in the 
case of co-localization, the two species, were in the same cellular location (Z-plane), and 
without the use of a three dimensional imaging system, such as confocal microscopy, we 
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could not exclude the possibility that the two species were, perhaps, independent and not 
co-localized. The same is true for the question of nuclear vs. cytoplasmic localization. 
The appearance of nuclear accumulation may actually be cytoplasmic accumulation 
located in the volume above or below the nucleus. More images will be presented 
throughout this dissertation that appear to exhibit co-localization or nuclear distribution, 
but when interpreting the data, one cannot must consider the alternative interpretations. 
This problem is more difficult to resolve in the case of determining with certainty 
whether aggregates are in the nucleus.  In contrast, when a cell contains a limited number 
of punctuate green objects, and the only red objects observed are found to exactly co-
localize with them, it seems unlikely that these objects are not truly co-localized; 
however, the possibility remains that they are distinct. 
Another limitation of the imaging method is the question of whether diffuse green 
fluorescence is actually indicative of monomer. As stated earlier, a diffuse staining 
pattern, like as observed in our cells, is often interpreted as monomeric species [Lunkes 
and Mandel 1998; Preisinger et al. 1999; Apostol et al. 2003].  However, in our 
experiments at least, the “diffuse green” areas often have a speckled appearance and 
don’t always provide a uniform distribution. It might thus be argued that the granular 
appearance of these “diffuse green” areas might arise from a field of microaggregates ( or 
htt-polyGln-GFP in organelles/lysomes/proteasomes) rather than monomeric protein. 
However, this granular appearance most likely is a consequence of the camera exposure 
time needed to capture the diffuse pattern (Section 4.4). This question could not be 
addressed by fluorescence microscopy – at least not with the available equipment – but 
instead was addressed by other, biochemical experiments (presented in Chapter 8). 
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CHAPTER 5  
DEVELOPMENT AND EVALUATION OF CELL MODELS EXPRESSING HTT 
EXON-1 CONSTRUCTS 
5.1 Rationale: 
Implementation and optimization of the AF stain were explored in two types of 
cell models: transient and stable. Transient models were explored first, as the most 
straightforward approach, while stable, htt-inducible models were utilized in later 
experiments and were found to be the superior model system. In this chapter, we will 
discuss the development of each of these cell model systems (transient and stable) 
expressing htt exon-1 constructs, the limitations, and the problems encountered along the 
way.   
5.2 Transient Cell Models Expressing Htt Exon-1: 
For these experiments, PC12 and SH-SY5Y cells were transiently transfected 
with truncated htt exon-1 constructs expressing Q25, 47, 65, and 103 (as described in 
Sections 3.1 and 3.2). Protein expression was monitored by virtue of the GFP tag 
associated with the htt exon-1 constructs and was calculated at 24 hours post-transfection. 
Therefore, no matter the expression pattern, diffuse, punctate, or AF, the images were 
scored the same: expression or no expression. Total htt-polyGln expression was similar 
for each cell line (Figure 5.1) and aggregation occurred in a polyGln length-dependent 






Figure 5.1: PolyGln expression was similar by flow cytometry and 
immunofluorescence. Flow cytometry data are shown in the left panels. M2 represents 
polyGln expression. Right panels are fluorescence microscopy images: blue – nuclei, 
green – htt-polyGln-GFP. Top row is data from PC12 cells transiently transfected with 
htt-Q65-GFP at 24 hours post-transfection. Bottom row is SH-SY5Y cells transiently 






Figure 5.2: Aggregation occurs in a polyGln-length dependent manner. PC12 cells 
were transiently transfected for 24 hours with various lengths of htt-polyGln-GFP 
constructs. (A) Q25, (B) Q47, (C) Q65, (D) Q103. Fluorescence color is blue for cell 
nuclei and green for GFP fusion constructs. Cells were exposed to the AF staining 
procedure as well but exhibit no red AF above background.  Aggregation was faster when 
cells expressed longer polyGln repeats. 
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exhibiting GFP fluorescence and did not necessarily reflect any species that exhibited 
AF, while microscopic measurements were calculated by counting cells that exhibited all 
types of htt-polyGln fluorescence (red and/or green) and dividing by the total number of 
cells in the microscopic field.  
For microscopic experiments, SH-SY5Y cells were differentiated in order to aid 
in cellular attachment. However, experiments involving PC12 cells were performed 
without differentiation because the cells did not possess the same detachment properties 
that were observed with SH-SY5Y cells (Section 3.2). Figures 5.3 and 5.4 show a 
temporal progression of polyGln expression in transiently transfected PC12 and SH-
SY5Y cells, respectively.  
Cells expressing htt exon-1-Q25-GFP exhibited a faint, diffuse green fluorescence 
throughout the cytoplasm (PC12 and SH-SY5Y cells) and/or the nucleus (SH-SY5Y 
cells) at all time points studied and never showed any aggregation foci. In contrast, cells 
transfected with htt exon-1-Q47, 65, or 103-GFP produced two types of aggregates 
(Figure 5.5).  One class consisted of punctate green-fluorescent aggregates that developed 
by 24 hours and whose numbers correlate with polyGln-repeat length (Figure 5.6). These 
aggregates were primarily located just outside the cell nucleus (perinuclear) in the PC12 
cells with some apparent localization in the nucleus for SH-SY5Y cells. The second class 
of aggregates were recruitment-competent but at the same time not observable by GFP 
fluorescence.  These were more evident in cells expressing htt exon-1-Q47 and Q65-GFP, 
and tended to form at early time points (Figure 5.6). Aggregates that exhibited GFP 
fluorescence appeared to be coincident with AF at early time points (Figures 5.3 – 5.6), 






Figure 5.3: Transiently transfected PC12 cells expressing various polyGln-length 
constructs. Blue – nuclei, Green – htt exon-1-Qn-GFP, Red – aggregation foci. (a) 
Columns from left to right represent the various lengths of polyGln constructs expressed 
in PC12 cells. Rows from top to bottom show the temporal progression of polyGln 
expression from 16 hours to 72 hours post-transfection. A magnification for observing 
specific detail will be provided for pictures of particular interest. For example, at 16 
hours and 12 hours post-transfection with htt-Q47-GFP and htt-Q65-GFP, respectively, a 
class of aggregates form that are recruitment-positive but do not exhibit green 
fluorescence (b). GFP aggregates are often found superimposed on AF in the same focal 
plane, yielding a yellow color mix which represent co-localization, as shown in cells 
transfected with htt-Q65-GFP for 24 hours (c). 
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Figure 5.4: Transiently transfected retinoic acid differentiated SH-SY5Y expressing 
various htt exon-1-Qn-GFP constructs. Blue – nuclei, Green – htt exon-1-Qn-GFP, 
Red – aggregation foci. (a) Columns from left to right show the different polyGln lengths 
expressed in cells. Rows from top to bottom show the time-dependent manner of polyGln 
expression. At 24 hours post-induction, SH-SY5Y cells transitioned from a mostly 
adherent cell line to a mostly floating cell line. A magnification for observing specific 
detail will be provided for pictures of particular interest. At 12 and 16 hours post-
transfection with htt-Q47-GFP AF were the predominant species (b). GFP aggregates are 
often found in the same focal plane as AF, which represent co-localization, as shown in 
cells transfected with htt-Q65-GFP for 16 hours (c) 
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Figure 5.5: Aggregated species observed in transiently transfected PC12 cells. (A) 
htt-Q103-GFP at 16 hours post-transfection. (B) htt-Q47-GFP at 16 hours post-
transfection. (C) htt-Q103-GFP at 72 hours post-transfection. Blue – cell nuclei, green – 
























Figure 5.6: Percentage of cells exhibiting different polyGln expression patterns in transiently transfected PC12 cells. 
Data were obtained from microscopy images. At least two independent fields were counted within a single experiment. No AF 
or punctate green aggregates were observed in cells expressing htt-Q25-GFP constructs (data not shown). Red bars represent 
AF, green bars represent punctate htt-polyGln-GFP aggregates, red/green stripped bars indicate the aggregates that exhibit both 





























































Interestingly, PC12 and SH-SY5Y cells expressing htt exon-1-Q47 exhibited an 
abundant population of AF at 16 hours post-transfection, prior to the formation of 
punctate polyGln aggregates detected by GFP fluorescence (Figures 5.3, 5.4, and 5.6). 
AF diminished with increasing transfection times as the larger, GFP polyGln aggregates 
became more abundant.  The implications of the timing of appearance of these two 
classes of aggregate will be considered in a later chapter.  
As expected, cells expressing the hyperexpanded htt exon-1-Q103-GFP construct 
were more aggressive in the formation of polyGln aggregates. Interestingly, there was a 
mixture of both recruitment-competent and recruitment-inert GFP-positive aggregates 
(Figure 5.6). The small number of AF observed only briefly exhibited coincidence with 
the punctate polyGln aggregates. At later stages of cell growth, green fluorescent 
aggregates inefficient at polyGln recruitment became more dominant.   
We observed inconsistencies in the expression patterns for both cell lines in 
multiple experiments, irrespective of the polyGln length (Figure 5.7). For example, one 
experiment would yield polyGln expression of 35%, while another experiment (following 
the same protocol) would yield an expression of 18%. These data were again confirmed 
by flow cytometry (Figure 5.8). The inconsistencies observed did not appear to correlate 
with the passage number of the cells before transfection.   
Regardless of the cell line, htt exon-1-Qn-GFP protein expression was never more 
than 35% at 24 hours post-transfection, and cells with aggregation foci numbered far less 



































Figure 5.7: Inconsistencies observed in percentage of polyGln expression. Data was 
obtained from at least 4 independent experiments. PolyGln expression was calculated at 
24 hours post-transfection as the percentage of cells expressing any detectible form of htt 
exon1: diffuse green, punctuate green, or red AF. This total expression figure was never 






Figure 5.8: Transfection efficiency varied between experiments. SH-SY5Y cells were 
transiently transfected for 24 hours with htt-Q47-GFP. Left panel: flow cytometry. Right 
panel: immunofluorescence, blue – nuclei, green – htt-polyGln-GFP. Expression levels 
















 restrictions on the kinds of experiments we could do and the kinds of interpretations we 
could make. With such low expression levels and the transient time frame in which AF 
were present; characterization of the various aggregates would have been challenging and 
not very fruitful. For example, in a cell population expressing only a handful of 
aggregates, as is evident in Figures 5.2 – 5.4, it is very difficult to make global 
interpretations from extracts of the entire population, especially when this population of 
cells is the minority. The above limitations led us to investigate an alternative model 
involving stably transfected cells engineered for inducible expression, described next.   
5.3 Stable PC12 Model Expressing Various Htt Exon-1 Constructs: 
Although the work on the transient protein expression systems provided the 
groundwork for the dissertation research, the majority of the experiments and the most 
exciting data were obtained from PC12 cells stably transfected for inducible expression 
of htt exon-1 (see Sections 3.1 and 3.2). This section will provide the details pertaining to 
the creation a viable cell model system that exhibited a high percentage of polyGln 
expressing cells and the troubleshooting that was addressed along the way.     
For these experiments, stable PC12 cells expressing complete htt exon-1 
constructs (Gln repeats: 25, 47, and 103) and truncated htt exon-1 fragments (Q103) were 
induced for 24 hours, as described in Section 3.2, to determine the initial polyGln 
expression levels in each of the cell lines. As with the transient models, polyGln 
expression was monitored by following the green fluorescence of the attached GFP 
molecule. Given that we found an excellent correlation between the quantitative flow 
cytometry data and qualitative immunofluorescence images in all our transient expression 
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experiments (Figures 5.1 and 5.8), in subsequent experiments only the microscopy data 
was used to determine levels of expression. As received from the Thompson lab, the 
25QP and 103QP cells had initial GFP expression levels of ~32%, while the 47QP cells 
had a beginning expression level of ~22%. Q103 cells, on the contrary, exhibited a high 
number of cells the expressed htt-polyGln-GFP (~65%).  
Considering the relatively low percentages of protein expression in the cells 
expressing the complete htt exon-1 constructs, these three cell lines were subcloned with 
selection for  high htt-GFP expression (Figure 5.9 for representative) (see Section 3.2) 
[Freshney 1987]. After the cells had been subcloned, percent expression increased to 
~56% in each cell line. While the 25QP and 103QP cell lines after subcloning maintained 
these expression levels, a stability issue arose with the cell line expressing the 
physiologically relevant Gln repeat (47QP). Following a freeze/thaw cycle of the 47QP 
cells, polyGln expression reverted back to the observed basal expression levels of ~22% 
(Figure 5.10). Furthermore, the intensity at which the polyGln species were observed in 
the subcloned cells prior to the freeze/thaw cycle was vastly superior to those seen 
afterwards. Repeated attempts at subcloning the parental 47QP cells did not yield 
satisfactory results. Finally, our collaborators kindly supplied a new parental vial of cells 
from an earlier passage and a separate clone. Upon subcloning these cells, we were able 
to achieve and maintain 47QP cells that exhibited high clonal integrity for exon-1 
production, irrespective of the amount of times they were subjected to freezing and 
thawing (Figure 5.11).    
Considering polyGln expression was stabilized after receiving the new vial of 
parental 47QP cells, the problem we encountered using the original lot of cells was 
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Figure 5.9: Representative sample of cells before and after clonal dilution. Top 
panel: 103QP cells prior to enrichment. Bottom panel: 103QP cells after selection for a 
high percentage of htt-polyGln-GFP expressing cells. (A & C) Phase contrast microscopy 











Figure 5.10: Stable PC12 cells expressing 47QP were unable to maintain high clonal 
integrity once subjected to a freeze/thaw cycle. (A) Cells were photographed at 48 
hours post-induction and exhibited ~56% htt-polyGln-GFP prior to being frozen. (B) 
Cells were thawed and induced for 48 hours. Expression levels dropped to ~20% after 












Figure 5.11: New 47QP parental cell line generated stable expression after repeated 
freeze/thaw cycles. Photograph was taken 48 hours post-induction. Blue – nuclei, green 
– htt-polyGln-GFP, red – AF.  
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probably due to poor stability of the inserted transgene into that particular parental clone. 
Obtaining a different clone of the 47QP parental cells appeared to resolve the problem, 
and additional subcloning provided a population with high clonal integrity that was 
unaltered by successive freeze/thaw cycles.  
Other complications arose during experiments with the stable PC12 cells.  A 
reoccurring obstacle that was addressed in many ways but was never quite resolved was 
the issue of cell detachment. Irrespective of the incorporated htt construct and inducing 
agent, each cell line had a tendency to lift from the coverslips on which the cells were 
grown. As mentioned with the transient cell lines (Section 3.2), this phenomenon limited 
cell numbers at later growth points and introduced the possibility that selective 
detachment might skew results. Several steps were taken to address this issue including 
the use of poly-D-lysine, a common attachment factor used in cell culture, as a coating 
agent. Another change that was integrated into the protocol was the use of the pH 
buffering agent HEPES.  While these efforts yielded some improvement, the most useful 
change was to the seeding density of the cells. These cells had a very quick doubling time 
(32-36 hours). Once the cultures became slightly overgrown, the cells began to detach; 
this may be due to a depletion of nutrients in the culture medium, but detachment seemed 
to occur regardless of how often the media was changed. In any case, decreasing the 
density at which the cells were plated provided the most beneficial results and decreased 
the detachment rate, which was especially evident in the later time points. Prior to these 
changes, an estimated 50% of the plated cells lifted from the coverslips; however, after 
the changes were incorporated, we estimated that <10% of the culture had detached. We 
also examined the detached cells, and found that the cells that had lifted from the 
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coverslips were a mixed population of cells that expressed the GFP transgene and those 
that did not. Thus, the detachment problem was not a direct effect of the incorporated htt 
transgene, and it is clear that detachment is not an indication of polyGln-dependent cell 
death or dystrophy. 
One of the biggest obstacles encountered was the inability to view polyGln 
recruitment via live cell microscopy. A drawback to the current staining technique is that 
in order for the cells to take up free monomeric peptide, the cells must be permeabilized. 
For this reason, there was no feasible way to view polyGln incorporation in real-time. In 
principle, this might be done by co-expression of an appropriately tagged short polyGln 
substrate, analogous to our biotinylated polyGln peptide; however, the problem of 
peptide uptake would have still been present. 
PRESENCE OF INDUCIBLE-HTT DOES NOT CAUSE CYTOTOXICITY 
Many cell models have shown reduced viability when cells express an expanded 
polyGln protein [Lunkes and Mandel 1998; Chai et al. 1999; Li, Cheng et al. 1999; 
Wyttenbach et al. 2001; Yang et al. 2002; Aiken, Tobin et al. 2004], while other groups 
have found contradictory results [Ding et al. 2002; Apostol et al. 2003; Webb, Ravikumar 
et al. 2004]. Prior to aggregate characterization (discussed in Chapter 6), we wanted to 
confirm whether or not the htt constructs were causing cell death.  As discussed earlier, 
while cell death might in some sense validate these cells as a valid model for HD, the loss 
of cells and their contents during the experiment – and before analysis – would clearly 
have complicated the interpretation of data. Microscopically, it did not appear that the 
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presence of the htt insert was causing cell death. However, it was imperative to determine 
whether or not this was true.  
We performed an MTS reduction assay (Section 3.4) to determine the number of 
proliferating cells within each induced culture at 24 hours post-induction. We found that, 
irrespective of the polyGln length insert, overt cytotoxicity was not detected (p>0.2, 
Figure 5.12). As is evident by the absorbance values in Figure 5.12, each cell line was 
plated at different seeding densities. Regardless of the plating density, polyGln 
expression had no effect on cell viability.  
It has been shown that, for reasons not entirely understood, these particular cell 
lines are not susceptible to polyGln-induced cytotoxicity [Apostol, Kazantsev et al. 
2003], and our data were consistent with these results. Recently, Apostol and colleagues 
performed gene expression profiling on this particular cell line and showed that genes, 
such as HSP27 and 70, involved in pro-survival pathways were significantly upregulated 
[Apostol et al. 2006], providing a possible reason why these cells do not die even with 
nuclear aggregates present.  
We were successfully able to subclone three of the four received stable cell lines. 
The fourth did not need further enrichment because they were initially obtained at an 
already high clonal integrity. Each cell line provided consistent expression levels from 
experiment to experiment, and the protein abundance (~60%) was far superior to that of 
the transient models (~30%). These data will be presented in the next chapter. The use of 
an inducible system was also beneficial because it provided more control of the 
experimental timeline, i.e. the experiment could be conducted for longer times. The 






















Figure 5.12: Polyglutamine expression does not cause cell death. Each cell line was 
plated at different seeding densities: 25QP cells were plated at a density of ~100,000 
cells/cm2; 47QP and 103QP cells were plated at a density of ~60,000 cells/cm2; and Q103 
cells were plated at a density of ~200,000 cells/cm2. A cell proliferation assay (MTS 
reduction) was performed to measure the number of viable cells. Although there were 
slight fluctuations in the number of measurable cells, no significant change was observed 





which provided more physiological relevance than the truncated models lacking the 
proline rich C-terminus. It has been well documented that the presence of a proline-rich 
sequence following polyglutamine in huntingtin significantly decreases the rate of 
aggregate formation [Bhattacharyya, Thakur et al. 2006; Dehay and Bertolotti 2006]. 
Inclusion of the proline-rich segment not only made the cell model more relevant to the 
disease situation, it also slowed down at least some aggregation reactions, providing an 
opportunity to observe the cells prior to the development of polyGln aggregates and to 
monitor the aggregation pathway (discussed in Chapter 6). This was in contrast to our 
transient transfection models in which aggregates developed very rapidly, making it 
difficult to dissect precursor-product relationships. The fact that the cells did not exhibit 
cytotoxicity was also an advantage because that allowed us to focus strictly on the 
aggregation pathway without complicating the interpretation with cellular demise. 
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CHAPTER 6  
CHARACTERIZATION OF POLYGLUTAMINE AGGREGATES IN STABLE PC12 
CELLS EXPRESSING HTT EXON-1 CONSTRUCTS 
6.1 Nomenclature for Identified PolyGln Species: 
With the detection of multiple polyGln species in the stable, htt-inducible PC12 
cells (to be discussed later in the chapter), a simple nomenclature is clearly required. 
During this section we will establish a nomenclature for the observed polyGln species, 
which will be used throughout the remaining dissertation. 
The species identified were categorized into four major divisions (Figure 6.1): 1) 
Diffuse, monomeric protein (designated Monomer, M), 2) Aggregation foci, which were 
recruitment-competent, diffusely scattered throughout the cytoplasm, and did not 
demonstrate green fluorescence (designated Green- Red(Cytoplasm)+, G-RC+), 3) Aggregates 
that showed GFP formation but did not exhibit recruitment-capabilities (designated 
Green+ Red-, G+R-), and 4) Aggregates that were large enough to be visualized via their 
GFP component but also exhibited polyGln recruitment (designated G+RC+), which 
represented only a small percentage of the observed species and were observed only in 
the cytoplasm. 
Furthermore, the class that was designated G+R- was found in two different 
cellular locations: the majority was perinuclear (designated GC for cytoplasmic 


























Figure 6.1: Distinct polyGln species identified within stable PC12 cells expressing 
htt-inducible proteins. (A) Diffuse monomeric protein. M, green fluorescent protein was 
found diffusely scattered throughout the cytoplasm of most cells. Diffuse staining was also 
found in some cell nuclei during later time points. (B) Aggregation foci. G-RC+, polyGln 
recruitment competent centers that were not detectable by the GFP component. (C) PolyGln 
aggregates that did not exhibit recruitment-competency located in the cytoplasm. GC+R-. (D) 
Nuclear aggregates that were recruitment-inert. GN+R-. (E) Perinuclear aggregates that were 
also capable of polyGln recruitment. GC+RC+, these structures were only visualized in the 
103QP cells at early time points. White inset shows that AF were coincident with GFP 
aggregates. Blue – nuclei, Greene – htt-polyGln-GFP, Red – AF.  
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localization, Figure 6.1D). Perinuclear aggregates are commonly defined as an 
aggregated structure that is found in the cytoplasm close to the nucleus or associated with 
the nuclear membrane [Kazantsev, Preisinger et al. 1999]. These structures are also 
generally quite large and even, in some instances, appear to distort the shape of the 
nucleus. In the case of the stable PC12 cells, perinuclear aggregates were often 1/5 or 
greater the size of the cell nucleus and were easily visualized by their fluorescent tag. 
Nuclear aggregates, on the other hand, have been described to be much smaller and are 
located inside the cell nucleus [Kazantsev, Preisinger et al. 1999] but can also be 
observed via their fluorescent label. 
 The remaining chapters of the dissertation will adopt this nomenclature and will 
present experiments specifically designed to provide insights into a key question that 
plagues HD research: Are these small, recruitment-competent aggregates that occur early 
in development precursors to the larger, recruitment-inert, GFP-positive aggregates, or do 
they form via separate, parallel assembly pathways?  
6.2 Microscopic Observations: 
  This section will present the findings of the data obtained using the stable PC12 
cells expressing htt exon-1 constructs of varying polyGln repeat lengths (25QP, 47QP, 
103QP, and Q103, described in Chapter 3). At least three polyGln species were 
visualized during the seven days in which the replicating cells were monitored by 
fluorescence microscopy (see Figures 6.2 and Figure 6.3). With respect to GFP 
fluorescence, cells expressing 25QP and 47QP exhibited only diffuse green, indicative of 
Figure 6.2:  Percentage of polyglutamine expression within huntingtin-inducible PC12 cells. Data were collected from at 
least two separate experiments. For each time point, cells were counted from three or more independent fields. The data are 
expressed as the percentage of total cells that exhibited either htt monomer (   ), htt-polyGln-GFP aggregates (   ), or 















































































Figure 6.3: Kinetic study of polyglutamine formation in huntingtin-inducible, stable 
PC12 cells and uninduced controls. Fluorescent color is blue for cell nuclei, green for 
GFP fusion constructs, and red for aggregation foci. Time labels indicate hours post-
induction.  (a) First panel: Untreated control PC12 cells. Second panel: Cells expressing 
25QP. Third panel: Cells expressing 47QP. (b) First panel: Cells expressing 103QP. 
Second panel: Cells expressing Q103. In each panel, the left column represents images 
taken by modified differential interference contrast (DIC) microscopy. The last column in 
each panel represents the red, green, and blue merged image. Where present, the middle 
column(s) show a merger of only the red and green images, where the detail of AF and 
htt colocalization may be more easily observed. In part b of the figure, two exposures of 
the same image were taken. The second image was taken at a longer exposure so that the 
monomeric species could be photographed (Section 4.3). In the 103QP cells, where htt 
aggregates were also recruitment-competent, insets (solid white boxes) are included 
showing the red image prior to the merger with the green image. Details of each image 
can be observed at a higher magnification. (c) Diffuse fluorescence and AF were the only 
species observed with 25QP and 47QP cells. Displayed images were taken at 24 hours 
post-induction. (d) Punctate aggregates were present in cells expressing both complete 
and truncated htt exon-1 constructs. Images were photographed at 24 hours post-
induction. The amount of htt-polyGln-GFP aggregates increased with longer induction 
times (Figure 6.2).  
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presumably monomeric htt expression (Figure 6.3c), throughout the seven day 
experiment; whereas cells expressing 103QP and Q103 developed punctate green htt 
(presumably aggregates) early in development that increased in number as the cells aged 
and divided (Figures 6.2 and 6.3d). In addition to green fluorescent species, a third 
species, AF (red fluorescence), was present only in cell lines expressing intact htt exon-1 
including the Pro-rich segment and were not observed (<3%) in Q103 cells that expressed 
truncated htt exon-1 (Figures 6.2 and 6.3c-d).  
 All three cell lines expressing complete htt exon-1 constructs exhibited steady M 
expression over the initial 72 hours (Figure 6.2). In all three cell lines, this expression 
peaked at peaked at 96 hours. While 25QP cells maintained this high M expression out to 
168 hrs, diffuse expression dropped somewhat after 96 hrs for the 47QP and 103QP cells.  
All three cell lines also exhibited steady levels of cells expressing G-RC+ over the first 72 
hrs, after which the percentage of cells with G-RC+ declined, generally by about a factor 
of 2.  Of these three cell lines expressing complete exon1 constructs, only the 103QP 
cells exhibited any significant formation of punctate green bodies; these increased in 
number from 24 to 120 hrs, after which levels remained fairly steady. 
In contrast, Q103 cells expressing a construct lacking the proline-rich region 
exhibited a rapid decline in M expression from 16 to 72 hours, with a commensurate 
rapid rise in punctate green bodies over the same time period.  By 144 hrs over 70% of 
cells had punctate green bodies and no cells exhibited diffuse GFP staining.  
Significantly, only a very low percentage (<3%) of G-RC+ were observed at any time 
point.   
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All cell lines exhibited very good homogeneity of expression, a reflection of their 
being products of rigorous subcloning procedures as well as an indication of the stability 
of their gene insertions.  Thus, by 48 hrs, the Q103 cell line exhibited 94% of cells with 
some manifestation of htt exon-1 expression.  By 96 hrs, 47QP and 103QP reached 
maximal expression of 84 and 66%, respectively.  The 25QP cell line reached maximal 
expression at 24 hrs, with 84% of cells exhibiting expression of the transgene. 
The AF expression patterns in the QP cell lines is especially interesting in several 
respects. First, the conventional view is that cells expressing htt exon-1 with normal 
length polyGln do not make significant aggregates, and indeed this is the case if 
aggregation is only detected as punctate green bodies.  However, using the recruitment 
stain we observe significant G-RC+ formation even at early time points and even in 25QP 
cells.  Second, in 103QP cells, G-RC+ form early while punctate green bodies form later, 
suggesting a possible precursor-product relationship.  Interestingly, at early time points in 
these 103QP cells, AF co-localize with punctate GFP bodies (Figure 6.4); while at later 
times, fewer punctate green bodies contain G-RC+ (Figure 6.5); this also suggests a 
precursor-product relationship where AF develop first. The Q103 cells are also consistent 
with a progression of AF to punctate GFP bodies; since removal of the proline rich 
sequence is expected to lead to more aggressive aggregation (more than triple the number 
of GC/N+R- species, see Figure 6.2), AF may progress so rapidly to punctate GFP bodies 
that few G-RC+ are ever detected. However, these data alone were not sufficient to rule 
out the possibility that they were forming via alternate assembly pathways.  These results 
will be considered further in the last chapter. 








 Blue – cell nuclei, green – htt-polyGln-GFP fusions, red – G-RC+. The first and 
second panels show the separate images taken with the green and red filter sets, 
respectively. The third panel shows a merger of the images including the cell nuclei. 



































Figure 6.5: Co-localization of G R  and G R  aggregates in cells expressing 








 PolyGln aggregates measurable by their GFP 
fluorescence were counted and scored for their apparent coincidence with AF. Data were 
collected from at least five non-overlapping fields in two independent experiments. Data 
is expressed as percentage of GFP aggregates that were coincident with AF. Earlier time 




Another intriguing observation was noted in cells expressing Q103. These cells 
exhibited small GN+-R- aggregates (Figure 6.6), which were not seen with any other cell 
line. Figure 6.7 shows that the percentage of cells that contained nuclear aggregates were 
far less than those that contained the larger GC+R- aggregates. Why does this cell line 
uniquely produce nuclear aggregates?  One possibility is that the proline rich segment is a 
nuclear export signal, so that when it is present it strongly counter-balances some 
intrinsic ability of htt exon-1 to enter the nucleus.  Another possibility is that there is 
always some cycling of htt exon-1 through the nucleus, which however normally does not 
lead to accumulation because of a stronger export signal.  However, with Q103, rapid 
aggregation within the nucleus traps the exon-1.  Other explanations are possible.  
Previously it was shown that when recruitment-positive polyGln aggregates are delivered 
to the nuclei of PC12 cells, they rapidly die [Yang, Dunlap et al. 2002].  Presumably the 
GN+R- aggregates observed here are not toxic because they are not recruitment positive 

















Figure 6.6: Cells expressing Q103 exhibited G R  aggregates.  ImagesN+ -  were obtained 
at 24 hours post induction. The left column represents green images (htt-polyGln-GFP 
fusions), while the right column represents a merger of the image with the blue (nuclei). 
Both top and bottom pictures are the same microscopic field. (A) Images were taken at a 
longer exposure time to photograph diffuse and nuclear entities (500msec). (B) 





























Figure 6.7: G R  aggregates were observed but were less abundant than G R  





 Data were obtained from two separate 
experiments and from at least 3 independent microscopic fields. Data are expressed as 







MECHANISTIC STUDIES OF AGGREGATE FORMATION 
7.1 Rationale:  
We were successful in identifying multiple polyGln species within stable PC12 
cells that are inducible for htt expression. Identification of two of those species, G-RC+ 
and GC+RC+, relied solely upon the development and implementation of a stain that is 
based upon the ability of aggregated polyGln proteins to recruit free monomeric polyGln 
[Berthelier et al. 2001; Chen et al. 2001; Chen et al. 2002; Osmand et al. 2006]. This 
characteristic is similar to other amyloid diseases, in which a proposed mechanism of 
fibril growth is facilitated by monomer addition [Lomakin et al. 1996; Lomakin et al. 
1997; Collins et al. 2004; O'Nuallain et al. 2005]. With the identification of the various 
species, the next logical step was to undertake the challenge of discerning each of their 
roles in the aggregation process. This question was addressed in two manners: 1) utilizing 
a compound that has been shown to inhibit amyloid formation in vivo [Yang, Lim et al. 
2005]  and 2) using other compounds to alter cellular processes that have been implicated 
in aggregation [Johnston et al. 1998; Webb et al. 2004; Ross and Poirier 2005; Chang et 
al. 2006].   
7.2 Curcumin Inhibits G-RC+ Species in a Dose-dependent Manner: 
Curcumin, the main ingredient in the Indian curry spice tumeric, has been used 
therapeutically for its anti-inflammatory, anti-oxidant, and anti-amyloid properties [Lim 
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et al. 2005; Yang et al. 2005]. Curcumin is a low molecular weight compound that has a 
favorable toxicity profile and is currently being investigated as a potential 
chemotherapeutic agent for cancer [Kelloff, Boone et al. 1996]. Curcumin has been found 
effective at inhibiting the formation of Aβ fibrils at concentrations ranging from 0.5µM-
8µM. Recently, curcumin was also shown to reduce aggregate formation and ameliorate 
rearing deficits in an HD mouse model [Zhu 2006]. Because of the possibility that 
curcumin might selectively inhibit amyloid formation, and not other aggregation 
reactions, we chose to treat our stable PC12 cells with curcumin and to monitor any 
effects on the aggregation pathway.  
To monitor the effects of curcumin on aggregate formation, we chose to use the 
htt-inducible cells expressing 25QP and 47QP, a benign polyGln length and a disease-
relevant polyGln length, respectively. In vivo, the most common Gln repeat length is ~42 
(Figure 1.12). These particular cell lines exhibited diffuse monomeric staining and never 
displayed punctuate GFP-positive aggregates within a one week time frame. However, 
~40% of the population expressed G-RC+ species (Figure 6.2) at any given time. The 
question we wanted to answer was if curcumin inhibited or accelerated the production of 
AF.  
 Cells were plated and maintained under the same conditions as previously 
described (Section 3.2). 25QP and 47QP cells were induced with 5µM Ponasterone and 
simultaneously treated with 0.1, 1, or 10µM of curcumin (10mM stock in ethanol) for 24 
hours. After one day of incubation with the compound and inducing agent, the cells were 
fixed, permeabilized, and subjected to the AF stain (Section 3.3).  
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As shown in Figures 7.1 and 7.2, curcumin treatment decreased the formation of 
G-RC+ in both 25QP and 47QP cells by >40% at all concentrations tested (p≤0.02), while 
not appreciably altering the M expression. This effect was dose-dependent, with 10µM 
curcumin (the highest concentration tested) showing a 75% reduction in AF, p≤0.003 
(Figure 7.2). While shifting the balance of AF in the cultures, there was no alternate build 
up of GFP-positive aggregates as one might expect based on other data using other 
polyphenolic compounds (Figure 7.3A) [Mazzulli et al. 2006; Berthelier unpublished 
data]. Our lab has shown in vitro that the treatment of Q50 synthetic aggregates with 
catechols modifies polyGln aggregate morphology so that the aggregate appears more 
truncated than an untreated fibril (Figure 7.3B) and are incapable of extension in a 
polyGln elongation assay (Section 3.8) [Berthelier unpublished data]. These data support 
other in vivo findings where catechols were found to be inhibitors of α-synuclein 
aggregation while facilitating the formation of oligomeric intermediates [Mazzulli et al. 
2006]. Furthermore, curcumin is similar in structure to CR in that both have charged 
poles and are symmetrical with a hydrophobic spacer. CR has been shown to inhibit the 
oligomerization of polyGln in cell cultures as well as had beneficial effects when 
administered to mice [Sanchez et al. 2003]. Also important to note is that no visual 
cytotoxic response was induced by curcumin treatment. For this reason, a cell 
proliferation assay was not performed. Implications of these results will be discussed in 
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Figure 7.1: Effects of curcumin on aggregation foci in 25 QP and 47QP cells. Cells were simultaneously exposed to the 
curcumin and inducing agent for 24 hours. Top row: 25QP cells. Bottom row: 47QP cells. From left to right cells were treated 
with 0, 0.1, 1, or 10µM curcumin. Fluorescence colors: blue – cell nuclei, green – htt-polyGln-GFP fusion protein, red – 


















































Figure 7.2: Curcumin inhibited G R  in a dose-dependent fashion. - C+ Cells were plated 
at a density of 100,000 cells/cm2 16-24 hours prior to the addition of ponasterone and 
curcumin. Results are calculated from four independent fields within a single experiment. 
More than 100 cells per field were counted. Data are expressed as percentage of cells 
expressing either species. An unpaired Student’s t-test was used to calculate the p values.  
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Figure 7.3: Curcumin is similar to Myricetin, which alters aggregate morphology. 
(A) Curcumin and Myricetin are antioxidants that contain phenol groups. (B) Q50 
synthetic fibrils untreated or treated with 10µM Myricetin. Myricetin alters aggregate 









7.3 Demecolcine inhibits GC+R- Species:  
Since similar anti-amyloid effects of curcumin are seen in vitro, the role of 
curcumin in the above experiments is probably to attack the biophysical mechanism of 
aggregate assembly as it would occur in a simple in vitro experiment.  Another approach 
would be to test a compound that interferes with a cellular mechanism potentially 
involved in modulating protein aggregation. 
Therefore we now describe experiments in which cells were treated with a 
compound known to disrupt a vital cellular mechanism, i.e., microtubules, that are critical 
in aggresome formation [Johnston et al. 1998; Webb et al. 2004; Ross and Poirier 2005; 
Chang et al. 2006]. Aggresome formation is initiated in response to a cellular stress 
response, such as the overexpression of an insoluble, misfolded protein. Aggresomes are 
also characterized by perinuclear, large aggregates reminiscent of those seen in the Q103 
expressing PC12 cells. It has been well documented that aggresome formation can be 
inhibited by disrupting microtubule polymerization [Johnston et al. 1998; Garcia-Mata et 
al. 1999; Dul et al. 2001; Webb et al. 2004]. It was, therefore, important to examine the 
possibility that GC+R- structures might be aggresomes and whether treating the culture 
with a microtubule disrupting compound might alter aggregate formation.  
Demecolcine is a compound known to synchronize the cell cycle and interfere 
with microtubule polymerization [Luduena and Roach 1991; Nishiyama and Fujii 1992; 
Sherwood et al. 1994; Wang et al. 1998; Dul et al. 2001; Knockaert et al. 2002]. At the 
same time, demecolcine has not been shown to exhibit any remarkable effects on other 
biochemical events within the cell [Nishiyama and Fujii 1992].  
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DETERMINATION OF THE APPROPRIATE COMPOUND CONCENTRATION 
Htt-inducible cells expressing Q103, which make aggregates very aggressively, 
were chosen to test the effects of the compound because of the abundance of perinuclear 
Gc+R- species in these cells. The assumption was that this cell line would display the most 
measurable amount of inhibition if these aggregates were formed via a microtubule-
dependent mechanism. Q103 cells and the 25QP control cells were subjected to the same 
induction protocol as previously described (Section 3.2) with the simultaneous addition 
of demecolcine for 24 hours. Percentage of htt-polyGln was calculated based on the 
number of cells expressing GFP-positive monomers and/or aggregates. The data were 
obtained by assessing a minimum of 200 total cells within five non-overlapping 
microscopic fields.   
Based on the literature, a variety of compound concentrations (70ng/ml (190nM)-
400ng/ml (1.1µM)) have been shown effective at inhibiting aggresome formation 
[Sherwood et al. 1994; Dul et al. 2001; Knockaert et al. 2002]. For this reason, it was 
important to establish an effective inhibitory dose in our inducible cell system. We tested 
demecolcine in a concentration range of 0ng/ml-1,000ng/ml.   
Based on an examination of diffuse staining, polyGln monomer expression (M) in 
25QP cells was unaffected by the compound treatment (Figure 7.4A), suggesting the 
compounds did not interfere with the normal protein production within the cells. Without 
demecolcine treatment, Q103 cells yielded ~38% GC+R- species and ~5% GN+R- species 
(Figure 7.3B). However, upon compound treatment, there was a significant reduction in 



















































































* p < 0.0003
*
Figure 7.4: Effects of demecolcine on M and GC+R- expression. 25QP and Q103 cells 
were treated with various concentrations of demecolcine. (A) Monomeric expression was 
relatively unaffected by compound treatment, as indicated in 25QP cells. (B)Percentage 
of Q103 cells that expressed GC+R- or GN+R- species. GN+R- species were relatively 
unaffected by demecolcine treatment; however, GC+R- species were dramatically reduced. 
Percent expression was calculated based on the number of GFP-positive cells/total cell 
number. At least 200 cells in five non-overlapping fields were counted.  
 
159 
contras re was no statistically significant difference in the number of cells expressing 
GN+R- species (Figure 7.4B).  
he effects we observed appeared to be dose-independent at the concentrations 
that we tested: 50ng/ml had the same significant GC+R- reduction as the 1,000ng/ml dose 
(Figure 7.4B). Figure 7.5 shows a representative image of Q103 cells prior to 
demecolcine treatment and an image after 24 hours treatment with 50ng/ml demecolcine. 
7.4 Use of the PolyGln-recruitment Stain on Demecolcine Treated Cells: 
itial experiments indicated that demecolcine treatment mediated a significant 
+ -
recruitm ion 3.3) (Figure 7.6).  
The results revealed that upon demecolcine treatment, the observed polyGln species (M, 
GC+R+, and G-RC+) in 25QP, 47QP, and 103QP cells were relatively unaffected (Figure 
7.7). In 47QP cells, M species remained at ~50% expression while G-RC+ species were 
representative of ~30% of the expressing cells. In 103QP cells, ~25% of the polyGln 
expressing cells were M and another ~20% expressed the G-RC+ species. Perinuclear 




reduction in GC R  aggregates; however, it was uncertain whether the compound had any 
effect on the GC+RC+ or G-RC+ species. In order to test the effects of demecolcine on each 
of the polyGln species, all htt-inducible cells (25QP, 47QP, 103QP, and Q103) were 




Figure 7.5: Treatment with demecolcine effects GC+R- species in Q103 cells. Cells 
were treated with 0ng/ml demecolcine and 50ng/ml demecolcine for 24 hours. Compound 
treatment significantly reduced the percentage of cells that expressed GC+R- but not 
G +R-. Blue – cell nuclei, Green – polyGln-GFP fusion constructs. These images are of 
cells that were not subjected to the AF stain; therefore, no red fluorescence should be 

















Figure 7.6: Microscop e effects of d Gln 
species Fluorescence color is blue for cell nuclei, green for GFP fusion constructs, and 
red for aggregation foci. In each panel, the left column represents images taken by 
ic observations of th emecolcine on htt-poly
. 
modified DIC microscopy. The last column in each panel represents the red, green, and 
blue merged image. The middle columns show a merger of the red and green images, 
where the detail of AF and htt colocalization may be more easily observed. The top rows 
of the cell lines are representative of untreated cells, while the bottom rows show cells 






























































































































er demecolcine treatment. Data were collected 
rom a minimum of five independent fields. The data are expressed as the percentage of total cells that exhibited either diffuse 
expression (   ), GFP aggregates (   ), or AF (      ). Data shown are 24 hours post-induction and compound treatment.  
F
f
igure 7.7: Percentage of expression of the various polyGln species aft
In contrast to the modest effects of demecolcine treatment of rious full 
length exon-1 (“QP”) constructs, we observed a remarkable demecolcine effect in the 
Q103 cell line.  These cells normally aggregate very robustly yet fail to exhibit any AF. 
In the presence of demecolcine, there was a significant knockdown in the number of 
GC+R- species by 75% (Figure 7.7D), yet, as shown previously, GN s were 
relatively unaffected (Figure 7.4B).  Interestingly, we observed that in addition to a 
reduction in the GC+R- species, the G-RC+ species was remarkably incre  1% to 
30% (Figure 6.2)). The total htt-polyGln protein expression (M, GC+R G-RC+), 
however, was relatively unchanged.  
Demecolcine treatment did not have a profound effect on any of the cells 
expressing the complete htt exon-1 and was only effective in altering the polyGln 
expression profile in cells expressing the truncated htt exon-1 fragment. cations 
of these data will be discussed in Chapter 9.   
EFFECTS OF DEMECOLCINE ON CELL PROLIFERATION 
Microscopic examination of demecolcine treated cells revealed ence of 
some (<10%) apoptotic cells (condensed or fragmented nuclei and cytop bbing); 
however, the observed amounts did not appear to be considerable. To be certain, a cell 
proliferation assay was performed as described in Section 3.5 on all htt-inducible cell 
lines (25QP, 47QP, 103QP, and Q103). The results indicated that the effects of 
demecolcine mimicked the observed microscopic data, with the exception of the 25QP 
cells (Figure 7.8). In this case, the microscopic data suggested only a slight reduction in 

























Figure 7.8: Effects of demecolcine on cell proliferation. Cells were plated at various 
densities: 25QP cells were plated at a density of ~100,000 cells/cm ; 47QP and 103QP 
cells were plated at a density of ~60,000 cells/cm
2
2 TS reduction) was performed 
ber of viable cells is directly correlated to 
the absorbance readings. 
2; and Q103 cells were plated at a 
density of ~200,000 cells/cm . A cell proliferation assay (M
























+ p < 0.01











Figure 7.9: Minimal apoptotic bodies were observed in 25QP cells treated with 
demecolcine. These results were in contrast to the MTS reduction assay (Figure 7.8). 
Blue – nuclei, green – htt-polyGln-GFP, red – AF.  
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that demecolcine trea P viable cells (p < 
0.01) (Figure 7.8).  
he reasons for the co  results are not clear; however, the simplest 
explanation may be that when the cell proliferation assay was performed, there was an 
uneven distribution of the cells such that fewer 25QP demecolcine treated cells were 
plated than the untreated counterparts, which is consistent with the design of the assay 
(absorbance signal is directly proportional to the number of viable cells present). Also, 
considering demecoline arrests cellular division [Luduena and Roach 1991; Nishiyama 
due to the randomness of transgene insertion) than a different subclone of the same cell 
line. These hypotheses were not tested due to time constraints; however, additional work 
should be performed to better understand this occurrence.   
The positive effects seen on demecolcine treatment suggests the operation of 
microtubule-dependent processes in the intracellular aggregation of these truncated exon-
1 proteins. M and GN+R- species were unaffected by this treatment, while G-RC+ and 
GC+R- species were only affected in cells expressing truncated htt exon 1 fragments 
lacking the proline-rich region. These results suggest that there are multiple aggregate 
assembly pathways and that factors in the cellular environment may govern the rates at 
which aggregates are formed.  The implications of these results will be discussed later. 
tment significantly reduced the number of 25Q
T nflicting
and Fujii 1992], some cell death is inevitable. An alternative rationale would be that this 
particular subclone of the cell line was more susceptible to apoptotic induction (possibly 
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7.5 Effects of Nocodazole on Aggregate Formation:   
We wanted to confirm the observed effects of demecolcine are really attributable 
to its microtubule-depolymerizing activity by also testing another compound 
(nocodazole) also shown to be an effective microtubule-depolymerizing agent [Johnston, 
Ward et al. 1998; Shimohata et al. 2002; Webb, Ravikumar et al. 2004]. The major 
mechanistic difference between the two compounds is that the effects of demecolcine are 
reported to be irreversible, while removal of nocodazole treatment allows restoration of 
microtubule formation [DeBrabander 1981; Zieve 1984].  Since reversibility might 
provide some unique advantages in our experiments, we also investigated nocodazole. 
Like with demecolcine, a range of effective nocodazole doses have been reported 
(100ng/ml (330nM) – 200ng/ml (650nM)) [Shimohata et al. 2002; Webb et al. 2004]. 
Therefore, we treated Q103 cells with doses ranging from 50ng/ml-400ng/ml (Figure 
7.10). Treatment with nocodazole (400ng/ml) for 24 hours was effective at reducing 
G +R- species (Figure 7.11); however, we also observed a drastic reduction in the number 
of attached cells, indicating that this concentration was detrimental to the cells in our 
system. Because of the loss of cells observed with nocodazole and the dramatically 
higher concentration needed to achieve aggregate inhibition, we terminated this line of 

























Figure 7.10: Nocodazole reduced GC+R- aggregates at a concentration of 400ng/ml. 
hours. (A) Monomeric expression was relatively unaffected by compound treatment, as 
indicated in 25QP cells. (B)Per
G
25QP and Q103 cells were treated with various concentrations of nocodazole for 24 
centage of Q103 cells that expressed htt-GFP aggregates. 
ere dramatically reduced. Percent expression was calculated based on the 
number of GFP-positive cells/total cell number. At least 120 cells in five non-overlapping 







































Figure 7.11: Nocodazole effectively inhibited GC+R- species in Q103 cells but caused 
f cells. Blue – nuclei, green – htt-GFP fusion proteins. AF stain was not appl











CHAPTER 8  
EMICAL CHARACTERIZATION OF OBSERVED POLYGLUTAMINE 
PHENOTYPES 
8.1 Rationale: 
Considering a number of polyGln species have been identified in the PC12 cell 
system, and some of these species were affected by compound treatment, the next logical 
step was to try to gain some biochemical information about each class that corroborated 
the microscopic observations. These measurements were necessary to address some key 
observed species, and 3) 
to obtain functional data, for example that might allow us to determine which species is 
the mo iting biotinylated polyGln monomer in vitro. In the long run, the 
bility to prepare enriched cellular aggregate fractions might allow f studies, for 
xample to determine the non-htt-exon-1 components of these fractions. 
In recent years, several groups have shown that multiple aggregated forms of 
polyGln-containing proteins exist [Poirier, Li et al. 2002; Ellisdon, Thomas et al. 2006; 
Wanderer and Morton 2007]. A considerable amount of effort has been spent trying to 
isolate polyGln aggregates and learn more about their biochemical makeup [Scherzinger 
et al. 1999; Steffan et al. 2000; Suhr et al. 2001; Webb et al. 2004; Chow et al. 2006; 
BIOCH
questions that we were unable to address with the microscopic data: such as, 1) whether 
the observed diffuse expression pattern actually represents monomer or microaggregate 
structures, 2) whether it was possible to physically separate the 




Cong et al. 2006; Schilling et al. 2007]. Many isolation techniques have been explored. 
For example, the most common is has been to utilize centrifugation 
[Scherzinger, Sittler et al. 1999; Steffan, Kazantsev et al. 2000; Suhr et al. 2001; Webb, 
Rav on 
chromatography [Cong et al. 2006 finity purification (purification by 
 to the protein or to the fusion tag) [Chow et al. 2006]. Each method 
was successful in the crude isolation of polyGln proteins with affinity tags proving 
especially effective.  This chapter will discuss the methods we evaluated for isolating the 
various classes as well as the gamut of other techniques utilized to gain more information 
about the observed species.  
Whole cell lysates of each cell line were prepared at 24-72 hours post-induction 
as described in Section 3.6. Briefly, cells were collected by centrifugation, resuspended in 
the isotonic lysis buffer containing Triton  X-100, vortexed, and sonicated resulting in 
disruption of the cellular material. Cell lysates were then fractioned (via gel filtration or 
differential centrifugation) and examined for the presence of the polyGln proteins of 
interest by virtue of Western blot analysis and reactivity to anti-GFP (Santa Cruz 
Biotechnology) and 1C2 (Chemicon) (anti-polyglutamine) antibodies.  
olation approach 
ikumar et al. 2004; Schilling et al. 2007], while others have used size exclusi
], and immunoaf
using an antibody
8.2 Cell Lysis: 
®
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8.3 Gel Filtration: 
 We began our efforts to fractionate cell lysates using size exclusion 
chromatography (gel filtration). For these studies, Q103 cells (24 hours post-induction), 
which produced a high percentage of cells expressing G +R- and some M, were subjected 
to this technique (Section 3.6). Each gel filtration fraction collected was tested for the 
presence of polyGln-containing proteins and reactivity with an anti-GFP antibody (data 
not shown). 1C2 and anti-GFP reactivities were only detected in fractions that were 
collected within 7-9 ml (less than one column bed volume). Interestingly and 
contradicting our original hypothesis, we found no detectable protein (polyGln or 
otherwise) in the void volume, suggesting that only soluble, low molecular weight 
ere being isolated. From these results, three alternative hypotheses 
were formed: 1) the lysis buffer that we used to extract the proteins was solubilizing the 
aggregates, 2) the large aggregates were getting trapped in the gel filtration column, or 3) 
there are no aggregates in these cells (i.e., the punctuate green staining does not indicate 
aggregated material). 
To address the first concern, preformed synthetic aggregates, which have been 
shown to be SDS-resistant [Chen and Wetzel 2001], were treated with the lysis buffer 
and subjected to SDS PAGE as described in Section 3.7. Synthetic and recombinant 
exon-1 polyGln aggregates have been shown to be similar to late-stage htt aggregates 
[Cooper, Schilling et al. 1998; Kazantsev, Preisinger et al. 1999; Chen, Berthelier et al. 
2001] in that they are SDS-resistant. Lysis treatment did not alter the SDS solubility of 




gel (Figure 8.1). Although this experiment was important to conduct, perhaps it did not 
fully resolve the question.  The purpose of conducting such biochemical experiments was 
to learn more about the nature of all the aggregates and other polyGln species within the 
cell culture. By only testing the lysis buffer with very stable, end-stage polyGln 
aggregates, the possibility cannot be excluded that less stable, early aggregates might be 
dissociated by the lysis buffer.   
The second concern was addressed, by sampling the top of the column for 1C2 
reactive proteins. A small portion of lysis buffer and the column bed (500µl) was 
removed by a pipette, homogenized, and subjected to the SDS-PAGE protocol (Section 
3.7). One set of the SDS gels were stained with Coomassie Blue, while the other set was 
transferred to a nitrocellulose membrane and subjected to the Western blot protocol using 
the 1C2 antibody (Section 3.7). In support of the hypothesis that polyGln aggregates did 
not enter the column, the Coomassie stained gels exhibited a small amount of protein was 
associated with the top of the column (Figure 8.2). However, this protein appeared to not 
be related to the transgene product, since it was negative in Western blots using the 1C2 
antibody.  The source of the Coomassie-positive, 1C2-negative material was not clear.  It 
could have represented non-htt-exon-1 related high MW proteins from the cell.  Failure to 
detect polyGln aggregates might also be explained by a failure of the “aggregated” 
protein to transfer to the membrane. To test this, the gel after electrotransfer was stained 
with Coomassie and found to exhibit no residual protein staining, consistent with 
complete protein transfer (data not shown).  
Thus, clear results on the gel filtration fractionation of cells shown by 



















Figure 8.1: Lysis buffer does not affect SDS-resistance in K2Q47K2 synthetic 
aggregates. Aggregates were subjected to SDS treatment, gel electrophoresis, and 
Western blot analysis with 1C2 antibody. Irrespective of treatment, the preformed 
aggregates did not migrate into the gel but remained at the top of the well, as indicated by 




Figure 8.2: Material at the top of a gel filtration column was 1C2-negative. (A) Q103 
fractions subjected to SDS-PAGE and stained with Coomassie blue. (B) 1C2 reactivity of 
transferred gel. While there was Coomassie staining in the top of the gel, usually 
















































































exten mine stretches are inhere y known to be very cky molecules, 
hich might account for loss of protein. Alternatively, the chosen method of evaluating 
e top o column could have been better designed. Since, for whatever reasons, 
olation of the polyGln species by gel filtration was unsuccessful, we investigated an 
lternativ oach at fractionation: centrifugation.   
8.4 Differential Centrifugation: 
lysates prepared as described in Section 3.6 were fractionated by the 
ifferen entrifugation protocol shown in Figure 3.4. Four fractions were analyzed 
om each cell line 24-72 hours post-induction: 1) whole cell lysate (W), 2) washed pellet 
om 15,000xg spin (P1w), 3) pellet from 100,000xg spin (P2), and 4) supernatant from 
contain M species. Each fraction was subjected to electrophoresis under denaturing 
conditions (Section 3.7) after which the proteins were electrotransferred to a 
nitrocellulose membrane where they were probed for their reactivities with anti-GFP and 
1C2 antibodies (Section 3.7). Positive antibody binding was detected using 
chemiluminescence.  
Initial experiments were performed to confirm that the GFP aggregates were 
indeed co-localized with polyGln. GFP has been shown to self-aggregate (a rare 
occurrence) in the presence of small peptides [Link et al. 2006], these aggregates 
maintain there fluorescence. Therefore, we needed to be certain that the observed 
fluorescence was not due to the proteolytic cleavage of GFP from htt exon-1, which then 
ded polygluta ntl sti
w







100,000xg spin (S2).  The hypothesis was that P1w should contain the large GC+RC-/+ 
species, P2 should contain the relatively small GN+R- and G-RC+ species, and S2 should 
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self-aggregated. Cell lysates from Q103 cells were tested for this occurrence. 
Microscopically, these cells expressed an abundant population of cells with GC+R- 
aggregates.  Western blot analysis revealed that there was an overwhelming 1C2 anti-
polyGln reactivity co-localizing with the anti-GFP antibody (Figure 8.3), suggesting that 
no measurable proteolysis of the construct occurred prior to aggregation.   
Next, the question of whether the observed diffuse fluorescence was due to 
monomeric species or microaggregates was addressed. This question was most cleanly 
address
pelleting of the small G-RC+ aggregates.  At the same time, there 
seems 
ed with the 25QP cells.  At 24 hours post-induction, 25QP cells have been shown 
by fluorescence microscopy to have 40% of the cells expressing M and 40% of the cells 
expressing G-RC+ aggregates, with no cells expressing G+R- aggregates (Figure 6.2). 
Western blot analysis of lysate centrifugation fractions of these cells supported the 
fluorescence microscopy in showing the htt exon-1 immunoactivity to be associated only 
with the high speed centrifugation supernatant (presumably M) and pellet (presumably G-
RC+).  The S2 fraction from the 25QP cells showed a high reactivity with both the 1C2 and 
anti-GFP antibodies (Figure 8.4), suggesting that the observed diffuse green staining 
pattern was due to intact (monomeric) GFP-htt-exon1 fusion proteins. The fact that there 
was a quantitative difference between the gel and microscopy results for 25QP cells may be 
due to the inefficient 
to be no reason to expect quantitative agreement, given that the scoring of the 
microscopy was not based on molar measurements.   
While the possibility that some of the diffuse green in these and other cells may be 
due to SDS-stable microaggregates cannot be eliminated, the results in Figure 8.4 suggest 







reactivity.  Q103 cell lysate samples (24h) showed that the only GFP detected runs at a 















Figure 8.3: Representative autoradiograms that show 1C2 and anti-GFP co-
MW consistent with that of the full length exon1-GFP fusion. Abbreviations: P1w – 






































igure 8.4: Autoradiograms of 25QP cells lysates 24 hours post-induction. The 
predominant 1C2 and anti-GFP reactive bands are found in the S2 fraction; however, there 
was also some GFP reactivity found in the P2 fraction. Abbreviations: P1w – washed pellet 

























groups are consistent with the idea that the diffuse staining pattern is representative of 
onomeric species [Lunkes and Mandel 1998; Preisinger et al. 1999; Apostol et al. 2003].  
In this thesis, we will be assuming that diffuse staining comes exclusively from monomers.  
Parenthetical  
etimes migrate in more dense centrifugation fractions due to association with cellular 
embranes/debris.      
Microscopically, the appearance and disappearance of the different polyGln species 
ith increasing indu es were able to nitored. We, therefore, wanted to 
examine whether or nderstanding of the nature of these 
species by analyzing cell . Cell fraction udies focused on the time period 24-
2 hours post induction, mainly b  of the significa bserved in the 103QP 
nd Q103 cells during this time frame. At each time point in these fractions, the most 
polyGln repeat length1. Figure 8.5 shows a representative 1C2 blot from each of the cell 
line lysates at 48 hours post-induction. In the Q103 blot, it is important to note that non-
transformed PC12 cells as well as uninduced control samples were also assayed. The 
uninduced controls had some slight reactivity with the 1C2 antibody that corresponded to 
our positive bands in the induced samples. This was not unexpected 
  
                                                
m
ly, we also cannot formally exclude the possibility that monomer might
som
m
w ction tim  be mo
not we could develop a better u
 fractions ation st
7 ecause nt changes o
a
reactive gel band  (according to the Western blot analysis) was, as expected, our expressed 
htt-polyGln-GFP constructs, which can be observed between 45-55kDa depending on the 
 
1In these gels, there is a consistent discrepancy between the calculated molecular weights and the observed 
molecular weights of the polyGln containing proteins (Table 8.1). These differences are routinely seen in SDS gels 
of polyGln proteins by our group and by others, and can be accounted for by some not-well-understood interaction 
between polyGln and polyacrylamide producing aberrant mobility of polyGln proteins in SDS-PAGE.    
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Figure 8.5: 1C2 Western blot analysis of all cell line lysates at 48 hours post-
induction. Lysates were fractionated by differential centrifugation. The htt-polyGln-GFP 
construct of interest is denoted by a black arrow.  
 
Table 8.1: Approximate molecular weights of polyglutamine proteins and 
 
fragments. 
Protein fragment Calculated MW (kDa) Observed MW (kDa) (±4kDa)
25QP 37.4 46 
47QP 40 49 
103QP 46.8 59 
Q103 43 54 
Free GFP 25.9 -- 
Free N1-17 2 -- 

































































































because it has been shown [Apostol, Kazantsev et al. 2003] that these cells do have some 
on each 1C2 
W n blot. Protei dance was calculated for each major fraction. The numbers 
obtained from the P1w, P2, and S2 fractions are expressed as percentages of total gel 
staining material, an efore sum to 100%.  In contrast, the microscopy data was 
n ly expressed a ercentage of c ntaining each ion of htt exon-1.  
Since 10-30% of cells generally exhibit no expression of the transgene, the data were 
As mentioned previously, cells expressing 25QP exhibited a population expressing 
n equal mixture (±10%) of about 40% diffuse protein and 40% AF, which was relatively 
Western blots revealed a similar trend, with fractions representing the soluble protein 
remaining at ~60% and the P2 fraction, which we interpret as AF, remaining at ~40% 
(Figure 8.6B) during the 3 time points. 
Cells expressing 47QP produced similar data to 25QP cells (Figure 8.7). Both 
microscopic results and densitometry analysis revealed 40% expression of AF or P2 and 
60% expre ffuse or S2 at the 24 me points. There was, 
however, a slight discrepancy at 72 hours post-induction. Microscopic analysis showed that 
60% of the cells were expressing AF and  of the cells were expressing monomer, 
whereas densitometry analysis revealed 5% of the protein was found in the P1w fraction 
“leaky” expression of the transgene.   
Each cell line was examined independently for correlations between the microscopy 
data and the cell fractionation data. Densitometry analysis was performed 
ester n abun
d ther
ormal s the p ells co manifestat
normalized to 100% in order to put the microscopy data on an equal footing for 
comparisons.  
a
unchanged over the 24-72 hours period (Figure 8.6A). Densitometry analysis of the 1C2 








etry comparison of 25QP cells. (A) Microscopic 











Figure 8.6: Microscopic and densitom
analysis of 25QP cells from 24-72 hours post-induction. 
ecies was normalized to 100% expression. (B) Densitometry analysis of 25QP cell 
tions from 24-72 hours post-induction. P1w- washed pellet from 15,000xg, P2 
– pellet from 100,000xg, S2 – supernatant.  
  
(A) 25QP -Microscopy AF

























































































 Figure 8.7: Microscopic and densitometry comparison of 47QP cells. (A) 
Microscopic analysis of 47QP cells from 24-72 hours post-induction. Percentage of cells 
expressing each species was normalized to 
Aggregation foci
Diffuse expression






















100% expression. (B) Densitometry analysis 
of 47QP cell lysate fractions from 24-72 hours post-induction. P1w- washed pellet from 
15,000xg, P2 – pellet from 100,000xg, S2 – supernatant.  
186 
(normally associated with larger aggregates), 45% of the protein was found in the P2 
fraction, and 50% of the protein was found in the S2 fraction. The small portion of material 
pelleting at low centrifugation speed found in these cells may be due to some aggregates 
not detected in the microscopy, or to M that is physically associated with cell debris and 
was not dislodged by washing.        
d polyGln species, appear to be a 
more complex situation (Figure 8.8).  At the 24 hour time point, it appeared that the 
major species by microscopic examination were G-RC+. According to the densitometry 
data at this same time, the P2 fraction also represented the most abundant species. At 48 
hours, the microscopic and densitometry analyses correlate fairly well, with 10% of the 
protein being large aggregates, 40% being smaller aggregated material, and ~50% of the 
protein being monomeric. By 72 hours, however, there was a small disagreement 
between the two data sets. Microscopically, we saw that 20% of the population had large 
GC+RC+ aggregates; however, the densitometry analysis revealed the P1w fraction 
represented only ~10% of the protein abundance. It is possible that the larger aggregates 
may be partially broken down by the detergent treatment used to prepare the lysate (see 
below).  Even considering the slight disagreement at 72 hrs, the match between the 
 (Figure 8.9A). Consistent with 
this, densitometry of the 1C2 stained gel on Q103 cells shows a corresponding time-
dependent increase in the P1w fraction that was expect to contain large aggregates (Figure 
103QP cells, which exhibited all the observe
centrifugation data and the microscopy data is striking. 
Finally, microscopy showed that in Q103 cells there is a time-dependent increase in 
GC+R- species that we interpret as large exon-1 aggregates
187 






















































Figure 8.8: Microscopic and densitometry comparison of 103QP cells. (A) 
Microscopic analysis of 103QP cells from 24-72 hours post-induction. Percentage of 
cells expressing each species was normalized to 100% expression. 
analysis of 103QP cell lysate fractions from 24-72 ho
(B) Densitometry 








Figure 8.9: Microscopic and densitometry comparison of Q103 cells. (A) Microscopic 
analysis of Q103 cells from 24-72 hours post-induction. Percentage of cells expressing 
each species was normalized to 100% expression. (B) Densitometry analysis of Q103 cell 
lysate fractions from 24-72 hours post-induction. P1w- washed pellet from 15,000xg, P2 























































8.9B). However, inconsistent with the microscopic data is the relative abundance in whi
this species was found. The microscopy data revealed an increase from 40% GC+R-
to >80% GC+R- species from 24-72 hours; however, the densitometry data showed onl
increase from 20% to 40% in the P1w fraction. Additionally, while the densitometry data 
shows that 40% or greater of the protein population was collected in the P2 fr
opy found none of the G-RC+ species in these cells that, in the “QP” series of
discussed above, consistently correspond to material in the P2 (high speed) pellet fract
e of this more-difficult-to-pellet material may derive from the relatively small G
species (<10%) observed by microscopy at these times (Figure 6.7). We hypothesize that 
ainder of the material in the P2 fraction is from small aggregates generated by the
lysis procedure from labile G-RC+ species.   
Overall, the cell fractionation data agrees remarkably well with the fluorescence
opy.  These data comparisons can be used to address another important ques
concerning the interpretation of the fluorescence microscopy data, the issue of whet
perinuclear, punctate, green fluorescent bodies are really composed of aggregates of htt





microsc  cells 
ion. 
Som N+R- 






e cell of a number of kinds of organelles, it is 
formally possible that punctate fluorescence might sometimes be due to the organization of 
monomers within a membranous compartment. The Western blot analysis revealed at this 
same ti e point that ~10% of the 1C2-positive population was found in the soluble fraction 
(Figure 8.8B), which was in remarkable agreement with the microscope data that revealed 
aggregated protein, and in fact use the terms interchangeably [Fink 1998; Johnston et al. 
1998; Lunkes and Mandel 1998; Garcia-Mata et al. 1999; Preisinger et al. 1999; Apostol et 
al. 2003].  However, given the presence in th
m
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that ~5% of the cells contained diffuse staining interpreted as “monomeric” species (Figure 
8.8A). If most of the GC/N+R- species were collections of monomers, much more material 
would have been seen in the S2 fraction.  We think these results justify our working 
assumption, shared with most of the field, that punctate inclusions represent some kind of 
aggregated material.   
Some minor difficulties were encountered in the Western blot analysis. While 
polyGln-positive bands always were mirrored by a GFP-reactive band, the latter was 
often of a much lower intensity.  This was especially evident in lysates produced from 
cells 24-72 hours post-induction (Figure 8.10). This problem was addressed by testing 
two different GFP antibodies: a rabbit polyclonal and a mouse monoclonal antibody. 
Although we used both antibodies at the lowest dilution suggested (1:150), the antibodies 
still failed to produce an intensity equal to that of the 1C2 antibody, even at extended 
exposure time (data not shown). There are several possible reasons for the reduced 
sensitivity: 1) the primary antibodies were not matched in their efficiencies, 2) the 
secondary antibodies (which were different for the rabbit and mouse derived primaries) 
could have also had different relative affinity, and 3) the GFP binding sites were either 
less accessible than polyGln binding sites or may not have been present due to some 
protein degradation. A proper GFP-positive control was never tested, so without this 
piece of data, we cannot be certain why we experienced less intense GFP-reactive bands.  
Importantly, the lower intensity of the anti-GFP bands cannot be interpreted as an 
indication that some of the polyGln-containing proteins may have lost their GFP.  If that 






























Figure 8.10: GFP antibody was not as sensitive as the 1C2 antibody. Regardless of 
antibody dilution or exposure time of the membrane to the x-ray film, the anti-GFP 
antibody was not as effective in recognizing the GFP-tagged proteins as the 1C2 
antibody. Abbreviations: W – whole cell lysate, P1w – pellet from 15,000xg, P2 – pellet 









DEMECOLCINE TREATED CELLS 
ioche  t le c  trea  with demecolcine. 
As described in Chapter 7, the immunofluorescence data revealed that demecolcine had 
little effect on 25QP, 47QP, and 103QP cells (Figures 7.5 and 7.6), but had a major effect 
on Q103 cells.  In view of this, fractionation studies were conducted on Q103 and 25QP 
cell lysates. Cell lysates corresponding to 24 hour incubation with or without 
emecolcine treatment were su d to SDS-PAGE a  blot analysis using the 
showing no effect of demecolcine, but also exhibited remarkable quantitative agreement 
with the microscopy analysis (Figure 8.11). 
Analysis of demecolcine-treated Q103 cells also showed very good agreement 
between the two measurement techniques.  In the demecolcine treated cells, the relative 
amounts of material in the M, GC-R+, and GC+R- species by microscopy were closely 
matched by the amounts of material in the S2, P2, and P1w fractions (Figure 8.12).  It is 
interesting that there was a poorer agreement in the untreated cells.  As discussed 
previously, this can be explained if the perinuclear GC+R- aggregates were somewhat 
unstable, breaking apart into smaller aggregates and monomer under lysis conditions.  
The better agreement of the demecolcine-treated cells may be due to the presence of a 
substantial fraction of GC-R+ in these cells; as highly stable, mature amyloid fibrils, these  
 
B mical data was also ob ained from stab ells ted
d bjecte nd Western
protocol previously described in Section 3.7.  
Analysis of 25QP cells with and without exposure to 50ng/ml demecolcine gave 
cell fractionation results that not only agreed with the previous microscopy results in 
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Figure 8.11: Microscopic and densitometry comparison of 25QP cells treated with 
demecolcine. Percentage of cells expressing each species was normalized to 100% 
50ng/ml demecolcine. P1w- washed pellet from 15,000xg, P2 – pellet from 100,000xg, 
demecolcine. (A) Microscopic analysis of 25QP cells treated with 0 or 50ng/ml 
expression. (B) Densitometry analysis of 25QP cell lysate fractions treated with 0 or 
S2 – supernatant.  
 









































































































Figure 8.12: Microscopic and densitometry comparison of Q103 cells treated with 
demecolcine. (A) Microscopic analysis of Q103 cells treated with 0 or 50ng/ml 
demecolcine. Percentage of cells expressing each species was normalized to 100% 
expression. (B) Densitometry analysis of Q103 cell lysate fractions treated with 0 or 
50ng/ml demecolcine. P1w- washed pellet from 15,000xg, P2 – pellet from 100,000xg, 
S2 – supernatant.  
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aggregates were expected to withstand the lysis conditions and hence retained an 
appropriately sized signal in the Western blot analysis of the P2 fraction. 
8.5 Microtiter Plate Extension Assay of Various Polyglutamine Lengths: 
In a functional assay, the centrifuged fractions were examined for their ability to 
seed the fibrillogenesis of polyglutamine peptides. A modified protocol of a microtiter 
plate polyGln extension assay (Section 3.8) that was previously designed in our lab 
[Berthelier, Hamilton et al. 2001] was used. Immobilized cell lysate material and 
preformed synthetic K2Q47K2 aggregates (positive control for polyGln elongation) were 
incubated with 100nM biotinylated polyGln monomer (the same as used in the 
microscopy experiments) for a determined amount of time. After which, the plates were 
washed and incubated with a streptavidin-labeled Europium (Eu) solution. Eu-
incorporation was then measured by time-resolved fluorescence and converted to 
femtomoles using a determined standard curve. 
Experiments were performed on 103QP cell lysate material from the 48 hour time 
point. The reason for choosing this polyGln length and time point was because at 48 
hours post-induction, multiple polyGln species (M, GC+R-, GC+RC+, and G-RC+) were 
observed by immunofluorescence, including the AF fraction that is the only material we 
expected to be positive in this assay. Logically this appeared to be the best cell line for 
optimizing the elongation assay. Multiple experiments, however, yielded only 
inconclusive and inconsistent results (data not shown), which were not a consequence of 
196 
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The lack of reproducibility in the experimental data may be due to the fact that the 
starting material was cell lysates. In general, cell lysates contain many contaminants such 
as lipid
eat deal of time was spent attempting to 
optimiz
expected a better outcome for the elongation assay. However, even if conditions were 
experimental technique as was evident by the consistent positive recruitment of our 
positive control (data not shown).   
s, cell and nuclear membranes, and other cellular proteins, all of which might 
interfere with the assay (although controls in which untransformed cell lysates were 
added to control polyGln aggregates, to see if they affected elongation activity, were not 
done). Another problem with cell lysates is that, because they are not homogenous, 
aggregates may not dry in a monolayer when they are plated, such that superficial cell 
debris material may mask potential polyGln binding sites.  
For each assay, equivalent amounts of material were plated per well; however, 
this amount did not actually reflect the amount of polyGln-containing proteins that was 
immobilized. It simply represented the total protein that was plated. This is yet another 
problem with the assay as it stands. While a gr
e this procedure, the data produced from these experiments were equivocal.  
Nonetheless, these efforts should provide a good foundation for future work using this 
assay on cell lysates.   
One suggestion for improving the microplate assay would be to improve the cell 
lysate preparation. By introducing a purification step, such as immunoprecipitation with 
1C2 antibody (which would remove any non-polyGln containing or associated proteins 
from the mixture), or by the use of a density gradient for protein separation, one might 
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scence microscopy and Western blotting are very 
sensitiv
f the polyGln species. Taken 
togethe
e polyGln species.  
optimal, there is still the question of quantity regarding polyGln recruitment-competent 
proteins within the lysate. Fluore
e techniques, and we have no independent estimate of how much protein is being 
made in these cells on a molar or weight basis.  Therefore, although these cell lines were 
of high clonal integrity, it is possible that the quantities of aggregates are simply too low 
to give a positive result in the microplate assay.  As mentioned previously, it is also 
possible that other cellular factors, associated with the aggregates upon cell disruption, 
inhibit the aggregates’ ability to stick to the plates or their ability to bind monomer. 
Despite the pitfalls along the way, we identified a method (differential 
centrifugation) that was effective for the crude separation o
r, these biochemical experiments clarified a number of uncertainties about the true 
natures of the species observed in fluorescence microscopy, providing a critical 
foundation for the interpretation of this data.  The knowledge acquired from the 
biochemical characterization has provided important details on the larger GFP-positive 
aggregates and insights about the aggregation pathway of Huntington’s disease. Finally, 
these results have provided a solid basis for future attempts at the chemical 
characterization of thes
CHAPTER 9 
DISCUSSION AND CONCLUSIONS 
Experimentation with the stable cell lines led to the identification of several 
polyGln species (M, G
9.1 Possible Aggregation Mechanisms:  
er in 
isolatio
e formed via kinetically competing pathways 
(Figure 9.1B). In this chapter we will discuss those possible modes of aggregation and 
speculate on the implications of these various models.  We will then review some of our 
experimental work, namely the response of htt exon1 expression patterns to certain 
compounds and to sequence variation within htt exon1, and discuss the results in the 
context of these models.   
 
-RC+, GC+RC+, GC+R-, and GN+R-) some of which were recruitment-
competent and others that were recruitment-inert. These species could be found eith
n or within the same microscopic field, and in some instances even within the 
same cell. The identification of multiple aggregated polyGln species corroborated other 
findings from in vitro experiments with isolated protein that such structures do exist 
[Poirier, Li et al. 2002; Wacker et al. 2004; Mukai et al. 2005; Thakur unpublished data]. 
There are many possibilities for how the assembly pathways of the various species are 
intertwined (Figure 9.1). One possible mechanism is that AF are online intermediates in 
GFP inclusion formation (Figure 9.1A), while another possibility is that, conversely, 
recruitment-inert GFP inclusions are precursors to amyloid-like AF (Figure 9.1C). A 








Figure 9.1: Possible modes of polyglutamine aggregation. M - diffuse, monomeric 
GFP formation but did not exhibit recruitment-capabilities; G +R + - aggregates that were 
recruitment (only observed in the cytoplasm). This schematic represents possible 
representation, where Part B provides visual aides. Models A-C address possible 
where aggregation foci (G-R +) are precursors to mature polyGln aggregates (G +R-) 
formation. The rapid conversion of M  G +R- appears to be a reversible process 
on in vitro data, where recruitment-inert aggregates occur prior to the formation of 
A-C with the inclusion of G +R- species being on a separate assembly mechanism 
 
protein; G-RC+ - aggregation foci; GC/N+R- - aggregates that showed cytosolic or nuclear 
C C
large enough to be visualized via their GFP component but also exhibited polyGln 
pathways for polyGln aggregation. Part A shows all proposed models without picture 
aggregation mechanisms for cytoplasmic species. Model A proposes a linear relationship 
C C/N
[Osmand 2004]. Model B suggests a competitive pathway for G-RC+ and GC/N+R- 
C
governed by the lack of aggregate stability. Model C represents a linear pathway, based 
recruitment-positive fibrils [Thakur unpublished data]. Schematics D-F parallel models 
N











































Figure 9.1B. Continued. 































Why are AF not always green?  During many of the experiments, AF were 
detected in species that did not exhibit detectible GFP fluorescence.  There are several 
possible interpretations of this counterintuitive finding. One hypothesis is that AF did not 
accumulate enough mass to be visualized by their GFP fluorescence. The fluorescence 
yield of AF on a mass basis is expected to be determined by (a) the number of 
biotinylated polyGln monomers residing on each aggregate after staining, (b) the number 
of dye molecules per streptavidin, and (c) the quantum yield of the dye. It may be that 
this produces a fluorescence yield, per htt exon1 molecule in the aggregate, that is 
substantially brighter than the yield of the GFP associated with each exon1 molecule. 
Another possibility is that AF are com d largely of htt-exon-1 constructs that have 
lost all or part of their GFP component due to intracellular proteolysis (not consistent, 
however, with the SDS gel d  third, related possibility is that, although AF retain 
e GFP component of the htt 1 fusion, the GFP has lost its fluorescence due to its 
becoming unfolded during the amyloid formation process intrinsic to AF formation.  
While it would be interesting to know the reason for the poor GFP fluorescence of AF, 
this property does not impact any of the key interpretations of this data discussed here.   
9.2 Effects of Curcumin Treatment e Aggregation Pathway: 
The effects of curcumin were explored in cells expressing a benign polyGln 
repeat length (25QP) and a physiologically re t polyGln repeat length (47Q ach 









in a corresponding decrease in cells with other forms of htt exon1 (Figure 6.2). By 144 
RC+ aggregates. Curcumin treatment inhibited the formation of G-RC+ in a dose-
dependent fashion, while only slightly altering the percentage of cells producing M.   
Other experiments suggest that curcumin is specifically an anti-amyloid inhibitor, 
rather than being non-specific [Frautschy et al. 2001; Nakagami et al. 2002; Lim, Jin et 
al. 2005; Yang, Lim et al. 2005].  Because of their strong ability to grow by monomer 
addition, a property unique among aggregates to amyloid and amyloid-like fibrils, we 
think that G-RC+ aggregates are amyloid in nature.  The ability of curcumin to effectively 
knock down G-RC+ production in cells is consistent with their expected amyloid-like 
structure. While it is clear from our results that curcumin down-regulates AF in cells, it 
could be that this is a result, not of the inhibition of their formation from M, but rather a 
result of altering the aggregate morphology to interfere with its ability to recruit, or in 
fact to simply bind to AF and directly inhibit their recruitment of M in the AF stain.   
  Curcumin treatment was only investigated in cells expressing 25QP and 47QP, 
which never exhibited any GC+R- aggregates. These experiments simply address the 
relationship of M and AF, and therefore, do not specifically address the central question 
of whether AF and GFP-positive aggregates are on linear or competing pathways.    
9.3 Effects of Demecolcine Treatment on the Aggregation Pathway
The central meaning of the data presented in this dissertation can best be 
considered by focusing attention on stable PC12 cells expressing Q103. These cells very 





implications for intracellular aggregation mechanisms.  Here we consider, in turn, the 
aggregation mechanisms outlined in Figure 9.1 A-C.  If one of the pathways (A or C) 
contain
hours post-induction, >70% of the cell population exhibited GC/N+R- aggregates with no 
cells exhibiting detectable M species. Furthermore, AF were present in less than 1%
s.  
We examined the effects of two modifications with Q103-producing cells. The 
first set of modifications of Q103 producing cells involves the addition of cell-pathway 
modifying compounds to the cells in culture.  Because GC+R- aggregates resemble 
perinuclear aggresomes that require microtubules for their formation [Johnston et al. 
1998; Webb et al. 2004], we treated Q103-producing cells with the microtubule-
disrupting agent demecolcine. Demecolcine treatment significantly changed the 
aggregation pattern in cells in both expected and unexpected ways.  First, as expected, 
drug treatment almost completely eliminated GC+R- aggregates in cells.  Second, as 
expected, this resulted in cells harboring greatly increased amounts of M and smaller 
aggregates.  Surprisingly, however, the smaller aggregates turn out to be G-RC+ 
aggregates (AF) rather than smaller versions of GC+R- aggregates (Figure 7.7).   
The fact that demecolcine-treated Q103 producing cells contain essentially no 
GC+R- aggregates, but large amounts of both M and G-RC+ aggregates, has prof
ing GC+R- and G-RC+ in a precursor-product relationship represents the correct 
assembly mechanism, then demecolcine treatment should have had different effects than 
what was observed.  Pathway A posits that M is converted entirely to G-RC+, which 
subsequently are converted to GC+R-, presumably by virtue of being collected into 
208 
ccording to this mechanism, the blocking of GC+R- formation by demecolcine 
should
aggresomes. (This mechanism doesn’t explain why simple collecting AF into aggresomes 
should allow them to acquire GFP fluorescence while at the same time losing recruitment 
ability.)  A
 lead to an accumulation of 100% of the htt exon-1 material in G-RC+.  Since G-RC+ 
represent very stable, polyGln-core amyloid fibrils [Berthelier et al. 2001; Chen et al. 
2001], it is very unlikely that, once formed, any significant amount of these G-RC+ 
aggregates will dissociate to M within the cell. 
Pathway C posits that M is first efficiently converted to GC+R-, which 
subsequently are converted directly into G-RC+.  As in pathway A, there seems to be no 
simple way under this mechanism to explain the formation of M in response to 
demecolcine treatment.  If  GC+R- are the initial aggregates – formed from M as mediated 
by the microtubule network,  and if they are also obligate intermediates in the formation 
of G-RC+, one would expect disruption of the microtubule network by demecolcine to 
lead to a complete reversal of aggregation to regenerate 100% M. 
The only mechanism that seems to be capable of producing, in response to 
demecolcine elimination of GC+R-, a mixture of both M and G-RC+ aggregates, is pathway 
B.  In this mechanism, in Q103 cells, formation of GC+R- aggregates is so rapid that the 
more slowly developing G-RC+ aggregates do not form; in the competition for M, G-RC+ 
aggregates lose.  However, if the stabilization of GC+R- within aggresomes is blocked by 
demecolcine treatment, monomers persist and partially convert to G-RC+, now no longer 
in competition with GC+R-.   
209 
tes, suggesting that these are the earliest 
formed
r stable cells as well. 
Compo
9.3 PolyGln Flanking Sequences Influence Aggregation:  
ile the 103QP cells expressed intact exon-1, including the 
The poor stability of the GC+R- aggregates implicit in this analysis is consistent 
both with the literature [Muchowski et al. 2000; Muchowski et al. 2002] and with the cell 
fractionation experimental results described in Chapter 8 and highlighted in Figures 8.9 
and 8.12. As discussed in Chapter 1, growth of htt exon-1 aggregates in vitro leads to two 
classes of aggregates – those that are soluble by SDS-treatment and those that are not 
[Muchowski, Schaffar et al. 2000]. Growth in the presence of some molecular chaperones 
increases the fraction of SDS-soluble aggrega
 in the assembly pathway.  Only the amyloid-like end products of htt exon-1 
aggregation are SDS-stable [Cooper et al. 1998; Kazantsev et al. 1999; Chen et al. 2001].  
In our cell fractionation experiments (Figures 8.9 and 8.12), disrupting Q103 cells rich in 
GC+R- aggregates was sufficient to render about half of the htt exon1 material incapable 
of being sedimented by a high-speed centrifugation step (and hence, we assume, 
monomeric).   
 The affects of demecolcine were examined in the othe
und treatment did not alter the aggregate balance in any of these cells, which 
suggested that the polyproline stretch modulated the types of aggregates being produced.   
The second modification was contained within the construct itself and consisted 
of a direct examination of the role of the proline-rich region neighboring the polyGln 
sequence of htt exon-1. Wh
210 
proline
ttacharyya, Thakur et al. 2006].  This effect is also observed in peptides 
also co
polyGln, these peptides result in much more rapid aggregation kinetics than for a 
comparable polyGln sequence and lead to an initial aggregated product that is neither 
fibril-li
containing both polyGln and the N-terminal 17 amino acids, the initial aggregation rate 
-rich segment, the Q103 cells expressed htt exon-1 constructs lacking this flanking 
sequence.  
It has been consistently shown that polyGln flanking sequences have profound 
effects on polyGln aggregation kinetics [Bhattacharyya, Thakur et al. 2006], aggregation 
mechanism [Ellisdon, Thomas et al. 2006], protein stability [Bhattacharyya, Thakur et al. 
2006], toxicity [Dehay and Bertolotti 2006], and subcellular localization [Rockabrand, 
Slepko et al. 2007]. In vitro, it has also been shown that various lengths of synthetic 
polyGln lacking any other htt sequences, always produce aggregates, at all stages of the 
aggregate assembly reaction, that are fibril-like and recruitment-competent [Chen, 
Berthelier et al. 2001; Chen et al. 2002; Thakur and Wetzel 2002; Yang, Dunlap et al. 
2002].  When peptides including a proline-rich sequence following polyGln are 
examined, the aggregation kinetics are slowed and the aggregates formed appear to be 
less stable [Bha
ntaining the N-terminal 17 amino acids of htt, even though this sequence alone 
radically affects the aggregation mechanism. Thus, in contrast to simple polyGln 
peptides, when the first 17 amino acids of the huntingtin protein are included along with 
ke nor recruitment-competent (thus resembling protofibrils/oligomers); with 
recruitment-competent, amyloid-like fibrils forming later in the aggregation reaction 
[Thakur unpublished data]. When a proline rich sequence is included in the peptide 
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s, is retained2 [Thakur unpublished data].  Thus, regardless of the 
aggrega
significantly decreases, but the assembly mechanism, including various non-fibrillar early 
intermediate
tion mechanism and the nature of the aggregated products, addition of a proline-
rich sequence on the C-terminal side of the polyGln consistently slows aggregation. 
Consistent with these in vitro findings, our data demonstrate that the presence of 
flanking oligoproline sequences significantly decreases the rate at which GC+R- 
aggregates form. Rather than simply leading to a buildup of diffuse GFP monomers in 
cells, however, the ability of the proline-rich sequence to inhibit formation of GC+R- 
aggregates surprisingly leads to the accumulation of substantial levels of G-RC+ 
aggregates (AF) that are not detected in cells expressing oligoproline-minus htt exon-1. 
Information we acquired from cells expressing 103QP suggest that G-RC+ and GC+R- are 
on parallel assembly pathways (Figure 9.1B) and that the presence of polyproline affects 
the formation of GFP-positive inclusions while not altering the formation of AF. If the 
species were on a linear pathway, where AF were precursors to GC+R- aggregates, then 
one would expect that the presence of oligoproline would, indeed, slow down the 
aggregation reaction, and fewer GFP inclusions would be observed, which is consistent 
with Mechanism A. However, one would also expect that if this model were true, then 
eventually, all the G-RC+ aggregates would be converted to GC+R- aggregates. Our data 
show that while aggregation does occur more slowly in the absence of proline and that 
                                                 
2While we did not specifically address the importance of the first 17 aa of htt, it has been shown that this 
sequence can act as a cytoplasmic retention signal even in the presence of a nuclear localization signal 
[Seffan, J.S., et al. 2004]. Our findings that the aggregated species were predominantly found in the 






9.4 Role of Nuclear Aggregates in the htt Exon-1 Aggregation Pathway: 
to occur independently of compound treatment, GN+R- aggregate formation was proline-
GFP-positive aggregates become more abundant with increasing time (Figure 6.2), AF 
levels remained constant (~20%) throughout the time course, which would be 
inconsistent with Mechanism A.    
As in Mechanism A, Mechanism C would also be inconsistent with our find
 presence of polyproline slows down the aggregation mechanism. In this case, if 
Mechanism C were viable, then G-RC+ aggregates would form much later than the initial 
times at which they were observed (Figure 6.2), and there would be an early abundance 
of GC+R- aggregates, which would more slowly convert to G-RC+ aggregates.  
Therefore, the mechanism that seems the most possible is Mechanism B, where G-
RC+ and GC+R- are on competing pathways, producing a more diverse mixture of polyGl
species.  
The data we gathered from the treatment of Q103 cells with demecolcine also 
brought forth the possibility that the two forms of recruitment-inert aggregates (GN+R- 
and GC+R-) were on separate, competing pathways (Figure 9.1D-F). While demecolcine 
treatment significantly reduced GC+R-, the compound treatment did not significantly 
affect GN+R- species (Figure 7.4B), suggesting that GN+R- aggregates formed via an 
assembly pathway that did not involve microtubules. While nuclear aggregation appeared 
dependent. Nuclear aggregates were never seen in cells expressing complete exon-1 and 
were only apparent in cells expressing Q103. Presumably monomeric protein gained 
213 
 recruitment-positive aggregates in the nucleus died 
and we
 only cells 
that ge
 and may thus explain why our cells did not exhibit toxicity. 
ll 
Dystrophy:  
In HD, there is a lack of correlation between polyGln inclusions and cell death 
[Gutekunst, Li et al. 1999], suggesting that there may be other unreported species 
responsible for cellular demise. Our model directly addresses this important question 
lingering over HD research. The presence of AF in cells expressing 25QP demonstrate 
that studies focusing strictly on the larger polyGln inclusions are not comprehensive in 
their aggregate analysis. Often, AF form in the absence of GFP-positive inclusions and 
may provide a better correlation with cell dystrophy in the human disease.  Similarly, we 
have shown that inclusions can be recruitment-positive or recruitment-inert. Previous 
attempts to correlate cell death to inclusions did not take this characteristic into account.  
access to the nucleus by an unspecified means where it then aggregated. It is unclear why 
the nuclear aggregated species never exhibited recruitment-competency. However, one 
possibility is that cells that formed
re never visualized.  
It is has been shown that nuclear penetration is necessary for cell death to occur 
[Cooper et al. 1998; Hackam et al. 1998; Yang et al. 2002]. In most of these cases, the 
nuclear aggregates are amyloid-like and are, therefore, recruitment-competent [Yang, 
Dunlap et al. 2002]. Cells expressing truncated htt exon-1 fragments were the
nerated GN+R- species; however, no nuclear AF were ever seen. These results are 
consistent with published findings that nuclear amyloid aggregates are extremely 
cytotoxic,
9.5 Current Detection Methods May Ignore Important Indicators of Ce
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 While these data have provided many insights into the aggregation pathway, there 
are many questions still unanswered and hypotheses incompletely proved. For example, 
an important hypothesis coming out of this work is that the large, perinuclear G +R- 
aggregates are detergent-soluble and/or labile to mechanical stress. This hypothesis 
emerges from the comparison of fluorescence microscopy data with cell fractionation 
data, as summarized in Figures 8.9 and 8.12. The hypothesis is also consistent with the 
apparent ability of microtubule disruption to block formation of, or destabilize, G +R-.  
Thus, providing more experimental support for this hypothesis would strengthen many of 
the conclusions of this thesis. To further test this hypothesis, we would propose to 
prepare cell lysates of demecolcine treated and untreated cells in the absence of detergent. 
 absence of detergent should exhibit less monomer and more aggregate, 
and pe
 
9.6 Future Directions: 
C
C
If the aggregates were indeed denatured by the presence of the detergent, then cells 
disrupted in the
rhaps more easily pelleted aggregates. This set of experiments would provide a 
new set of biochemical data that may reflect the severe aggregate burden that we see 
microscopically.  
 Results from our biochemical data have demonstrated that our method of cell lysis 
in conjunction with differential centrifugation was sufficient for the crude preparation of 
various protein fractions. It is, however, imperative to improve upon this method so that 
the nature of each polyGln species can be more closely examined. As alluded to earlier 
(Chapter 8), the introduction of an immunoprecipitation step prior to fractionation would 
provide a much cleaner sample. For example, if the whole cell lysate material were
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 1C2 antibody, then the fractions would be rich in polyGln-
containing proteins. Then there are a host of experiments that could be conducted with 
the purified material. For example, to address the critical question of which, if any, of the 
species could further support fibril growth in vitro. One would expect that the only 
species capable of this feat would be AF. It would also, then, be possible to examine the 
samples by EM. This would provide more information about the amyloidogenic 
properties the species actually possess. Alternately, one could also examine whether or 
not the large aggregates freely dissociate to monomer.    
 Finally, the most definitive experiment to gain information regarding whether the 
various species are formed “on-” or “off-pathway” would be to design an experiment 
where live-cell imaging could be performed to monitor the formation or dissociation of 
the various types of aggregates. In order to conduct such an experiment, one would need 
to design a fluorochrome-labeled (preferably one of the stable red variants that are 
offered from Molecular Probes) polyGln peptide of benign length that could be 
introduced to the cells and detected by microscopy. Entry of biotinylated monomer into 
the cell with our current AF staining method, as mentioned earlier, is dependent upon the 
permeabilization of fixed cell material. Fixation and permeabilization, while useful for 
many applications, does indeed kill the cell. There are, however, cell permeabilzing 
agents (saponin) that can be used to introduce temporary pores in cell membranes without 
killing the cell cultures, thus allowing aggregate formation to be studied in real-time. The 
information gained from such experiments would provide direct evidence of the 
interactions of M, GC R , and G RC  species.   
immunoprecipitated with the
+ - - +
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 In summary, we were successful in developing a novel polyGln stain that relies on 
the recruitment-capabilities of polyGln sequences. This stain combines a functional assay 
and a visual means for detecting recruitment-positive entities, which were not always 
detected by normal polyGln staining methods. We were able to optimize an existing 
stable, htt-inducible PC12 model for maximum protein expression in which we 
implemented our polyGln-recruitment stain.  
 With the aid of our polyGln-recruitment stain, we were able to identify several 
phenotypically distinct polyGln aggregates. We successfully tested the effects of two 
compounds on their ability to modulate aggregation. One compound had a profound 
effect on AF while the other compound significantly reduced G +R- aggregates.  
 Our data have also shown that polyGln flanking sequences play important roles in 
altering aggregation kinetics and protein stability. While the mechanism of polyGln 
aggregation is still a mystery, our data suggest that G +R-, G +R-, and G-R + aggregates 
form via alternate assembly pathways (Figure 9.1E). Further experimentation is needed to 
determine which, if any of these species represent the toxic entity responsible for HD 
pathogenesis.   
Our data support a model of polyGln aggregation which defines three competitive 
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